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ABSTRACT 
Despite receiving oxygen therapy, many COPD patients experience extended 
periods of hypoxemia during routine daily activities. In others, inappropriately high oxygen 
flow rates can depress hypoxic drive leading to worsening CO2 retention. As flow-rates during 
LTOT are fixed, oxygen delivery will not respond to patients' fluctuations in oxygen demand. 
The research project has aimed to develop and evaluate a closed-loop control method capable of 
actively varying flow-rates in response to the measured oxygen demand. We demonstrate how 
SpOz from ambulatory or overnight pulse oximetry can be used as feedback into an automated 
O2 flow-rate controller. 
A model to mimic the patient oxygen saturation response has been developed in a 
computer simulation to help characterize the closed-loop system. With the collaboration of the 
Academic Unit for Sleep and Breathing at the Royal Brompton Hospital, the controller response 
has also been validated against patient saturation measurements recorded during overnight pulse 
oximetry monitoring. Preclinical computer simulations indicated an improved matching 
between oxygen supply and demand, maintaining SpO] above threshold to maximize 
therapeutic efficacy. 
An investigational system capable of regulating the Saturation Driven Oxygen Therapy 
(SDOT) was constructed. In a randomised cross-over clinical pilot study, we further evaluated 
the SDOT system against constant-flow LTOT during exercise. The clinical results indicate that 
compared to standard oxygen therapy, SDOT produced a significant reduction in time spent 
with hypoxemia, decreased the extent of hypoxemia and lowered mean heart rates during 
exercise. Moreover, for patients with acceptable resting oxygen levels, SDOT provided 
conservation benefits by reducing the rate of oxygen consumption. The study established the 
potential to significantly improve the efficacy and economic delivery of this gold standard 
therapy. 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.1 Overview 
The aim of work presented in this thesis has been to develop and evaluate a method for 
automatically regulating oxygen delivery using a closed loop system for people with respiratory 
disorders who require supplemental oxygen therapy. 
1.2 Respiratory Medicine 
The respiratory system's primaiy function is to provide the mechanism for exchanging 
atmospheric gases within the body, in order to replenished oxygen as it undergoes cellular 
metabolism and expel the by-product carbon dioxide. While the cardiovascular system 
transports these molecules throughout the body, the respiratory system makes possible their 
exchange with the atmospheric gases. The complimentaiy interaction between the respiratory 
and circulatoiy systems is often underscored by the effect respiratory disorders can have on a 
patient's cardiac function. Much attention is now being given to understand the extent of this 
connection between respiratory disorders and congestive heart failure. 
For example, conditions such as Chronic Obstructive Pulmonary Disease (COPD), 
which impair the body's ability to exchange respiratory gases, are marked by an associated 
increase in the cardiac workload. A study by Selinger et al. reported on the effects of stopping 
low-flow oxygen therapy in COPD patients receiving long-term oxygen therapy [7]. After 
stopping oxygen therapy, there was a direct correlation between the decreased levels of arterial 
oxygen saturation and an increase in pulmonary artery pressure and pulmonary artery resistance, 
as well as a decrease in stroke volume. As these results indicate, one of the primary benefits 
from oxygen therapy treatment for COPD is to alleviate the strain on the heart. The focus of the 
work presented here is aimed to increasing the effectiveness of oxygen therapy. 
Similar emphasis in treating other related respiratory disorders has led to significant 
breakthroughs. Sleep apnoea is a disorder from either upper airway obstruction or dysfunction 
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in the natural respiratory drive. Obstructive sleep apnoea (OSA) causes momentary arousal due 
to declining levels of oxygenated blood and contributes towards progressive cardiovascular 
disease. OSA has been linked with hypertension, myocardial infarction and stroke. Continuous 
positive airway pressure (CPAP) treats this condition by maintaining an open airway through 
applying continuous positive air pressure. The technique has been pioneered by ResMed Inc 
(Bella Vista, Australia) whose evolution is an example of the exciting new advances in 
respiratory medicine. Founded in 1989 to commercialize this new therapy developed in the 
University of Sydney, ResMed has become a global leader in CPAP for people with OSA. This 
new technique of CPAP has helped treat millions of patients worldwide. The chronic disorder 
OSA is especially pertinent to the work presented here with reference to the detrimental 
consequences from even brief periods of inadequate oxygen supply to cardiovascular function. 
1.3 Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonaiy disease is categorized by progressive obstruction to 
airflow from either emphysema and/or chronic bronchitis. As emphysema and chronic 
bronchitis frequently coexist, they are grouped together as COPD. The disease is predominantly 
caused by smoking. As a result, smokers are 10 times more likely to die from COPD than non-
smokers. Another risk factor strongly associated with contracting COPD is occupational 
exposure to certain industrial pollutants. 
Inflammation and fibrosis of the bronchioles, 
small airways terminating in the alveoli, is the 
major cause of airflow obstruction. In 
emphysema the alveoli undergo destructive 
changes leading to a permanent enlargement of 
the airspaces distal to the terminal bronchioles. 
The accumulative effect is to diminish the 
lungs' gas exchange performance often creating 
Figure 1.1: Lung Anatomy, 
a ventilation-perfusion mismatch, consequently American Lung Association 
[http://www.discoverycampus.eom/pub002 
Bronchus 
Alveolus 
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reducing arterial blood oxygen saturation to the point of hypoxemia. 
Typical symptoms of COPD include chronic cough, exertional breathlessness, wheezing, 
and excessive sputum production. Radiography can be used to detect signs of emphysema, 
however, spirometry is the standard diagnostic tool for assessment of COPD. The forced 
expiratory volume in 1 second (FEV,) is a reliable measure of airway dynamics with accurate 
predictions for age, sex and height. FEVi is more sensitive to changes in the small airways than 
peak expiratory flow measurements. An FEVi below 75% and above 50% of the normal value 
corrected for age and weight is classified as mild airflow obstruction. Often an improvement in 
FEVi can be observed in response to treatment with bronchodilators. This reversible 
improvement will vaiy from patient to patient. For patients with moderate to severe obstruction, 
50%> FEVi > 30% and FEVi < 30% respectively, further evaluation of arterial blood gas is 
necessary to consider giving Long Term Oxygen Therapy (LTOT). The prognosis in persons 
with FEV] values < 0.75 1/s is limited, the approximate mortality rate at 1 yr is 30% and at 10 yr 
95% [8], 
FEVi Percent Predictions Degree of Airway Obstruction 
75-50% Mild Obstruction 
50-30% Moderate Obstruction 
<30% Severe Obstruction 
In the United Kingdom it is estimated that nearly 900,000 people have been diagnosed 
as having COPD and around half as many again are living with undiagnosed chronic airflow 
obstruction [9]. This accounts for a combined annual direct and indirect cost to the NHS of 
approximately £982,000,000 [9]. Figures from the UK also revealed up to 25% of all emergency 
medical admissions were accounted for by acute respiratory admissions [10]. Furthermore, 
acute exacerbations of COPD resulting in hospitalization have a 26% mortality rate [11]. 
Similar statistics highlighting the immense impact and costs associated with COPD have been 
established world-wide. According to the American Lung Association, COPD claims the lives 
of over 100,000 annually in the US, and is ranked as the fourth leading cause of death. The 
corresponding US national annual healthcare expenditure for COPD exceeds $18 billion. LTOT 
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is the gold standard treatment in those who fulfil standard criteria, as it can increase exercise 
ability and improve long-term outcomes. 
1.4 Oxygen Therapy 
The Medical Research Council (MRC) trial of long-term domiciliary oxygen therapy 
and the Nocturnal Oxygen Therapy Trial (NOTT) completed in the 1980's were the first major 
randomised clinical studies to quantify that oxygen therapy led to increased survival among 
patients with COPD [12,13], Figure 1.2 illustrates the survival data fi-om these two fundamental 
patient trials. The MRC study evaluated survival over 60 months between an LTOT group (n= 
42) receiving 15 hours of oxygen per day and a control group with no oxygen (n=45). In the 
NOTT study, survival over 36 months was monitored in 101 LTOT patients receiving 
continuous oxygen (24 h/day) compared against a control group receiving 12 hours of oxygen 
therapy per day. Although 12 h/day of oxygen therapy only slightly improved survival 
compared to no oxygen therapy, 15 h/day and 24 h/day revealed progressively better outcomes 
[12]. These studies demonstrated almost a directly proportional reduction in mortality between 
oxygen therapy durations of 15 h/day and 24 h/day (ratio 0.63) with 3yr survival of 55% and 
77%, respectively (ratio 0.71). 
O j 24 h/day 
O215 h/day 
~ O g l E h/day 
Controls (no added Og) 
« 90 
50 60 
Time (months) 
Figure 1.2: Combined survival data from MRC and NOTT studies of LTOT 
in COPD [Rees, P J et al. BMJ 1998;317:871-874] 
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Other recognised benefits from LTOT include a decrease in hypoxia-induced elevations 
of haemoglobin, lower pulmonary artery pressure and vascular resistance, increased stroke 
volume index, improved exercise tolerance, and subjective improvement in quality of life 
[14,15]. Despite the positive benefits of LTOT, even short periods of intermittent hypoxemia 
can lead to right ventricular hypertrophy from increased pulmonary arteiy pressure and 
pulmonary vascular resistance [7]. Unfortunately with the current delivery of LTOT, the 
patient's varying oxygen demand may not be well matched by the fixed flow-rate oxygen 
delivery. 
At present the oxygen flow is provided by an oxygen cylinder or concenfrator 
delivering a constant prescribed flow of oxygen. Other oxygen sources like liquid oxygen are 
available for ambulatory use. Continuous oxygen is most commonly delivered via nasal cannula 
which can effectively deliver 100% oxygen. During inspiration this O2 mixes with room air to 
increase the fraction of inspired oxygen (FIO2). Adjusting the Xable 1 2- Fraction of 
O2 flow rate will effect the FIO2, such that each iifre per 
minute approximately increases the FIO2 3 to 4% above room 
air [16]. It is recommended to use flow rates between 0 to 5 
1/min for continuous oxygen therapy. Flow-rates above 5 1/min 
O2 Flow Rate FIO2 
(1/min) (%) 
0 21 
1 25 
2 29 
3 33 
4 37 
are rarely prescribed and must be used in conjunction with external humidiflcation. The final 
FIO2 will depend on a number of patient variables: anatomy, shunt fraction, and respiratory rate. 
For constant O2 flow, the FIO2 is inversely proportional to respiratory rate. Nevertheless, low-
flow continuous O2 is usually sufficient to increase the resting arterial oxygen content to 
clinically acceptable levels. 
The current prescription and reimbursement guidelines advocate using LTOT if a 
COPD patient has either a resting partial pressure of oxygen in arterial blood (Pa02) < 55mmHg, 
or a resting Pa02 < 59mmHg if exhibiting signs of tissue hypoxia [9,16]. Desaturation only 
during exertion or sleep can be sufficient to prescribe supplemental O2 for those settings. 
Respiratory patterns often change during sleep and hypoventilation can contribute to worsening 
hypoxia. Using arterial blood gas analysis (ABG), the resting Pa02 is measured after 30 min of 
breathing room air. While the patient remains at rest, the oxygen flow rate is roughly tifrated to 
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achieve a clinically acceptable level of arterial oxygen saturation (SpO; > 90%) as measured by 
pulse oximetry. The pulse oximetry should be calibrated against the initial ABG at rest. Further 
exercise testing can be performed during tasks such as a timed walk, treadmill or bicycle at a 
patient's normal pace. In general the guideline suggests increasing O2 resting flow rate by 1 
1/min for either exercise or sleep hypoxemia. This rather subjective regimen and fixed therapy 
does not account for natural fluctuations during daily activities and could promote significant 
periods of latent or undocumented hypoxemia. 
1.5 Ambulatory Pulse Oximetry Findings 
Several recent outpatient studies using ambulatory pulse oximetry have confirmed the 
existence of hypoxemic periods despite LTOT. In a study by Morrison et al. of 20 COPD 
patients receiving LTOT, they showed that patients who did not have resting hypoxemia still 
spent on average 22% of the 24-hour study period with SpO; < 90% [17]. In a similar study by 
Sliwinski et al. of 34 COPD patients receiving LTOT, they reported an average of 29 ± 26% of 
the monitored time with SpOi < 90% [18]. Pilling also demonstrated that the current oxygen 
therapy prescriptions resulted in patients spending a substantial amount of time with latent 
hypoxemia despite of LTOT [19]. In that study 20 of 27 patients spent more than 10% of the 
monitored time with Sp02 < 90%, and 9 of 27 patients spent more than 25% with hypoxemia. 
Over the course of daily activities, these corroborating studies revealed an average of 
approximately one quarter of each day (6 h/day) with detrimentally low blood oxygen levels 
[20]. As oxygen flow-rates remain fixed during LTOT, oxygen deliveiy will not respond to 
patients' fluctuations in oxygen demand resulting in intermittent periods of hypoxemia. 
In light of the proportional benefit established by the NOTT and MRC studies, this 
indicates many patients are not realizing the full potential benefit of oxygen therapy. Selinger et 
al. has shown in COPD patients that brief periods of hypoxemia caused increased pulmonary 
artery pressure and pulmonary vascular resistance [7]. Furthermore, animal studies in rats 
revealed that long-term exposure to intermittent hypoxemia (2 h/day) led to right ventricular 
hypertrophy from increased pulmonaiy arteiy pressures [21,22], In COPD patients with 
accompanying hypoxemia, right ventricular hypertrophy is common and congestive heart failure 
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remains a prevailing cause of death [23]. Therefore, ensuring patients do not spend a significant 
percentage of time with Sp02 < 90% should improve long-term outcomes from oxygen therapy. 
In addition, some patients are particularly oxygen sensitive and providing too much 
oxygen can be harmful. In COPD patients with hypercapnia, too much oxygen can depress 
ventilatory drive thereby worsening CO2 retention. In these patients it is particularly critical not 
to over-supply oxygen during acute exacerbations. C02 retention can result in acidaemia, blood 
pH below 7.3, leading to depression in cardiorespiratory function and multi-organ failure and is 
associated with a higher incidence of intensive care admission [24,25]. With the present fixed-
flow oxygen delivery systems, the patient's oxygen demand is not well matched and does not 
achieve the maximum potential health and economic benefits. 
The advent of non-invasive pulse oximetry monitoring has greatly facilitated identifying 
patient hypoxia in a wide variety of medical settings from emergency medicine to surgical 
anaesthesia and postoperative care. Pulse oximetiy measures the absorbance of light either 
transmitted or reflected through the tissue. Two separate wavelengths are commonly used at 
roughly 660nm (red) and 940nm (near-infrared) to measure the amounts of reduced 
haemoglobin and oxyhaemoglobin, respectively. Each wavelength is preferably absorbed by the 
agent of interest. To isolate the component of absorption contributed by the arterial blood, the 
pulse oximeter cancels out the static DC component of absorption leaving only the variable AC 
pulsatile component. This eliminates the absorption from the tissue or venous blood, measuring 
only the absorption by the pulsatile arterial blood. The ratio of absorbed light at each 
wavelength is then converted into a value of arterial oxygen saturation (SpOi) utilizing 
experimentally derived calibration curves [26]. 
Variable absorption 
(Due to arterial pulsatile) 
O 
o 
Arterial blood absorption 
Venous Wood absorption 
Other tissue absorption 
Time 
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Figure 1.3: Comparative light absorption through tissue. 
[Sinex, JE. (1999). American Journal of Emergency Medicine, 17 (1); 60] 
While studies of pulse oximetry monitoring have provided important new observations 
into SpO] fluctuations, two notable shortcomings of pulse oximetry deserve mention. Due to 
motion artefacts, roughly 8% of the oximetiy recordings needed to be manually deleted. Overall, 
motion artefact is considered the main factor impairing the accuracy of pulse oximetry. In 
addition, absolute values may not be accurate during exercise as a result of changing peripheral 
perfusion [16,27,28,29]. However, new signal processing techniques beyond simple averaging 
filters use adaptive digital filters to compensate for motion artefact, low perfusion, and intense 
ambient light [30,31]. These advancements promise to further increase the accuracy and 
robustness of this important wide-spread diagnostic tool. 
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CHAPTER 2 
CONTROLLER DESIGN 
2.1 Introduction to Closed Loop Oxygen Controller 
This research project aims to develop a closed-loop, flow-rate control method for 
patients with chronic obstructive pulmonary disease undergoing treatment with long-term 
oxygen therapy. The controller will use arterial oxygen saturation measurement from pulse 
oximetry to regulate oxygen flow-rate during treatment. Feedback from the pulse oximeter is 
used to maintain the patient SpO] within an ideal range. This technique is termed Saturation 
Driven Oxygen Therapy (SDOT). The hypothesis to be tested is that SDOTwill more accurately 
correct Sp02 during exercise and rest than conventional fixedflow-rate LTOT. 
No prior scientific data has been presented on such a therapeutic device for people with 
COPD. The only relevant studies have attempted to control the oxygen concentration of 
mechanical ventilators in acute hospital settings [32,33], Feedback from a pulse oximeter 
enabled a microprocessor controller to manage the oxygen-air mixer during mechanical 
ventilation. In these studies the patients' oxygen levels were able to recover from hypoxic 
events within about 2 minutes. Another study on very low birth-weight infants, subject to 
frequent episodes of hypoxia which are difficult to manage manually, used a closed-loop 
controller to maintain the Sp02 at a fixed level. The study demonstrated an improvement in 
oxygen saturation over the monitored period compared to the manual control [34]. These 
positive results point to the merit of implementing feedback control for respiratory therapy. 
Nevertheless, constant flow LTOT is prescribed for domiciliary and ambulatory use. Applying 
closed-loop control for oxygen therapy and the associated complications of treating active, 
mobile COPD patients has not yet been investigated. 
Figure 2.1 is a schematic of the proposed closed-loop SDOT system. A microprocessor 
receives measurements from a pulse oximeter and computes the optimum oxygen flow-rate. The 
controller then outputs a signal to a flow regulator managing the delivery of oxygen to the 
patient. An oxygen saturation target of 91% is maintained by changing the flow-rate subject to 
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feedback from the pulse oximetry. The control scheme for this system has been implemented in 
a computer simulation on Simulinki""^ (Mathworks Inc, Massachusetts USA) using a closed-loop 
proportional-integral-derivative (PID) algorithm. The controller is evaluated using a model 
developed to approximate the patient oxygen saturation response. 
Flow Regulator 
I 
r-J 
Oximeter 
Patient 
Controller 
Source 
Figure 2.1: Saturation Driven Oxygen Therapy (SDOT), closed-loop schematic 
Simulink™ is commonly used for modelling, simulating, and analyzing dynamic 
systems. It supports linear and nonlinear systems, modelled in continuous time, or discrete time. 
Models are built as block diagrams from a reference library of sinks, sources, linear and 
nonlinear components, and connectors. Complex systems can be built with external input and 
output such as serial port connections. Moreover, the utility allows for stand alone applications 
to be developed with customized Graphic User Interfaces. 
2.2 Simulation and Flow Controller 
The SDOT simulation consists principally of two components, the Controller and 
Patient model as shown in Figure 2.2. The controller computes the error (E) between the target 
setpoint and measured oximetry value. It then determines the oxygen flow-rate output to the 
patient. The patient saturation is modelled as a composite value, dependent on the oxygen flow 
rate and a local disturbance. Each of the main components is discussed in detail below. The 
simulation also accounts for the discrete sampling from the pulse oximeter which is assumed to 
have a sampling rate of I Hz. 
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Figure 2.2: Top level block diagram 
The controller was based around the well-known PID algorithm used extensively in 
controls whose function is given in Eqn.l, where E is the input error (difference between actual 
and target SpC^), U is the oxygen flow rate in 1/min, and Kp Ki Kq are the proportional, integral 
and derivative coefficients. Overall, the PID function endeavours to correct any input errors. 
The response of the PID function is characterized by the parameters Kp, Kj and Kd. The output 
(U) represents the oxygen flow-rate in litres per minute (1/min). The PID function can also be 
expressed in terms of its Laplace transfer function as in Eqn.2. Often for single input, single 
output systems (SISO) as illustrated in Figure 2.2, some form of linear PDD control is the most 
appropriate choice despite the potential limitations such as a sluggish response due to a long 
dead time. As a first approach, the SpO] input from the pulse oximeter maybe sufficient to 
create a stable and accurate control response. 
In the future it may be advantageous to expand the PID controller to include multiple 
inputs from transcutaneous CO2 or heart rate measurements. Additional methods for treating 
feedback delay in closed loop PID control could be explored for example using the Smith 
Predictor. Furthermore, more sophisticated methods for treating feedback delays could be 
investigated such as incorporating predictive control loops such as Internal Model Control 
(MPC) or Model Predictive Control (MPC). Then alternate heuristic control methods such as 
fuzzy logic could also be implemented as effective controllers. 
U(t) = KpE(t) + K, \E(t)dt + 
t / ( S ) = 
(1) 
(2) 
A second order Butterworth lowpass filter was used to screen out higher frequencies 
near the sampling rate to reduce the potentially detrimental affects of noise or spurious 
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measurement from the pulse oximeter. To ensure a stable flow-rate response from the control 
algorithm, the Butterworth lowpass filter (cut-off frequency: 6.5 mHz) was applied to the PID 
output. The transfer function for the second order lowpass filter is presented below. 
W(S) = A 
S^-BS^ 
For patient safety, the oxygen flow-rate must include maximum and minimum limits. 
This is accomplished via a non-linear saturation regulator. The minimum flow-rate limit is 0 
1/min, and the maximum limit is set to 5 1/min. Thus the flow controller is confined to output 
values within this predetermined range. A controller block diagram is depicted in Figure 2.3. 
GD • 
In1 
PID - K j D 
Oui1 
PID Con t ro l l e r S a t u r a t i o n Discre te Fil ter 
Figure 2.3: Flow Controller block diagram 
2.3 Modelling the Patient Response 
The patient arterial oxygen concentration (Pa02) is modelled by the function given in 
Eqn.4. This model was developed from previous clinical studies in literature on LTOT and 
pulse oximetry measurements [35,36,37,38], specifically to provide a general pre-clinical 
validation as to the potential feasibility and efficacy of the control method. The function has 
three distinct components; a baseline level (Po), an arbitrary disturbance (P^), and an oxygen 
flow-rate dependence (Py). Combined together, their sum represents the patient PaO] in mmHg. 
Po can be considered the default value. In the absence of any disturbance or oxygen flow, this 
baseline level is set to 60 mmHg (approximately 91% saturation). 
Pa02{t ) = PQ+ P^{t) + Pj{t) (4) 
Where Po ~ 60mmHg 
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{t) = - 3 + 3 cos(2;r * / * 0 (5) 
Where/= Frequency (Hz) 
The arbitrary disturbance, Pd(t), is a driving function that introduces fluctuations from 
the baseline level. These fluctuations simulate the variable conditions possible in COPD patients 
during changing exertion or sleep. Negative disturbances will induce hypoxemia (PaO] < 60 
mmHg), while positive values raise the PaOa > 60mmHg. Initial tests of the simulation used Pd(t) 
as given in Eqn.5, a cosine function with a bias of -3 and amplitude 3, oscillating between 0 and 
-6 mmHg. The frequency of the cosine disturbance was varied between 10"^  to 10"' Hz. This 
frequency sweep of sinusoidal functions can provide an indication of the system response across 
a broad range of expected patient disturbances. Nevertheless, any arbitraiy input can be given to 
the system. The simulation is later validated using actual patient oximetry recordings as the 
driving input. 
Representing the oxygen flow-rate dependence, Pf(t), requires a more complicated 
differential equation. A change in the fraction of inspired oxygen (F1O2), takes time to diffuse 
from the mouth to lungs and down to the blood capillaries where the pulse oximetry measures 
the oxygen saturation. This is known as the lung-to-capillary circulatory time [35]. A typical 
patient response for a step change in oxygen flow-rate is shown in Figure 2.4. Looking at the 
patient response, two time constants can be identified. The time from the change in the inspired 
oxygen until a measurable change in saturation is known as the dead time (T,). The lag time (T2) 
was defined as the time between the first measurable change and approaching the final stable 
measurement (rather than the engineering convention of 67% the final value). It should be noted 
this definition of lag time was adopted to draw better comparison to the clinical literature 
referring to lung-to-capillaiy circulatory time. In an effort to draw parallels with the clinical 
lung-to-circulatoiy time, the sum of the dead time (TO and time lag (T2) will be defined as the 
time delay. 
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Figure 2.4: Flow-rate step response 
Several studies have investigated the lung-to-capillaiy circulatory time based on pulse 
oximetry measurement [35,36], It appears that sensor placement is a key factor affecting the 
lung-to-capillary time. Pulse oximetry is commonly obtained from sensors at the foot, hand or 
ear. Overall, measurements from the ear displayed the shortest time delays [35]. Ear sensor 
measurements also were the least sensitive to error from either exercise or cold [37]. Based 
upon these studies, T, and T; are approximately 6 and 15 seconds, respectively [38]. However, 
these values are certain to contain variability between patients from physiological parameters 
such as shunt fraction, respiratoiy rate, heart rate, cardiac output. 
The patient's oxygen flow-rate dependence, Pf (t), is described by a second order linear 
differential equation. Eqn.6 relates the oxygen flow-rate (U) to the arterial oxygen concentration. 
M,B,K are all parameters given to the model to yield the appropriate lag time (Tj). Furthermore, 
the dead-time (T,) is also included in corresponding transfer function, Eqn.6. Since Pf(t) is in 
mmHg, a sensitivity factor (a) is utilized. This factor is derived from the rule of thumb that for 
each additional 1/min of oxygen flow-rate provided, the fraction of inspired oxygen increases by 
approximately 3% [16]. We assumed a corresponding direct relationship in the PaO; of 3% 
increase for each 1/min of oxygen flow-rate. 
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PAt) = a 
dt' dt (6) 
PAS) = a*e 
MS^+BS+K 
-] 
(7) 
The pulse oximeter measures the arterial oxygen content in terms of percent saturation 
rather than mmHg. The approximate saturation can be related to the arterial oxygen pressure 
using the Severinghaus oxyhaemoglobin dissociation relationship [39] shown in Figure 2.5. 
This relates the Pa02 (mmHg) to the arterial oxygen saturation (SpO^) which can be shifted by 
specific factors such as blood pH, and PaCO] that influence the oxyhaemoglobin dissociation. 
The final SpO] value is then fed back into the closed loop controller. 
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Figure 2.5: Oxyhaemoglobin disassociation curve 
The SDOT system response is modelled at disturbance frequencies between 10"^  to 10"' 
Hz. Simulated responses of the Sp02 measured by the pulse oximeter, and the oxygen flow-rate 
determmed by the controller were obtained which directly relate to clinically relevant 
parameters. Also, a deviation measure is defined as the maximum difference between target 
saturation and the SpO; for a given disturbance frequency. 
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These values have been compared against a simulation of an untreated patient with no 
supplemental oxygen. SDOT is hypothesised to attenuate fluctuations by appropriately vaiying 
the oxygen flow-rate. A ratio of the maximum deviation between the controlled model versus 
the untreated model illustrates the attenuation provided by the closed-loop system. For reference, 
the block diagram of the patient model has been provided below in Figure 2.6. 
AipFi^  ^ 
Pf (mmHg) 
Transfer Fen Time Delay 
(M,B,K) (T1) 
Po (mmHg) 
Oxy Dissociation Curve 
-»CD 
S p 0 2 
Pd (mmHg) 
Figure 2.6: Patient model block diagram 
2.4 Simulation Results 
In terms of clinical effectiveness, the controller response must be analysed in terms of 
its ability to reject or suppress a measured disturbance in the pulse oximetiy by regulating the 
oxygen flow to the patient. Two representative simulation results are provided in Figures 2.7 & 
2.8. They demonstrate the controller response and effectiveness for disturbance frequencies at 
3.2 & 32 mHz respectively. 
The flow controller proved most effective for low frequency disturbances below 10 
mHz (periods greater than 1.5 minutes). The upper plot in Figure 2.7 demonstrates the 
attenuation of SDOT compared against the untreated model (No-OT). From the lower plot in 
Figure 2.7, it is evident that the oxygen flow-rate follows closely in phase with the disturbance 
function at low frequencies. The result is very minor deviations from the target saturation of 
91% using SDOT. In this example, the disturbance with a period of 5 minutes is suppressed by 
better than -17 dB. 
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Figure 2.7: Simulation Results for 3.2 mHz disturbance. Attenuation. = -17dB 
Top: SpO] for SDOT and No-OT, Bottom: O2 Flow-rate plotted with Disturbance 
As the period of the disturbance decreases, the observed suppression also diminishes. In 
the Figure 2.8, the disturbance frequency is 32 mHz with a period of about 30 seconds. Here the 
amplitude of the flow-rate response no longer corresponds with the disturbance function. 
Instead the flow-rate settles around an elevated average value. In high frequency disturbances 
above 32 mHz, the attenuation approaches -6 dB. Note that the SpO; fluctuates with the same 
amplitude in Figure 2.8 despite the SDOT. However, the flow-controller does manage to correct 
the bias of the disturbance to be around 91%. Even with high frequency disturbances, the flow 
controller achieves a mean saturation near the target saturation value. 
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Figure 2.8: Simulation Results for 32 mHz disturbance. Attenuation. = -6dB 
Top: Sp02 for SDOT and No-OT, Bottom: O2 Flow-rate plotted with Disturbance 
Such high frequencies disturbances are assumed to be due to noise or motion artefact, 
and the controller design is intended to help disregard the input signal. As the simulation results 
indicate, the flow controller attempts to find an optimum stable average flow-rate. Combining 
the lowpass Butterworth filter with the non-linear saturation element as shown in Figure 2.3 
successfully regulates the flow-rate output for high frequencies. As previously mentioned, large 
fluctuations in flow-rate are potentially detrimental if their frequency exceeds the patient's 
respiratory rate. 
In Figures 2.9 and 2.10 the outputs of each controller subcomponent (PID, Limit, and 
Filter) have been displayed to show their individual contributions to the final controller O2 
output. Figure 2.9 illustrates the response for a disturbance with a 300s period, while Figure 
2.10 has a much shorter 90s period. As the input disturbance period decreases and approaches 
the feedback time delay, the amplitude of the PID response to the input error signal increases 
causing greater oscillations. This is a known limitation of PID controls in closed loop systems 
with long feedback delays. By capping the PID output within minimum and maximum limits, 
this issue at high frequencies can be reduced. In addition, incorporating the lowpass filter further 
decreases the final output in response to high frequency input disturbances. 
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Figure 2.9: Simulation for 3.2 mHz 
disturbance. Top; Error signal (Target-
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controller O2 output 
Figure 2.10: Simulation for 11 mHz 
disturbance. Top: Error signal (Target- SpO;), 
Bottom: Component terms for controller O2 
output 
These plots depict the transition in flow controller's dynamic response between lower to 
higher disturbance frequencies. A plot of the simulated flow controller's effectiveness as a 
function of frequency is given in Figure 2.11. It shows the closed loop Bode magnitude plot for 
the disturbance rejection. As seen in the two previous examples, the attenuation increases in 
relation to the period of the disturbance. At steady state or at rest, the controller will 
automatically provide the optimum therapeutic oxygen flow-rate. It can then significantly reject 
disturbances with periods greater than a couple of minutes. Even for faster disturbances, the 
flow controller will still correct the bias offset. 
Bode Plot: Effectiveness 
CO - 1 0 
10 
Freq (Hz) 
Figure 2.11: Bode magnitude plot of closed loop disturbance rejection 
(Attenuation in SpO] fluctuations) 
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The simulated closed-loop flow control demonstrates beneficial improvement in oxygen 
saturation, throughout a range of possible disturbance frequencies (10s < period < 15min). 
Potentially eliminating the need for a single prescribed flow-rate, the SDOT is capable of 
automatically respond to a patient's changing needs. 
These preliminary results are representative of the closed loop system behaviour. With 
additional controller refinements the dynamic response may yield further improvement. 
However, it is anticipated the system parameters will be modified to better accommodate patient 
variability not present in this simulation. One step towards this is to input patients' real-time 
pulse oximetiy data as the disturbance function into the simulation. Simulation results based 
upon patient measurements taken during activities, such as sleep, are presented in Chapter 3 to 
provide further insight into the potential effectiveness of the controller. 
2.5 Simulation Parameters and Limitations 
For tuning the control system parameters, the best overall response was obtained by 
iterative tuning the control parameters through trial and error. An example of the closed loop 
system tuning is shown below in Figure 2.12 for an 8 mmHg step disturbance function. The 
lower plot illustrates the oxygen flow-rate rejection response (left axis) together with the step 
disturbance (right axis). In the upper plot of SpOa, the system response and settling time is 
shown. Notice the feedback time delay can also be identified in this plot. Other analytical 
methods for tuning such as the Zieger Nichols method were attempted, however did not produce 
adequate control response. This may be attributed to the nonlinearity inherent to the system 
design particularly in the patient response. Another contributing factor may be the considerable 
time delay in the feedback signal. 
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Figure 2.12: Controller Simulation for disturbance rejection step response 
Top: Sp02 for SDOT, Bottom: O2 Flow-rate plotted with Disturbance 
It must be noted that the patient model parameters have largely been selected based 
upon average values from literature which may limit scope of the results. For instance the lung-
to-capillary time is influenced by several physiological variables such as heart-rate, cardiac 
output, respiratory rate, and shunt fraction. These parameters differ between patients and even 
within the same patient depending on the circumstance. Thus the control parameter may require 
future modification to prevent potential complications not encountered within the data sets such 
as hunting. While these positive results indicate the potential of the closed-loop method, they do 
not provide evidence to the robustness of the technique. 
The simulation approximates the potential effectiveness of the SDOT, however it is 
uncertain how patients will adapt to the responsive therapy. As the oxygen saturation fluctuates 
within the body, the patient will naturally attempt to compensate. The dynamic interaction 
between the flow controller and the patients' homeostatic response will be particularly 
interesting to study clinically. As part of the next phase in development, the PID parameters 
were validated against a database of patient oximetry measurements. Ultimately, clinical data 
from a randomized controlled study with sufficient sample size was carried out to fully 
evaluate the effectiveness of the flow controller. 
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CHAPTERS 
SIMULATION USING PATIENT DATA 
3.1 Overview 
In this chapter actual patient data has been used as the input disturbance to the 
controller simulations. Several modifications to the controller design intended to enhance the 
dynamic response are also presented. The SDOT simulation results are compared to untreated as 
well as standard oxygen therapy models. 
3.2 Introduction to Patient Data Set 
Patient data were obtained from five subjects with COPD during overnight pulse 
oximetry monitoring. These COPD patients were undergoing routine clinical assessment for 
oxygen therapy to detect the presence of nocturnal hypoxia. Measurements were taken using a 
Nellcor N200 pulse oximeter, and values stored locally to a PC at 5 second intervals. 
Recordings were taken over 8 hours while the patients slept. All data were anonymized at the 
clinic prior to the analysis. Of the five recordings, only the three studies illustrated below in 
Figure 3.1 contained significant hypoxic events. Two data sets revealed less than 2% of the 
monitored period with SpOa <90%, and have been excluded from this discussion as no 
supplemental oxygen was required. 
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Figure 3.1: Patient overnight pulse oximetry data sets 
Arterial oxygen saturation measurements from the Nellcor N200 pulse oximeter are 
integer values between 0-100%, with an accuracy of ±2% in the range between 70-100%. The 
pulse oximeter also utilizes a default 5-7 second averaging filter to compensate for any motion 
artefact. From the representative plots shown in Figure 3.1, it is apparent these patients 
experienced large fluctuations in their oxygen saturation. The percentage of the monitored time 
found with Sp02 <90 was 55%, 27%, and 12% for patients 1, 2 and 3, respectively. 
To incorporate the patient recordings into the controller simulation, the data sets were 
resampled to 1 Hz using linear interpolation. The patient data was transformed from SpO] to the 
corresponding PaO] using the inverse of the general Severinghaus oxyhaemoglobin dissociation 
relationship. Then this PaO] value is subtracted by 60 mmHg to obtain a net disturbance 
waveform for the computer simulation. Thus these patient disturbance signals retain all the 
challenges associated with real-time physiological measurement such as signal noise and 
artefacts. Evaluating the controller response to these actual patient measurements will provide 
much greater insight into the predicted effectiveness of implementing a closed loop flow-rate 
system. 
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3.3 Modifications to Controller Simulation 
Incorporating the patient pulse oximetry recordings required two key design changes to 
accommodate the natural variety inherent in the 8 hr patient disturbance signals. Modifications 
were necessary to the preliminary controller design illustrated previously in Chapter 2, Figure 
2.3. The two fundamental improvements discussed in this section are an anti-windup control 
scheme, and a phase compensator. 
Integrator windup is a condition which can result when a hard non-linearity such as a 
maximum or minimum limit is used to constrain the final output of a PID controller. In the case 
of the oxygen flow-rate controller, these limits have been set between 0 and 5 1/min. If the 
controller is unable to correct the input error signal because the output has reached a limit, the 
integral component will nevertheless continue to increase without bound. This can result in limit 
cycling or even instability. To eliminate the issue of integrator windup, an internal positive 
feedback (Kc) has been added. Below in Figure 3.2 each element of the proportional-integral-
derivative controller is now shown explicitly. Any difference between the summed PID output 
and the controller output after limits and filtering is fed back to the integrator. This 
configuration places a cap on the integral component when either a maximum or minimum limit 
is reached to prevent any instability. 
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Figure 3.2: Adapted SDOT controller diagram 
The second modification which has been added to improve the PID controller response 
is a phase compensator (C). From the results presented previously in Figure 2.10, it is clear that 
for high fi-equencies the controller flow-rate response lags behind the input disturbance. This 
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was increasingly significant as the period of the disturbance became shorter causing the 
response to become increasingly out of phase with the disturbance. Using the transfer function 
for C(s) shown in Eqn.lO, it is possible to create a positive phase shift within a select frequency 
range. 
(1 + aTs) 
C ( ^ ) 
(1 + 7 5 ) (10) 
Where a > 1 
The size of the phase shift is determined by the variable a. Using the variable T, the phase 
compensator can be tuned to a desired frequency range. The best overall response was obtained 
from the flow-rate controller through further iterative parameter optimizations. The phase 
compensation is set around the initial region of lag caused by the lowpass filter. 
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Figure 3.3: Phase compensator bode plot 
Figures 3.4 and 3.5 compare the controller response before and after incorporating the 
phase compensator. In this example the phase shift can be seen between the lower plots of the 
flow-rate responses. The flow-rate in Figure 3.5 leads in phase with the 10"^  Hz disturbance as a 
result of the phase compensator. This effect produces an additional significant attenuation to the 
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Sp02 fluctuations. While the previous configuration produced an attenuation of-10 dB, the 
controller with a phase compensator achieved -15 dB for the same disturbance. 
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Figure 3.4: Controller response without Figure 3.5: Controller response including phase 
phase compensator. Attenuation = -10 dB compensator. Attenuation = -15 dB 
In Figure 3.6, the improved response performance is shown across the range of 
frequencies. As expected, the phase compensator has the greatest impact near the region of 
maximum phase shift. 
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Figure 3.6: Comparison Bode magnitude plot 
3.4 Controller Response to Patient Data 
Typical results are shown in Figure 3.7 where the original SpO] recording is displayed 
together with the SDOT results. As the saturation falls below the 91% setpoint, the controller 
responds by increasing the O2 flow-rate. Whenever the saturation rises above the set point, the 
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controller then decreases the O2 flow-rate. Overall the controller response can rapidly react to 
compensate for fluctuations in the patient SpO] and reduce the extent and severity of 
desaturation events. 
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Figure 3.7: Typical section of controller simulation results; 
Top: Simulated pulse oximetry of SDOT (solid line) vs. Patient Recording (dotted line); 
Bottom: Simulated Oxygen flow-rate 
A summary of the effectiveness of the controller is presented in Table 3.1. The SDOT 
group represents the results of automatically regulating the O2 flow-rate via the closed-loop 
controller. The effect of Constant-Flow LTOT was also simulated, using an oxygen flow-rate 
normalized with respect to the mean flow during SDOT to yield equivalent total oxygen 
consumptions. For each simulated therapy, the percent of time spent with hypoxemia (saturation 
less than 90%) was calculated. The percentage of time spent with hypoxemia for SDOT was 
compared with both the original untreated data, and that predicted with constant flow LTOT. 
The simulation results indicate the potential benefits of implementing closed-loop oxygen flow 
control, Figure 3.8. On average among the three patients, SDOT reduced the time spent with 
arterial blood saturation below threshold by 76% (range 58-86%). Moreover, given the same 
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amount of oxygen, SDOT produced a 63% (range 36-79%) improvement compared to 
conventional Constant-Flow LTOT. Such results highlight the improved efficacy of the closed-
loop control method. The judicious regulation of oxygen consumption will likely also lead to 
cost-efficient conservation benefits. 
Table 3.1: Comparison of Therapies 
Group Variables Patient 1 Patient 2 Patient 3 
iVo-OT Mean Overnight SaOj (%) 88.8 91.8 9.S.1 
Standard Dcv SaOa (9(i) •1.6 2.3 .1.3 
Percent Time vw' SaOi < 90 (%) 55.1 27..1 12.1 
Recording Duration (min) IR3 18.1 •183 
SDOT Mean Ovemipht SaOi (%) 91 92.5 95.1 
Standard Dev SaO, (%) 2.6 1.6 2.7 
Percent Time vw' SaO, < 90 (%) 22.9 1.3 1.8 
Mean How-rate (l /min) 2 J 0.9 0.1 
0> equivalent Canst-LTOT Mean Ov-emight SaO^ (%) 90.7 92.3 95.3 
Standard Dev SaOi (%) X7 2.1 3.2 
Percent Time vw' SaO^ < 90 (%) .36 15.9 8.5 
Therapy Comparison 
Patient 1 Pat ient 2 Pat ient 3 A v e r a g e 
• No Oxygen • Fixed Flow • SDOT 
Figure 3.8: Comparison graph; patient data results 
3.5 Discussion 
The results of these simulations provide ftirther preclinical evidence of feasibility and 
potential benefit possible through a system for Saturation Driven Oxygen Therapy. The results 
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indicate an improvement in the total time spent with hypoxemia for each patient compared with 
the standard fixed flow oxygen therapy. 
These results from the over-night sleep simulations are further supported by the 
sinusoidal frequency sweep analysis performed earlier. A closer inspection of the measured 
Sp02 found in Fig 3.7 can demonstrate the range of constituent frequencies found within the 
patient overnight oximetry. For instance, a predominant disturbance period observed in the Fig 
3.7 is between 45 to 60 seconds, which lies within the range of the system frequency analysis. 
Although the limited sample size can not provide any statistical significant comparative 
analysis, the chief basis for this evaluation was to validate the capability of the controller design 
to quickly and accurately match the oxygen delivery to meet the real-time patient need 
measured by Sp02. In the subsequent chapters, clinical results are presented from a randomised 
pilot study conducted at the Royal Brompton Hospital which compares SDOT to conventional 
oxygen therapy during standardised exercise assessments. 
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CHAPTER 4 
CLINICAL METHODOLOGY 
4.1 Pilot Study Overview 
In a supervised on-site clinical study at the Royal Brompton Hospital, we used 
continuous Sp02 measurements to actively control O2 flow rates. For the clinical study an 
investigational device was constructed to evaluate clinically the efficacy of the Saturation 
Driven Oxygen Therapy control method. 
The SDOT device was evaluated against constant-flow LTOT during exercise. A 
standardised exercise test was selected to achieve activity dependent O2 fluctuations between 
exercise and rest. In practice, the controller will have to manage quickly changing saturations 
such as during exercise as well as more gradual shifts in saturation. In this pilot study, fifteen 
patients were enrolled to participate in the exercise assessments. During the study, eveiy 
participant will receive each therapy once in a random order to act as his or her own control. 
4.1.1 Patient Selection 
COPD patients were recruited from the Academic Unit for Sleep and Breathing at the 
Royal Brompton Hospital, or through direct referral from their local GP. All patients were 
recruited on the basis of willingness to participate, and as volunteers they could choose to drop 
out at any time. Specifically participants had to show evidence of moderate to severe airflow 
obstruction, and self-reported exercise limitation due to breathlessness. 
Patient Inclusion criteria: Diagnosis of COPD fulfilling standard LTOT criteria. All ages. 
Patient Exclusion criteria: PaOi <6.0 kPa, PaCO^ > S.OkPa, on air. Exacerbation of COPD 
within last 4 weeks, unstable cardiovascular disease, unable to participate in shuttle walk, 
communication problems making it impossible for the patient to understand the study. 
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4.1.2 Investigational device 
For investigation purposes the controller was implemented using a PC with serial 
connections to read measurements from a pulse oximeter and output a signal to a flow regulator. 
Figure 4.1 illustrates the feedback controller schematic. A microprocessor receives 
measurements from a pulse oximeter and automatically computes the optimum oxygen flow-
rate. The controller outputs a signal to a programmable flow valve regulating the delivery of 
oxygen to the patient. An oxygen saturation target (91%) was to be maintained by changing the 
flow-rate subject to feedback from the pulse oximetry. The device can be used in conjunction 
with standard O2 gas cylinders, or O2 concentrators. 
Patient 
Concentrator 
Flow Regulator 
Ear Sensor 
Controller 
Pulse Oximeter 
Figure 4.1; SDOT, closed-loop controller schematic 
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Table 4.1: Investigational device component list 
Component Model Manufacturer 
Laptop (controller) 
USB to Serial Comm. 
Serial Cable 
Pulse oximeter 
Oximeter sensor 
Flow regulator 
Latitude C800 
USB-2COM-PL 
RS232 DB9F-DB9F 
N200 
DYSE 
MC-5SLPM-0/5M, RIN 
Dell 
EasySync 
Belkin 
Nellcor 
Nellcor 
Alicat Scientific 
In the hospital, the oxygen source was provided via piped oxygen. As with conventional 
oxygen therapy, a manual flow valve is incorporated in series with the automated flow 
controller. The purpose of this valve is to guarantee the oxygen flow rate does not exceed 5 
1/min. Only the Nellcor pulse oximetry & sensor was in electrical contact with the patient, and 
the Nellcor N200 unit thereby establishes an isolated circuit within the system. To minimize the 
effect of motion artefact, the default 5-7 second signal averaging mode was used. A laptop PC 
was used as the controller. In addition to the automatic feedback mode (SDOT), the controller 
has a constant mode (Cons) which delivers the standard fixed flow rate oxygen therapy. The 
flow diagram for the investigational device control software programme is given in Figures 4.2, 
4.3 and 4.4. Upon initiation of the investigational device Matlab programme, the device enters a 
Calibration mode as detailed in Figure 4.2. The Calibration mode verifies the component 
communications and prompts the user for the study parameters. After completing the 
Calibration mode the programme enters into the appropriate therapy mode, either SDOT or 
Cons as selected by the computer. For reference the detailed software code has been included in 
Appendix A.4. 
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Start Up & Calibration 
Turn on computer & 
Launch SDOT 
Turn on Pulse Oximeter 
& Flow Regulator 
Open Manual Flow 
Valve to 5 1/min 
Operator: > Start 
calibration sequence 
1. Test comm. to N200 
2. Test comm. to Flow Regulator 
3. Cycle 02 flow from 0 - 51pm 
4. Shut 02 flow 
Place Sp02 sensor and 
nasal cannula on patient 
Enter study ID, default flow rate ,^ and 
select study type and assessment 
If appropriate, input Sat Target (default 91%) 
If appropriate, manual over-ride 
randomized therapy 
Operator: > Start 
Controller 
Manual 
over-ride 
Prior 
Assessment 
Controller calibration 
sequence 
Check for prior data 
(Cannot Overwrite)^ 
Initiate therapy 
(SDOT or Cons) 
Check operator input 
values 
Manually over-ride 
therapy selected 
^ ' 
Operator: > Enter 
patient study info' 
1®': Randomly select 
therapy (SDOT or 
2° : Choose alternate 
therapy (SDOT or 
Notes. 'Error prompts are be provided if operator input is out of range. Program will not proceed. 
^Default flow-rate for Cons therapy as determined from Patient resting prescription. 
^Program cannot over-write prior study data. Controller will shutdown. 
Figure 4.2: Flow diagram for investigational device program; Calibration mode 
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SDOT Mode 
Update new flow-rate 
value 
Write data to file 
(Time, Sp02, Flow) 
Pause program 
execution^ 
Timer restarts program 
execution (at 1 Hz) 
Read Sp02 from N200 
pulse oximeter 
Compute difference 
(Target - Sp02) 
Step through PID 
algorithm 
Check status of flow 
regulator 
Update on-screen 
display' 
Check for missing or 
erroneous value 
1. If missing value, replace with prior 
2. Impose min/max limits 100 — 50% 
1. Sum PID components 
2. Pass through phase compensator 
3. Impose min/max limits 0 — 51pm 
4. Low pass filter 
1. Read 02 flow-rate 
2. Compare to desired value 
3. If difference greater than 10% full range, 
end program 
Notes. 'Missing values will display on screen and in file as % symbol. Pulse oximeter alarm will alert 
operator. 
^Operator terminates program by selecting Stop Button. Otherwise, loop runs indefinitely. 
Figure 4.3: Flow diagram for investigational device program; SDOT mode 
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CONS LTOT Mode 
Check for missing or 
erroneous value 
Update on-screen 
display' 
Read Sp02 from N200 
pulse oximeter 
Check status of flow 
regulator 
Update default 
flow-rate value 
Write data to file 
(Time, Sp02, Flow) 
Pause program 
execution^ 
Timer restarts program 
execution (at 1 Hz) 
1. If missing value, replace with prior 
2. Impose min/max limits 100 - 50% 
1. Read 02 flow-rate 
2. Compare to default value 
3. If difference greater than 10% full range, 
end program 
Notes. 'Missing values will display on screen and in file as % symbol. Pulse oximeter alarm will alert 
operator. 
^Operator terminates program by selecting Stop Button. Otherwise, loop runs indefinitely. 
Figure 4.4: Flow diagram for investigational device program; CONS mode 
A more detailed Instruction For Use and schematics of the investigational SDOT device 
can be found in the instructions for use (Appendix A.2). 
4.1.3 Safety & Risk 
This project involved the assimilation between two non-invasive, clinically approved 
devices. The system configuration was in compliance with the instruction for use of all the 
incorporated CE Marked devices. The device was not likely to create any patient safety issues, 
as the controller only delivers oxygen as determined by O2 saturation measured with pulse 
oximetry. There were no additional side-effects for the feedback flow-rate controller beyond 
those of conventional oxygen therapy. There was a theoretical risk with oxygen therapy of 
increasing the patient's carbon dioxide levels but this risk was thought to be minimal during the 
acute period of the study. In addition, continuous monitoring of patient vital statistics during the 
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study period was supervised by the present research doctor or physiotherapist. Nevertheless, the 
controller design had to guarantee an acceptable range of flow-rates, approximately between 0 
to 5 1/min, and demonstrate the safe operation in routine clinical use. Furthermore the 
investigational device testing demonstrated compliance with medical systems standard, lEC 
60601.1. Ultimate confirmation of compliance with lEC 60601.1 and Annex 1 of the Medical 
Device Directive was obtained from the Medical Engineering department at the Royal 
Brompton Hospital as final approval to use the investigational device. In addition, listed below 
in table 4.2 is a device risk analysis / failure modes effect analysis for the investigational device 
as per ISO14971. 
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4.1.4 Protocol Summary 
We identified two commonly used standardized exercise tests known to incur potential 
conditions where oxygen levels change 1) Incremental Shuttle Walk Test (ISWT) and 2) Six 
Minute Walking (6MW) test. Both tests are routinely clinically used to determine exercise 
ability, and will be discussed in more detail in the following chapters. 
A total of fifteen patients fulfilling criteria for LTOT assessment [40,41] at the Royal 
Brompton Hospital with stable COPD were recruited to assess the efficacy of conventional 
oxygen therapy (CONS) and saturation driven oxygen therapy (SDOT). This involved wearing 
a pulse oximeter, a small finger or ear probe attached to a small box about the size of a shoe box 
to give feedback to a computer regulating the oxygen supply. During CONS the computer 
programme was given the patient's normal prescribed flow rate, and did not change the flow 
setting of oxygen mimicking standard oxygen therapy. During SDOT, the computer programme 
regulated the oxygen flow depending on the patient oxygen saturation. Repeated assessment 
with CONS and SDOT took place during either 1) an exercise shuttle walk test (the normal test 
to assess for portable oxygen therapy) or 2) a six minute walk test. 
To avoid any researcher bias, every participant received each therapy once in a random 
order to act as his or her own control. The order of treatment will be chosen at random by the 
computer (envelope allocation). As to minimize any travel inconvenience, the repeated field 
walking tests were conducted on the same visit. As COPD patients may not remain stable over 
long periods, this also helped to avoid the possibility of a change in the patient's condition. A 
study protocol flow diagram has been included in figure 4.5 to illustrate the various stages 
during each patient study. 
Field shuttle walk tests are routinely used as simple clinical assessments of a patient's 
disability. A 10 m shuttle course is outlined along a flat hospital corridor. Patients are instructed 
to walk along the course, turning around at either end until too tired or breathless to continue. 
For practical purposes, a maximum cut off time is specified. For the ISWT it is recommended to 
do a complete practice test, as this stops a learning effect ensuring the results are valid and 
reproducible. Despite being relatively simple, these tests have been shown to provide a 
quantifiable measure of improvement following rehabilitation [42]. 
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Both the ISWT and 6MW are routine assessments conducted to establish the patient 
requirement for oxygen therapy with minimal risk of adverse events. The two therapies (CONS 
and SDOT) were compared for the presence and duration of low oxygen saturation periods 
using the outcome measures: mean SpO], min Sp02, percent time spent with SpO^ < 90%, and 
exercise tolerance, heart rate variation and visual analogue score during shuttle walk, time to 
recovery, and total distance walked. This monitoring also ensured the safety of participants 
throughout the study. 
The subjects were evaluated under both CONS and SDOT. This allowed crossover 
analysis with subjects acting as their own controls. The parametric data were assessed using 
either a Paired T-test with a two sided P value or a Wilcoxon Signed Rank Test, if data were not 
normally distributed. Based upon the estimated clinically significant difference of 20% in the 
treatment efficacy and assuming a measurement variance of 15%, the minimum required sample 
size to achieve p=0.05 was nine subjects. This sample size was then augmented to 15 subjects, 
including a margin for patient exclusion and drop-out. 
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stage 1: Patient 
selection 
Stage 2; Default 
flow-rate 
Stage 3; Device 
calibration & 
Practice walk 
Stage 4; Blind 
treatment 
selection & 
cross-over 
study 
Stage 5: Data 
analysis and 
conclusion 
Patient 
enrolment 
Startup/ 
calibration 
procedure 
Rest 
period 
Randomized 
treatment 
alocation 
Rest 
period 
Data 
collection and 
comparison 
Practice walk 
Subject 
evaluation; 
CONS 
Subject 
evaluation: 
CONS 
Subject 
evaluation: 
SDOT 
Subject 
evaluation: 
SDOT 
Determine Subject resting 
oxygen flow-rate 
Figure 4.5: Study protocol flow diagram 
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4.2 Project Significance 
Patients may derive additional symptomatic relief from the optimized LTOT, and gain 
increased exercise ability and/or improved sleep quality. Ultimately, minimizing periods of 
hypoxemia could improve survival and quality of life for patients, while reducing over-supply 
may reduce the risk of hypercapnia during acute exacerbations, and improve the efficiency of 
oxygen delivery. The extent of the short-term benefits will become apparent from the clinical 
results of the randomized crossover pilot study. 
4.3 Research Ethics Committee Approval 
For the clinical research conducted at the Royal Brompton Hospital NHS Trust, ethics 
permission to conduct research utilizing human participants was obtained from the relevant 
local Research Ethics Committee. Imperial College of London with the National Lung and 
Heart Institute agreed to act as the Research Sponsor. In addition to standard NHS indemnity 
cover, additional cover was granted by Imperial College's Zurich Municipal clinical trials (non-
negligent harm) policy: number NHE-OlCAlO-0013. Public Liability (negligent harm) cover 
was also provided for Imperial College under this policy reference number. 
The Research Ethics Committee Application was submitted for the clinical portion of 
the study as of 12 of September, 2005 (COREC REF 05/Q0404/102). It was reviewed by the 
Brompton, Harefield and NHLI Local Research Ethics Committee on their October 3"^^ meeting. 
A favourable decision from the committee was given on 27 October 2005 and the study period 
commenced on Jan T' 2006. The project entitled "Active Flow-Rate Feedback Control For 
Long-Term Oxygen" was then assigned a Research and Development Project Number 
(2005LF016B) with the Royal Brompton Hospital. A copy of the ethics approval letter is 
provided in Appendix A.3. 
4.4 Resources 
In 2005, grant applications were made for this project to the British Lung Foundation as 
well as the BUPA Foundation. These initial project grant proposals included an additional 
provision for crossover sleep studies comparing SDOT to standard oxygen therapy. The ethics 
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approved study protocol provided for both exercise and sleep assessment. Unfortunately the 
project grant applications were not awarded. Subsequently, the grant eventually obtained from 
the Clinical Research Committee at the Royal Brompton Hospital provided sufficient resource 
only for the exercise assessments. The sleep studies required continuous overnight monitoring 
that was too labour and cost intensive given present funding. This necessary change did not 
affect the main outcome of the pilot study, evaluating the method feasibility and impact. 
The Clinical Research Committee Grant was awarded for this project from the Royal 
Brompton Hospital in May 2006. The grant amount awarded of £4,052 was to cover a portion of 
the clinical phase of this project. The bulk of the resources were allocated for part-time staff. A 
Senior I Physiotherapist or equivalent Medical Technical Officer 3 (Band 7) at the Royal 
Brompton Hospital assisted by enrolling patients and conducting the shuttle walks. This 
temporary part-time staff member was required for up to a total of 120 hrs (up to 30 clinical 
sessions). The remaining expenses were to cover costs for a custom oximetry sensor required 
for the pilot investigation and related consumables. A small fund was also requested to cover 
the travel costs of the patients. 
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CHAPTER 5 
INCREMENTAL SHUTTLE WALK TEST 
5.1 Overview 
Chapter 5 presents the outcomes of the incremental shuttle walk tests. The analysis is 
first illustrated as a case study, with reference to one representative patient. Then the group 
trends and statistics are discussed. 
5.2 Introduction to ISWT 
During the pilot study the initial seven patients were evaluated using the standardized 
Incremental Shuttle Walk Test (ISWT) according to the protocol established by Singh and 
Morgan [43]. During the test patients are required to walk at progressively incrementing speeds 
along the 10 meter course. The standardized instructions and audio signals for determining 
walking speed are available on CD. With each minute the walking speed is increased as shown 
in Table 5.1. Patients are requested to continue the test until either unable to maintain the set 
pace or too breathless to continue. 
Table 5.1: Protocol for ISWT 
Level Speed (m/s) Time/shuttle (s) Laps/shuttle Total laps Total distance (m) 
1 0.50 20.00 3 3 30 
2 0.67 15.00 4 7 70 
3 0.84 12.00 5 12 120 
4 1.01 10.00 6 18 180 
5 1.16 8.57 7 25 250 
6 1.18 7.50 8 33 330 
7 1.52 7.67 9 42 420 
8 1.69 6.00 10 52 520 
9 1.86 5.46 11 63 630 
10 2.03 5.00 12 75 750 
11 2.20 4.62 13 88 880 
12 2.37 4.29 14 102 1020 
The ISWT was recently incorporated as part of the prescription guidelines for 
prescribing ambulatory oxygen therapy in England and Wales [41]. The guidelines stipulate that 
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when using the ISWT, a practice walking test is necessary to eliminate any learning affect and 
recommend a rest period of 30 minutes be given between tests. The aim of the exercise 
assessment is to evaluate the need for ambulatory oxygen and assess the appropriate oxygen 
flow-rate to prevent exercise hypoxemia. 
Using the SDOT investigational device, we evaluated the automatic method to regulate 
O2 flow rate in response to changes in arterial oxygen saturation. This was compared to standard 
constant flow oxygen therapy (CONS) during an ISWT in the double blind crossover study as 
described previously in Chapter 4. 
5.3 ISWT Group 
One of the initial seven oxygen therapy patients enrolled into the pilot study was 
subsequently excluded due to inadequate exercise ability. While meeting the study enrolment 
criteria. Patient No. 006 (age 69, FEV, 21.4% predicted) proved consistently unable to keep 
pace with even the slowest pre-recorded speeds. 
The remaining six patients (3 males & 3 females, mean age 57.5, range 51-68 years, 
mean FEVi 25.6% predicted) carried out repeated ISWT while receiving SDOT or CONS 
oxygen delivery in random order, with approx. 45min rest between tests. Table 5.2 contains a 
summary of the ISWT group baseline lung function taken just prior to commencing the study. 
Heart-rate, SpO], and O2 flow were recorded initially from rest until 5min after completing the 
ISWT. The total distance walked was noted, and participants ranked breathlessness using a 
modified Borg score before, immediately after, and 2 min post the ISWT. 
Table 5.2: ISWT Group age and lung function data (n = 6) 
Variable Mean Range 
Age (yrs) 57.5 51-68 
FEV, (% predicted) 25.6 12-49 
FEV,/FEC (%) 61.7 43-83 
Resting SpO] on LTOT (%) 95.6 92-99 
Prescribed O2 flow rate (1pm) 1.3 1-2 
In the ISWT group of patients, the SDOT system configuration and parameters 
remained unchanged to that used in the simulation presented in Chapter 3. For all of the studies 
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a target value of 91% saturation was set during SDOT mode. During the CONS mode, the 
patient prescribed flow rate was entered as the default oxygen flow. 
5.4 Results 
As per the study protocol described in Chapter 4, every patient repeated the ISWT a 
total of 3 times: one practice followed by SDOT and CONS modes in random order. To reflect 
the various active phases within each ISWT, the data sequence for each test was segmented into 
four sections: Baseline, Preparation, ISWT, and Return. The data recording and segmentation 
for one representative practice test is illustrated in Figure 5.1. The results for this patient will be 
described in detail to exemplify the analysis used. Each test sequence begins by capturing 
several minutes of baseline data (Baseline) while the subject remains at rest. The recordings 
continue uninterrupted as the participant prepares (Prep) for the ISWT until a few minutes after 
completing the walk (Return). For the ISWT group, there were no periods of missing data from 
the pulse oximeter. Minor signal noise probably associated with motion artefact, a known 
limitation of pulse oximetry, was most pronounced in the heart rate measurements. 
100 
OJ 
O 
Q . 
CO 
9 0 
80 
O 
LL 
Baseline Prep ISWT Return 
- L „ . 1 150 
' ^ E 
Q . 
-
Vva 
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ro cr 
1 1 1 1 f 1 1 1 1 1 
100 s % 
) 2 4 6 
-
1 1 1 
8 
1 
10 12 14 
T i m e ( m i n ) 
1 1 1 
16 18 20 22 
1 I 1 1 
) 2 4 6 8 10 12 14 
Time (min) 
16 18 20 22 
Figure 5.1: Practice ISWT on CONS, segmented to reflect activity (Patient No. 002) 
Top; SpO] and heart rate vs. time. Bottom: O2 flow rate vs. time 
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This data sequence remained similar across all patients and is characteristic of the 
profile seen during an ISWT while receiving a constant fixed flow of oxygen. To evaluate 
reproducibility and accuracy, data from the practice test was compared to the CONS test shown 
in Figure 5.2. As expected, the traces have similar profiles qualitatively as a result of the known 
reproducibility of the ISWT [43]. 
Baseline ISWT Return 
E 
Q. 
30"° 
120 ro 
1 1 0 ^ 
100 m 
8 10 
Time (miih 
Figure 5.2: ISWT on CONS, segmented to reflect activity (Patient No. 002) 
Top: SpO] and heart rate vs. time. Bottom: O2 flow rate vs. time 
At rest the patient saturation remains well above the hypoxic threshold. The 
supplemental oxygen effectively raises the FIO2 to prevent any desaturation. The heart rate is 
also at a minimum while resting. Then as the patient transitions from rest and begins the ISWT, 
the oxygen demand progressively increases with activity. In conjunction with the increased 
activity, the heart rate and breathing rate will also increase. Unfortunately, during fixed flow 
oxygen therapy the FIO2 is inversely proportional to breathing rate. Hence the exercise causes a 
decline in FIO2, which is compounded with the increased oxygen demand and results in 
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progressively worsening desaturation throughout the ISWT. Once the test is completed and the 
patient is at rest, the Sp02 and heart rate slowly return to their baseline values. 
In contrast to the characteristic data sequence observed in CONS mode, the profile of 
the SDOT mode is markedly different. Figure 5.3 represents test data from the SDOT mode in 
the same patient (Patient No. 002) as in Figures 5.1 & 5.2 above. The SDOT data demonstrates 
that the decline in oxygen saturation (Sp02 below 90%) triggered a response from the control 
system to increase the oxygen flow. Consequently, the SDOT mode was able to better match the 
oxygen supply to the measured oxygen demand. To better understand the differences between 
SDOT and CONS, a detailed case study of the segmented data analysis for Patient No. 002 is 
presented in the next section. 
Baseline ISWT 
8 10 12 
Time (min) 
Figure 5.3: ISWT on SDOT, segmented to reflect activity (Patient No. 002) 
Top: SpO] and heart rate vs. time. Bottom; O2 flow rate vs. time 
5.4.1 Case Study of Segmented Data Analysis 
Table 5.3 contains a list of the ISWT scores from Patient No. 002. The ISWT was 
conducted a total of three times, one practice and once per therapy in random order as per 
protocol. During the practice walk the total distance walked was 360m. In the following two 
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walks the distance only differed marginally between SDOT and CONS therapies, 490m and 
450m respectively. The difference observed between the first practice walk and subsequent 
shuttle walks agrees with the initial learning effect noted in the literature [43]. A Borg score was 
used to indicate the participant's breathlessness (1-10) before, immediately after, and 2 min post 
ISWT. The Borg scores were lowest while at rest, reached a maximum immediately following 
the ISWT, and quickly fell after the 2min recovery period. These Borg scores also reported no 
substantial differences between the two modes. 
Table 5.3: ISWT Borg scores (Patient No. 002) 
Test Resting Post ISWT 2min Post ISWT Distance 
Practice 0 3 1 360m 
r ' (SDOT) 0 5 2 490m 
2"'^  (CONS) 0 5 1 450m 
Baseline Sesment 
During the baseline period the two modes reveal their ftindamental difference. The 
CONS mode is set to deliver a fixed flow rate of 1 1pm. However, while the subject remains at 
rest his demand for oxygen is at a minimum. In fact, on air this participant displayed no 
requirement for supplemental oxygen while at rest. Consequently the mean SpO; during CONS 
mode was 99.0 ± 0.8 %. 
In contrast the SDOT mode is configured to maintain the saturation above the target 
setpoint 91%. Analysis of the baseline saturation during SDOT reveals the subject SpO] 
averaged 96.9 + 0.5 %. Since the subject remained at rest, with a healthy saturation, no oxygen 
was required. The mean flow rate during SDOT therapy was 0.1 ± 0.1 Lpm. No substantial 
difference was observed in the heart rate between the two therapies. 
Table 5.4; Baseline data values (Patient No. 002) 
Mode Flow (Ipm) SpOz (%) Heart Rate (bpm) 
mean ± SD mean ± SD mean ± SD 
SDOT 0.1 ± 0.1 96.9 ± 0.5 101.4 ±4.2 
CONS 1.0 ±0.0 99.0 ± 0.8 98.0 ± 2.5 
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Preparation Segment 
When the participant transitions between rest and starting to exercise, a repeatable 
pattern can be seen in each recording. The data recording is shown in Figure 5.4. First the heart 
rate elevates from the baseline of 100 bpm to over 110 bpm. This is followed by a minor decline 
in the Sp02. In the case of CONS mode the Sp02 decreases steadily to a minimum of 98%. In 
the case of SDOT, the SpO] decreases to a minimum of 94%. Since this remains above the 
setpoint of 91%, no response was triggered by the controller. The flow during this period using 
SDOT was 0.2 ±0.1. 
CONS SDOT 
100 100r 
CN 9 5 CM 9 5 
Q. 110 Q. 110 
lY 100 0^ 100 
100 
100 
5 0 
Time (s) 
5 0 
Time (s) 
100 
Figure 5.4: Preparation data segment (Patient No. 002) 
Left; CONS mode plots (Red), Right: SDOT mode plots (blue) 
ISWT Seement 
During the exercise walks, the participant experiences a systematically increasing 
demand as the walking speed rises each minute. This increase is evident in the increasing heart 
rate during the course of the walks shown in Figure 5.5. While both modes demonstrated this 
trend, there were subtle differences in the mean and maximum heart rates. While on CONS the 
mean heart rate was 122 ± 11 bpm with a maximum of 146, and on SDOT the mean was 121 ± 
11 bpm with a maximum of 141. 
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Tal )le 5.5: ISWT values (Patient No. 002) 
Therapy Mean heart 
rate (bpm) 
mean ± SD 
Max heart 
rate (bpm) 
Mean SpOz (%) 
mean ± SD 
Min SpOz (%) Max flow (Lpm) 
SDOT 
CONS 
121 ± 11 
122 ± 11 
141 
146 
92.0 ± 2.9 
92.6+ 4.4 
86 4.2 
1 
In comparing the Sp02 data during the ISWT, more differences are apparent between 
the two therapies. Although the mean arterial oxygen saturation were not substantially different 
at 92.6 ± 4.4% (CONS) and 92.0 ± 2.9% (SDOT), the standard deviation for CONS mode (4.4%) 
was greater than that of SDOT mode (2.9%). This is further confirmed in the minimum Sp02 
which was 84% for CONS and 86% for SDOT. A closer inspection of the SpO; profile indicates 
that the saturation in CONS mode steadily decreases over the course of the ISWT, finally 
reaching 80% immediately following the ISWT. In contrast, the SpO; profile during SDOT 
mode shows evidence of oscillating around the setpoint. This oscillation, which is not seen in 
either the CONS ISWT or the practice ISWT, must be attributed to the variable oxygen flow. 
The maximum flow during SDOT therapy was 4.2 1pm. 
CONS SDOT 
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Figure 5.5: ISWT data segment (Patient No. 002) 
Left: CONS mode plots (Red), Right; SDOT mode plots (blue) 
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On CONS mode the subject appeared to have a greater extent of hypoxemia as 
compared to the SDOT mode. To quantify this more accurately, we developed a measure of the 
Total Oxygen Deficit (TOD). The TOD represents the aggregate amount of hypoxemia by 
summing together the difference between the 90% threshold and each SpO; <90%. This 
measure also incorporates the depth of desaturation during a hypoxemic event as well as time. 
end 
Total Oxygen Deficit = ^ [90 - (Sp02 (0 < 90%)] 
/ = 0 
The corresponding values for the Total Oxygen Deficit highlight a potential key difference 
between the two therapies. During CONS mode the TOD calculated over the ISWT period 
together with the Return period = 751. The same calculation for the SDOT mode reveals a TOD 
of 259. The ratio of these two figures is approximately 3:1. By plotting the two therapies 
together we can better illustrate this key difference as shown in Figure 5.6. The difference in 
TOD is a consequence of the diminished time with Sp02 <90% as well as the lesser degree of 
hypoxia. 
While the TOD ratio is indicative of the improved matching between oxygen demand 
and supply, the SDOT mode has potential to be further refined. An oscillatory behaviour of the 
SDOT therapy is clearly evident in Figure 5.6, as the oxygen flow and saturation fluctuate about 
the target setpoint. This issue is presented in detail in Chapter 6 together with the associated 
system refinement. 
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Figure 5.6: Mode comparison - ISWT and Return data segments, 
CONS mode plotted in Red and SDOT mode plotted in blue, 
Top: SpO], Middle: Heart rate. Bottom: Flow rate 
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Return Seement 
This was the period of greatest difference between the two modes. A measure of 
recovery time was taken from the completion of the exercise test until the SpO] rose above 90%. 
The recovery time for the subject's SpO] was substantially improved with SDOT. The recovery 
time for CONS was 78s vs. 35s for SDOT mode. It also took significantly longer for the subject 
to return to mean baseline SpO; on CONS mode at 193s as compared to 109s with SDOT mode. 
Once at rest, as the subject returned to baseline, the SDOT mode also responds by decreasing 
the oxygen flow once it is no longer required. 
CONS SDOT 
100 100r 
CN 90 CM 9 0 
100 2 0 0 3 0 0 
CL 140 
rr 120 
100 2 0 0 3 0 0 
100 200 
Time (s) 
3 0 0 100 200 
Time (s) 
3 0 0 
Figure 5.7: Return data segment (Patient No. 002) 
Left; CONS mode plots (Red), Right: SDOT mode plots (blue) 
Table 5.6: Saturation recovery times (Patient No. 002) 
Therapy Sp02 < 90% Return to baseline 
SDOT 35s 109s 
CONS 78s 193s 
Please refer to Appendix A.l for individual case report summaries from each subject 
enrolled in the ISWT group. 
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5.4.2 ISWT Patient Group Results 
Several of the trends presented in the case study of Patient No. 002 are representative of 
the overall results observed in the ISWT Group. A complete table of the parametric data 
computed for patients in the ISWT Group is presented in Table 5.7. 
Table 5,7: ISWT Group parametric data 
Patient 1 Patient 2 Patients 
Variable SDOT CONS 1 SDOT CONS SDOT CONS SDOT CONS SDOT CONS SDOT CONS 
"lUlean Sp02 at 
Baseline (%) 94.1 96.9 96.9 99 96.7 97.5 92 95.4 90.5 92 92.2 93 
Mean Sp02 during 
ISWT (%) 89.2 88.2 92 92.6 91 88.6 88.7 82.8 85.4 81.4 90.9 91.4 
*SD Sp02 during 
ISWT (%) 2.2 3.8 2.9 4.4 3 4.2 2.5 7.9 2.6 3.9 1.8 1.9 
*Min Sp02 (%) 84 81 86 80 83 78 82 66 80 72 88 88 
Mean Flow (Lpm) 1.45 2 0.8 1 0.8 1 2.4 2 3.1 2 0.8 1 
Time equivalent 0 2 
consumption (L) 23.6 32.6 16.8 21 19.7 24.6 40.8 34 54.9 35.4 20.2 25.3 
*TOD 
TOD ratio 
393 
1 
1160 
2.95 
259 
1 
751 
2.90 
652 
1 
1475 
2.26 
631 
1 
3697 
5.86 
1977 
1 
3269 
1.65 
74 
1 
81 
1.09 
"Recovery time to 
Baseline (s) 105 165 109 193 152 226 61 173 157 187 54 98 
"Recovery time to 
90% (s) 52 112 35 78 77 84 41 112 136 164 5 45 
"Total Time Sp02 
< 90% (s) 163 228 120 187 209 277 295 366 470 486 76 65 
Distance walked (m) 130 140 490 450 400 370 200 240 180 140 110 80 
Grog Score Pre 
ISWT 1 1 0 0 1 0.5 0.5 0 1 2 0 0 
Brog Score Post 
ISWT 
(Difference: 
Pre-Post) 
5 
4 
6 
5 
5 
5 
5 
5 
4 
3 
3 
2.5 
4 
3.5 
4 
4 
9 
8 
9 
7 
5 
5 
5 
5] 
Brog Score 2 min 
Post 
(Difference: 
Post-2min) 
2 
3 
2 
4 
2 
3 
1 
4 
2 
2 
1 
2 
1 
3 
1 
3 
7 
2 
5 
4 
0.5 
4.5 
1 
4 
Max Heart Rate 
(bpm) 109 114 147 147 158 151 108 110 134 133 149 145 
'Mean Heart Rate 
at ISWT (bpm) 96 101 121 122 123 124 89 93 117 118 130 132 
* indicates p < 0.05, ** indicates p < 0.01 
From the data tabulated above, several statically significant trends are apparent. 
Compared to CONS, SDOT significantly reduced the time spent with SpOz < 90% by 17 ± 13% 
(p<0.05), improved the recoveiy time to baseline SpOz by 39 ± 17% (p<0.01) and decreased the 
minimum Sp02 from 77.5 ± 7.6% to 83.8 ± 2.8% (p<0.05). These trends all point towards an 
65 
overall reduction in hypoxemia with SDOT, which is further confirmed by the average TOD 
ratio 2.6 (CONS/SDOT, p<0.05). In addition, there is evidence of a small, but statistically 
significant, reduction in mean heart rate during the ISWT. This could be indicative of a reduced 
cardiac strain during exercise. 
Table 5.8: ISWT Group mode comparison 
Parameter CONS 
(Mean ± SD) 
SDOT 
(Mean ± SD) 
Difference 
(%) 
Significance 
(P) 
Mean baseline SpO; (%) 95.6 ±2.7 93.7 ±2.6 2 ± 1 0.007 
Min Sp02 (%) 77.5 ± 7.6 83.8 ±2.8 8 ± 7 0.04 
Total time w Sp02<90% (s) 268 ±146 222±143 17± 13 0.02 
Recovery time to baseline (s) 173 ±43 106 ±43 39± 17 0.002 
Mean heart rate during ISWT 115 ± 14.9 112.6 ± 16.3 2 ± 1 0.022 
(bpm) 
Total Oxygen Deficit 1738±1436 664 ± 680 Ratio: 2.6 0.047 
CONS/SDOT 
Nevertheless, several other physiological measures also did not reveal significant 
differences. The average Sp02 during the ISWT, maximum heart rate, and mean 0 2 flow rate 
did not appear to have been dependent on the oxygen mode. In patients No. 001, 002, 003 & 
007 whose resting saturation > 91% while breathing room air, the total volume oxygen 
consumed was reduced. For these patients with only mild hypoxemia, SDOT could lead to 
oxygen conservation benefits by automatically reducing the flow rate when resting, also 
reducing the likelihood of excessive oxygen delivery which can contribute towards hypercapnia. 
The increased risk of hypercapnia during CONS was also evident by the elevated baseline SpO; 
results between CONS 95.6 ± 2.7% and SDOT 93.7 ± 2.6% (p <0.01). 
No significant difference in ISWT distance or Borg scores was found. 
5.5 Discussion 
The results demonstrate the feasibility and potential for feedback control to reduce the 
extent of hypoxemia during exercise in COPD patients compared to standard oxygen therapy. 
The ISWT Group results indicate that compared to standard oxygen therapy, SDOT produced a 
significant reduction in time spent with hypoxemia, decreased the extent of hypoxemia and 
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lowered mean heart rates during exercise. Moreover, for patients with acceptable resting oxygen 
levels, SDOT provided conservation benefits by reducing the rate of oxygen consumption. 
Notwithstanding, several of the study parameters calculated did not reveal any 
statistically significant difference between SDOT as compared with CONS. Although no 
difference would be expected during the resting baseline Borg scores, patients self reported 
dyspnoea following the ISWT did not differ between SDOT and CONS. Despite the positive 
effect observed of SDOT on minimum arterial oxygen saturation, comparisons of the Borg 
breathlessness scores using the Wilcoxon Signed Rank Test did not indicate any substantial 
difference. The relationship between minimum Sp02 and Borg score immediately after 
completing the ISWT was evaluated using the Rank Correlation Coefficient (R = 0.017). The 
poor correlation would suggest the subject's own feeling of breathlessness is not very sensitive 
to the level of arterial blood oxygenation. This agrees with the findings from other studies [44], 
and illustrates the potential hazards if patients were encourage to simply self regulate their own 
flow of oxygen based on dyspnoea. 
Unexpectedly, the total distance walked during the ISWT did not appear to be affected 
by SDOT. In previous studies a direct correlation has been frequently documented between 
exercise tolerance and supplemental oxygen until a maximum limit of about 50% Fi02. 
Davidson's et al study on the effect of oxygen therapy on exercise using cycling endurance, in 
17 patients with severe airflow obstruction and mild hypoxemia, showed an increased 
endurance by 51% at a flow rate of 2 Lpm, by 88% at 4 Lpm, and by 80% at 6 Lpm for a 
constant workload [45]. Somfay also found an increase in endurance time using a symptom-
limited incremental exercise when breathing 30% oxygen compared to air, which fiirther 
increased when breathing 50% oxygen [46]. The data from our ISWT Group did not support 
this conclusion. 
One possibility might be a cumulative fatigue from the repeated shuttle walking tests. 
To exclude the fatigue hypothesis the walk distance between the first and second ISWT, 
irrespective of oxygen mode, were compared using the paired-t test revealing no statistically 
significant difference. It may simply be that these oxygen therapy patients, who often exhibit 
severe exercise limitation and advanced age, may not be able to physically maintain to the rigid 
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protocol of the ISWT due to the quickly progressing walking pace requirements. As the ISWT 
is designed to accommodate a very wide range of exercise ability, it may not provide the 
sensitivity required to detect a more subtle change for patients with more advanced exercise 
limitations. 
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CHAPTER 6 
DEVELOPMENT OF IMPROVED SDOT CONTROLLER 
6.1 Overview 
The focus of the work presented in this chapter was to further refine the controller 
response based upon the clinical results collected from the Incremental Shuttle Walk Test 
(ISWT) group data. In particular, modifications to the Saturation Driven Oxygen Therapy 
(SDOT) control design were proposed and evaluated to better account for the long time delay in 
the pulse oximetry feedback measurement. These changes were validated through additional 
patient simulations as well as further clinical ISWT. 
6.2 Hunting and Time Delay 
During the case study presented in Chapter 5 it was noted the SDOT mode, while 
successful in reducing the overall extent of hypoxemia, nevertheless exhibited periods of 
instability from exaggerated oscillations in the oxygen flow-rate regulation. In particular when 
attempting to maintain the target SpOi in the presence of increased or persistent oxygen demand, 
the SDOT mode could overcompensate the oxygen delivery leading to cyclic behaviour in the 
flow-rate. This type of instability is referred to as hunting behaviour and can be a consequence 
of long time delays in PDD controls of closed loop feedback systems. The extent of the PID 
hunting behaviour was variable from patient to patient, but was greatest during Study No. 004 
shown below in Figure 6.1. 
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Figure 6.1: ISWT on SDOT, segmented to reflect activity (Patient No. 004) 
Top: Sp02 and heart rate vs. time, Bottom: O2 flow rate vs. time 
From the bottom plot of flow-rate vs. time in Figure 6.1, a pattern of overcompensation 
is evident as the SDOT mode hunts to maintain the 91% arterial oxygen saturation target. 
Because of the observed lag in response of the Sp02 measurements, it is apparent that the PID 
controller is changing the oxygen flow too quickly. The controller is not providing the patient 
sufficient time to respond to the changing flow-rate which results in these hunting limit cycles. 
While the resulting oscillations in SpO; were relatively mild and did not present any acute risk 
to the patient, this instability can be readily removed with minor system adjustments. 
Figure 6.2 shows the baseline data segment taken from the Study No. 004 while the 
participant remained at rest. For this patient, the constant flow oxygen prescription was 2 Lpm 
indicating a persistent oxygen requirement even at rest. However, the SDOT mode was unable 
to settle around a stable equilibrium flow-rate. A common cause for such characteristic hunting 
behaviour results from inappropriate tuning of the PID control parameters leading to 
exaggerated output sensitivity. 
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The focus of the work presented in this chapter was to re-evaluate the preclinical patient 
model used develop the PID control parameters based upon the clinical ISWT group data. After 
revising the patient model to account for these observed results, the SDOT control configuration 
can be accurately modified in order to eliminate the undesirable hunting behaviour. 
100 
Setpomt = 91% 
800 850 900 950 1000 
900 
Time (s) 
Figure 6.2: Baseline segment during SDOT mode (Patient No. 004) 
Top: SpO] and heart rate vs. time. Bottom: O2 flow rate vs. time 
6.3 Revising the Patient Model 
The expected time delay associated with the lung-to-capillary time used in the 
preclinical model for the patient response considerably underestimated the time delays 
compared to the data collected from our ISWT study group. As previously described in Section 
2.3 & Figure 2.4, the expected time delay associated with the lung-to capillary time totalled 
approximately 21 seconds (T) = 6 s dead time, T2 — 15 s lag time). This turns out to be 
substantially shorter than the delay observed during the patient studies. Referring to Figure 6.2, 
the time delay was measured between the maximum peak oxygen flow and peak Sp02 was in 
fact 55 seconds in Study No. 004. On average among the ISWT group, this peak to peak delay 
measured to be about 43 seconds. This delay is more than double the expected total time delay 
value used in the preclinical model used to develop and tune the SDOT control parameters. 
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It was possible to simulate the effect of increasing the total time delay on the preclinical 
patient model, using the ISWT saturation data measured in CONS mode as the template for the 
input disturbance. The simulation was conducted according to the modelling methods presented 
in Chapter 3 on the preclinical sleep data simulations. The results are given in Figure 6.3. 
1 0 0 r 
CD 8 5 
N o 0 2 
S D O T 
8 10 12 
Time (min) 
Figure 6.3: SDOT mode simulation: Revised patient model (Patient No. 002) 
Top; SpO] vs. time. Bottom: O2 flow rate vs. time 
By revising the simulated patient model, the hunting behaviour exhibited during the 
study was reconstructed. The Sp02 data from the practice walk was entered as the input 
disturbance to the simulation. Then without changing any of the control parameters, the patient 
model is modified by increasing the total time delay (both dead time T,, and lag time T2) to 
match the clinically observed results. Compare the revised simulation results in Figure 6.3 to the 
ISWT data measured during the SDOT mode in Figure 6.4. The simulation result is a good 
approximation of the characteristic oscillation seen in Study No. 002, both in the profile and 
amplitude of the flow-rate and saturation responses. The correspondence of the simulated 
results to the clinical measurements also provides further independent validation of the method 
for the patient model. 
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Figure 6.4: ISWT on SDOT (Patient No. 002) 
Top: Sp02 and heart rate vs. time. Bottom: O2 flow rate vs. time 
6.4 Controller Improvements 
Given the revised patient model and clinical data based upon the ISWT group, several 
modifications were made to improve the overall response of the SDOT mode and eliminate the 
potential for hunting behaviour. Initially the SDOT saturation target was set just above the 
threshold for hypoxemia at 91%, which may be too close to the rapid fall in the 
oxyhaemoglobin dissociation curve as suggested by the ISWT data, and a change in the SDOT 
setpoint to a higher value (93%) might be beneficial. Raising the setpoint would provide a larger 
buffer to prevent desaturation. Additional changes were then made to better cope with the long 
feedback time delays discussed above. The aim was to damp changes in the output of the SDOT 
mode, preventing the oxygen flow-rate from changing too quickly before the feedback is given 
adequate time to respond. The key control parameters modified were the gains for the PID 
components as well as the cut-off frequency used for the lowpass filter. Together they regulate 
the sensitivity of the controller output response. Particularly by reducing the cut-off frequency 
of the lowpass filter, the final controller output response can be easily slowed down. 
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Another basic limitation of the arterial oxygen saturation is the integer precision of the 
measurement. The SpO] value is only expressed in integer values between 0 to 100%. 
Consequently, the profile of patient saturation measurements is a series of step changes over 
time. As a result, the error between the target saturation and SpO] feedback has only discrete 
incremental changes. In order to better cope with this form of input, the configuration of the 
control components was rearranged as shown in Figure 6.5. The derivative element of the 
original PID control has been removed, leaving only a PI controller preventing exaggerated 
output responses as a result of a step change. Furthermore, the phase compensator has been 
moved after the lowpass filter. This change also helps to smooth the output response with 
respect to the discrete step changes in arterial oxygen saturation. 
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Figure 6.5: Modified PI controller for SDOT mode 
In the final simulation shown in Figure 6.6, the controller has been modified to account 
for the updated patient model. Using the same input disturbance from Study No. 002 (as shown 
previously in Figure 6.3), the result is a dramatic improvement in the flow response and 
subsequently the patient saturation. According to the simulation, the improved controller would 
have completely eliminated any hypoxia for this patient. Using this revised model for the 
observed dynamic response of patients with obstructive lung disease, the controller performance 
was substantially improved with respect to the newly validated patient model. 
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Figure 6.6: SDOT mode simulation: Improved controller (Patient No. 002) 
Top: Sp02 vs. time. Bottom: O2 flow rate vs. time 
6.5 ISWT with Modified Controller 
The next step was to confirm the predicted simulation results clinically. The results of 
the ISWT using the modified SDOT mode for the next participant in the pilot study (Patient No. 
008) are given in Figure 6.7. This study was carried out according to the same protocol as the 
previous ISWT group studies in Chapter 5, where the patient repeated the incremental shuttle 
test either on CONS or SDOT mode in random order. Similar to the example presented earlier 
for Patient No. 004, this participant required a substantial flow of oxygen while at rest. The 
constant flow oxygen prescription was 2 Lpm. 
However with the modified SDOT mode, the controller no longer exhibited any hunting 
behaviour. During the baseline segment of Figure 6.7, the controller was able to maintain an 
almost steady SpO] very close to the target saturation (93%) averaging 92.8 + 0.7%. The 
corresponding mean oxygen flow rate was I.I ± 0.3 Lpm. The modified SDOT mode did not 
overcompensate the oxygen delivery, and the previous hunting limit cycles of the oxygen flow 
rate were eliminated. 
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Figure 6.7: ISWT on modified SDOT, segmented to reflect activity (Patient No. 008) 
Top: SpOz and heart rate vs. time, Bottom: O2 flow rate vs. time 
Furthermore, as predicted by the simulation results in Section 6.3, the modified control 
was able to almost completely prevent any intermittent episodes of hypoxemia. Only during the 
maximal portion of the ISWT segment shown in Figure 6.8, did the participant experience any 
sustained hypoxemia while using SDOT mode. Over the course of the whole ISWT, this 
participant spent only 86 seconds with hypoxemia. The total time spend with Sp02<90% 
decreased by 36% using the modified SDOT compared to CONS at 2 Lpm. 
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Figure 6.8: Mode comparison - ISWT and Return data segments, 
CONS mode plotted in Red and SDOT mode plotted in blue 
6.6 Discussion 
The clinical results from Patient No. 008 using the modified SDOT mode substantiate 
the simulation predictions based on the revised patient model. The previous hunting behaviour 
due to the long feedback time delay is better accommodated by the modified controller design. 
Table 6.1 presents a summary of the changes made to the SDOT controller. An additional group 
of clinical studies were performed using the modified SDOT mode in the next Chapter on the 
Six Minute Walk Test. 
MODIFICATION OBJECTIVE 
TARGET 
SETPOINT 
- Increased from 91% to 93% Buffer from rapid fall in 
oxyhaemoglobin dissociation 
curve 
CONTROLLER 
PARAMETERS 
- Revised PID gains and lowpass cut-off 
frequency 
Damp changes in output to 
prevent hunting 
CONTROLLER 
DESIGN 
- PID simplified to PI controller 
- Phase compensator relocated after lowpass 
filter 
Cope with input step changes 
in feedback measurement 
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CHAPTER 7 
SIX MINUTE WALKING TEST 
7.1 Overview 
Presented here is a second group of patient studies carried out with the modified SDOT 
controller design as presented in Chapter 6. For this second group, the studies were carried out 
using the standardised Six Minute Walking Test (6MWT). The analysis is first illustrated as a 
case study, with reference to one representative patient. Then the group trends and statistics are 
discussed. 
7.2 Introduction to 6MWT 
In contrast to the Incremental Shuttle Walk Test (ISWT) which measures the maximal 
exercise ability with progressively increasing walking speed, the 6MWT is a self paced exercise 
test. The object of the 6MWT is to walk back and forth along a level hallway for as far as 
possible within 6 minutes. Cones were set a fixed distance apart to mark the turning points, and 
all patients were read the standardised instructions at the beginning of each test. Upon the 
completion of each minute the participant is told the time remaining and given verbal 
encouragement. The standardised 6MWT's were conducted as per the guidelines set out by the 
American Thoracic Society [47]. 
During the 6MWT the participant is allowed to slow down, and even stop to rest as 
necessary. While resting the participant is permitted to lean against the wall, but must continue 
walking as soon as possible. Because the test is self-paced, it is well tolerated by people with 
exercise limitations. In a review by Solway et al., they compared the study results of the 2-min 
walk test, 6-min walk test, 12-min walk test, self-paced walk test, and shuttle walk test and 
found the 6MWT easy to administer, better tolerated, and more reflective of activities of daily 
living than the other walk tests [48]. 
Moreover, the 6MWT has been extensively used in a variety of studies to evaluate the 
effect of oxygen on exercise ability. In a study by Davidson et al. [45] on the effect of O? 
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therapy on exercise performance in COPD 17 patients, O2 administered via nasal cannula at 4 
1pm increased the 6-min walking distance by 17% as compared to air. Moreover, it has been 
previously shown that the 6MWT can be sensitive to the dose or flow-rate of oxygen delivery. 
Leach et al. study of 20 patients with severe COPD and 10 patients with interstitial lung disease, 
evaluated the 6MWT distance while patients were breathing compressed air at a flow rate of 4 
1pm or oxygen at 2, 4, or 6 1pm [49]. This study revealed an increase in the 6MWT distance by 
19.2%, 34.5%, and 36.3%, respectively, in comparison to walking while breathing compressed 
air at 4 1pm. Given that the results of the ISWT group data in Chapter 5 did not reveal any 
statistically significant difference in walking distance, the 6MWT was chosen due in part due 
this sensitivity to oxygen delivery. 
It must be noted due to practical constraints of the investigational device, the length of 
the course was set to 10 meters as in the ISWT. This is a consequence of the sensor cable length 
connected to the pulse oximeter. Although the ATS guidelines recommend a course length of 
30m, studies have not revealed any statistically significant difference in total walked distance 
based upon course length between 20m - 50m [50]. However, a possible limitation remains that 
the shorter 10m course length causes participants to take more time changing directions, thereby 
reducing the 6MWT distance. This effect should not be a factor in comparing the SDOT and 
CONS results from repeated tests along the same course, but must be acknowledged to 
potentially bias comparisons made to other studies. To help reduce any possible learning effect 
when comparing successive tests, a practice test was also conducted even though the ATS 
guidelines do not strictly require it. 
7.3 6MWT Group 
Enrolment of participants with only COPD as per the inclusion criteria outlined in 
Chapter 4, was lower than anticipated. Thus we submitted a Notice of Substantial Amendment 
to the Local Regional Ethics Committee for an expansion of the inclusion criteria to include 
other adult participants receiving oxygen therapy. On 24"* April 2007, the amended inclusion 
criteria were approved to include other chronic respiratory disorders which require long-term 
oxygen therapy such as cystic fibrosis, and interstitial lung disease. This change is not expected 
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to significantly alter the scientific value of the study as the main outcome is to evaluate the 
automated method of variable oxygen control as compared with standard oxygen therapy. 
Furthermore, the crossover study design means each participant acts as his/her own control. 
A total of seven oxygen therapy patients (4 males & 3 females, mean age 63.7, range 
49-72 years) carried out repeated 6MWT while receiving SDOT or CONS oxygen delivery in 
random order, with approx. 45min rest between tests. The primary diagnosis was COPD for all 
but two patients (No. 014 & 015), for whom the primaiy diagnosis was Interstitial Lung Disease 
(ILD). Table 7.1 contains a summary of the 6MWT group baseline lung function taken just 
prior to commencing the study. Heart-rate, SpO], and O2 flow were recorded initially from rest 
until 5min after completing the 6MWT. The total distance walked was noted, and participants 
ranked breathlessness using a modified Borg score before, immediately after, and 2 min post the 
6MWT. 
Table 7.1: 6MWT Group age and lung fimction data (n = 7) 
Variable Mean Range 
COPD (n=5) Age (yrs) 61.0 49-70 
FEVi (% 29.6 20-47 
predicted) 
FEVi/FEC 51.3 33-72 
(/o) 
Resting SpO; 92.6 90-95 
on LTOT (%) 
Prescribed O2 1.8 1-2.5 
flow rate 
(1pm) 
ILD (n=2) Age (yrs) 70.5 69-72 
FEC(L) 2.1 1.5-2.8 
FEVi/FEC 87.6 82-93 
(/o) 
Resting Sp02 94.7 94-95 
on LTOT (%) 
Prescribed O2 2.5 2-3 
flow rate 
(1pm) 
In the 6MWT group of patients, the SDOT system configuration and parameters were 
modified from those previously used in the ISWT group as described in Chapter 6. For all of the 
studies a target value of 93% saturation was set during SDOT mode. During the CONS mode, 
the patient prescribed flow rate was entered as the default oxygen flow. 
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Unfortunately in the 6MWT for Patient No. 014, a communication error between the 
pulse oximeter and PC caused a reset in the SDOT mode. During the SDOT reset, the oxygen 
flow must be initially set to 0 1pm. This occurred during the exercise portion of the test 
compromising any comparison of the results, consequently the data from this patient has not 
been included in the overall group analysis. Through subsequent investigation, it was 
discovered this error was due to a timeout error in the serial communication. 
7,4 Results 
The SDOT mode was compared to CONS mode during the 6MWT in the double blind 
crossover study as described previously in Chapter 4. As per the study protocol, every patient 
repeated the 6MWT a total of 3 times: one practice followed by SDOT and CONS modes in 
random order. Similar to the ISWT, the data sequence for each test was segmented into four 
sections: Baseline, Preparation, ISWT, and Return. The data sequence begins by capturing 
several minutes of baseline data (Baseline) while the subject remains at rest. The recordings 
continue uninterrupted as the participant prepares (Prep) for the 6MWT until a few minutes 
after completing the walk (Return). 
For the 6MWT group, momentary periods of missing data from the pulse oximeter were 
observed in Patients No. 012 and 015 (36s and l i s , respectively). For these periods, a linear 
interpolation was carried out between the closest measured values to approximate the missing 
data. Again minor signal noise probably associated with motion artefact was most pronounced 
in the heart rate measurements. These anticipated limitations of the pulse oximetry 
measurements had been considered as part of the SDOT design, and did not result in any 
adverse effects with regards to the automated oxygen flow control. 
The data recording and segmentation for one representative practice test is illustrated in 
Figure 7.1. The results for this patient are described in detail in section 7.4.1 to exemplify the 
analysis used. 
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Figure 7.1: Practice 6MWT on CONS, segmented to reflect activity (Patient No. Oil) 
Top: Sp02 and heart rate vs. time. Bottom: 0 2 flow rate vs. time 
The data sequence for the 6MWT is qualitatively different from the profile seen 
earlier in the ISWT. Instead of a progressive increased demand as in the ISWT, the exercise 
period in the 6MWT appears to reach a steady equilibrium oxygen saturation where the 
participant may try to maintain one particular workload or effort level. In general the results for 
the Practice (shown above) and CONS mode (shown in Figure 7.2) were similar in profile. 
During the Baseline rest period, the heart rate is at a minimum and the arterial oxygen saturation 
remains above 90%. A small increased demand can be seen as the patient transitions from rest 
to prepare for the 6MWT. The exercise segment of the 6MWT leads to a prolonged period of 
desaturation, followed by a gradual recovery as the patient returns to rest. 
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The data for the SDOT mode in Figure 7.3 reveals a much different outcome during 
the 6MWT. In SDOT the O2 flow is regulated by the arterial oxygen saturation measurement 
with a target value of 93%. The controller is intended to only deliver oxygen as required to 
maintain this target. While at rest the SDOT mode did not need to supply the patient with much 
supplemental oxygen. Only during the exercise segment of the 6MWT did the controller 
substantially increase the oxygen delivery. The results shown in this patient reveal the controller 
was almost entirely successful in preventing any hypoxemia over the course of the 6MWT. A 
detailed case study of the segmented data analysis is presented in section 7.4.1. 
The results of the 6MWT, however, were not as consistent across all patients as the 
ISWT results. Primarily this is due to the self-paced characteristic of the test. This feature 
allows the patient to select their own coping strategy which incorporates another degree of 
variability into the results. In particular when a patient has more advanced airflow obstruction 
and exercise limitation, they may require several rests over the course of the test. This 
intermittent start/stop activity is thought to more closely resemble behaviour of patients during 
routine daily activities. 
7.4.1 Case Study of Segmented Data Analysis 
Table 7.2 contains a list of the 6MWT scores from Patient No. Oil. During the practice 
walk the total distance walked was 220m. This was greater than in the following two walks, 
where the distance was slightly different between SDOT and CONS therapies, 190m and 175 m 
respectively. It appeared that the patient attempted to maintain a greater pace initially during the 
practice test. Later the patient adapted to a slower pace during the repeated assessments to avoid 
becoming too breathless. Because the test is self paced, patients may have the tendency to begin 
at a greater pace initially. Then once having completed the practice test, they may adopt a 
different approach to better moderate their dyspnoea and endurance. For this reason we felt it 
may still be potentially important to conduct a practice test even when using the 6MWT. 
A Borg score was used to indicate the participants' breathlessness (1-10) before, 
immediately after, and 2 min post 6MWT. In this study the Borg scores reported slight 
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differences between the two therapies. The dyspnoea reported immediately post the 6MWT 
during SDOT mode was scored lower than the corresponding CONS mode score. 
Table 7.2; 6MWT Borg scores (PatientNo. Oil) 
Test Resting Post 6MWT 2min Post 6MWT Distance 
Practice 0.5 10 4 220m 
1" (SDOT) 0 7 2 190m 
2"^  (CONS) 0 10 1 175m 
Baseline Sesment 
The CONS therapy is set to deliver a fixed flow rate of 1 Lpm. In the case of this 
participant, almost no supplemental oxygen was required at rest to maintain SpOi greater than 
90%. The mean resting SpOa during CONS therapy was 95.0 ± 0.2 %. 
In contrast the SDOT therapy is configured to maintain the saturation above the target 
setpoint (93%). Analysis of the baseline saturation during SDOT reveals the subject SpO] 
averaged 93.9 ± 0.5 %. Since the subject required very little oxygen at rest, SDOT mode 
adjusted the flow rate accordingly to maintain the target saturation. The mean flow rate during 
SDOT mode was 0.2 ± 0.2 Lpm. No substantial difference was observed in the heart rate 
between the two therapies. 
Table 7.3: Baseline data values (Patient No. Oil) 
Therapy Flow (Lpm) SpOz (%) Heart Rate (bpm) 
mean ± SD mean ± SD mean ± SD 
SDOT 0.2 ± 0.2 93.9 + 0.5 88 ± 3.9 
CONS 1.0 ± 0.0 95.0 ± 0.2 84 ± 2.2 
The modified SDOT controller was successful in reducing the oscillation noted in 
earlier studies of during the ISWT group. Slightly raising the setpoint to 93% also improved the 
response time. 
Preparation Sesment 
The Prep period encompasses the transition between when the patient is entirely at rest 
until the start of the 6MWT. These data recordings are shown in Figure 7.4. In SDOT, the flow-
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rate begins to rise appreciably as the patient oxygen demand starts to increase. No other major 
differences are apparent during this phase. 
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Figure 7.4: Preparation data segment (Patient No. Oil) 
Left: CONS mode plots (Red), Right: SDOT mode plots (blue) 
6MWT Sesment 
No substantial difference in the heart rate is observed from the 6MWT. Although, the 
peak heart rates were higher during SDOT therapy which might be due to some motion artefact. 
Table 7.4; 6MWT values (Patient No. Oil) 
Therapy Mean heart Max heart Mean SpOz Min SpOz Max flow 
rate (bpm) rate (bpm) (%) (%) (Lpm) 
mean ± SD mean ± SD 
SDOT 117.1 ± 18 173 91.8 ± 1.3 89 3.7 
CONS 116.2+ 8 134 86.2+ 2.9 83 1.0 
In comparing the Sp02 data during the 6MWT, more differences are apparent between 
the two therapies. The mean saturation showed substantial differences at 86.2 ± 2.9% (CONS) 
and 91.8 ± 1.3% (SDOT), the standard deviation for CONS therapy (2.9%) was greater than that 
of SDOT therapy (1.3%). A closer inspection of the SpOz profile indicates that the saturation in 
CONS therapy steadily decreases over the course of the 6MWT, finally reaching a plateau at 
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83% during the 6MWT. In contrast, the SpO] profile during SDOT therapy shows evidence of 
remaining very close to the target threshold. The minimum SpO] was 89% using SDOT therapy, 
but occurred towards the beginning of the walk and then was quickly corrected by the increased 
oxygen flow. During the remaining exercise the peak SDOT oxygen flow of 4.7 Lpm was 
sufficient to almost completely prevent any desaturation. During the 6MWT the mean flow 
using SDOT was 3.7 ± 0.9 Lpm. 
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Figure 7.5: 6MWT data segment (Patient No. Oi l ) 
Left: CONS mode plots (Red), Right: SDOT mode plots (blue) 
Comparing the 6MWT data from the two therapies, the time spent with Sp02<90 
improved by a remarkable 95% using SDOT. On CONS therapy the subject appears to have a 
much greater extent of hypoxia as compared to the SDOT therapy. In fact during SDOT, the 
participant spent only a total of 14 seconds with Sp02<90 as compared to 302 during CONS. By 
plotting the two therapies together we can better illustrate this difference as shown in Figure 7.6. 
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Return Segment 
The Return segment also saw substantial differences between the two therapies. The 
recovery time for the subject's SpO] to rise above 90% was again substantially improved with 
SDOT therapy. The recovery time for CONS was 23 s vs. Os for SDOT therapy. It also took 
significantly longer for the subject to return to baseline on CONS therapy at 78s as compared to 
7s with SDOT therapy. Once at rest, as the subject returned to baseline, the SDOT therapy also 
responds by decreasing the oxygen flow once it is no longer required. 
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Figure 7.7: Return data segment (PatientNo. Oil) 
Left: CONS mode plots (Red), Right: SDOT mode plots (blue) 
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Table 7.5. Saturation recovery times (Patient No. Oil) 
Therapy SpOz < 90% Return to baseline 
SDOT Os 7s 
CONS 23s 78s 
Please refer to Appendix A.l for individual case report summaries from each subject enrolled in 
the 6MWT group. 
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7.4.2 ISWT Patient Group Results 
Many of the trends highlighted above for Patient No. 011 turn out to be statistically 
significant findings within the overall 6MWT Group results. A complete table of the parametric 
data computed for patients in the 6MWT Group is presented in Table 7.6. 
Table 7.6: 6MWT group parametric data 
P a t i e n t s P a t i e n t 11 P a t i e n t 1 2 P a t i e n t 1 3 P a t i e n t 1 5 P a t i e n t 1 6 
Variable SDOT CONS SDOT CONS SDOT CONS SDOT CONS SDOT CONS SDOT CONS 
Mean Sp02 at 
Baseline (%) 91.8 91.1 93.9 95 92.4 92.8 93 93.5 93.6 94 92.1 90.4 
Mean Resting Flow 
(Lpm) 2.4 2 0.2 1 1.4 1.5 2.3 2 0.5 2 2.9 2.5 
* Median S p 0 2 
during 6MW(%) 91 90 92 85 91 87 87 80 92 91 82 79 
*Mean S p 0 2 
during 6MW(%) 91.7 91.4 91.8 86.2 90.6 87.8 88.3 82.4 93.1 91.9 83.7 79 3 
SD Sp02 during 
6MW (%) 3 3.4 1.3 2.9 1 2.9 3.4 7 2.7 1.5 4 8.2 
Min S p 0 2 (%) 85 85 89 83 89 84 84 67 91 90 78 58 
**Mean 6MW Flow 
(Lpm) 2.9 2 3.7 1 4 1.5 4.1 2 2.5 2 4.3 2.5 
Mean Flow (Lpm) 2.6 2 1.5 1 2.2 1.5 3.1 2 1.2 2 3.4 2.5 
•TOD 
TOD ratio 
228 
1 
273 
1.20 
14 
1 
1565 
111.79 
51 
1 
1242 
24.35 
1058 
1 
4370 
4.13 
0 
1 
0 
1.00 
2766 
1 
5154 
1.86 
•Recovery time to 
Baseline (s) 45 65 7 78 40 93 79 231 57 76 85 193 
•Recovery time to 
90% (s) 23 45 0 23 0 70 47 200 0 0 67 193 
•Total Time S p 0 2 
< 90% (s) 144 222 14 324 57 368 311 473 0 0 433 747 
Distance walked (m) 105 100 190 175 370 370 320 320 245 305 360 360 
Brog Score Pre 
6MW 0.5 1 0 0 0.5 0.5 0 0 2 2 0 0 
Brog Score Post 
6MW 
(Difference: 
Pre-Post) 
10 
9.5 
7 
6 
7 
7 
10 
10 
1 
0.5 
1 
0.5 
5 
5 
5 
5 
4 
2 
5 
3 
5 
5 
3.5 
3.5 
Brog Score 2 min 
Post 
(Difference: 
Post-2min) 
3 
7 
3 
4 
2 
5 
1 
9 
1 
0 
0.5 
0.5 
2 
3 
2 
3 
2 
2 
2 
3 
2.5 
2.5 
1 
2.5 
Max Heart Rate 
(bpm) 172 155 173 134 172 139 117 137 121 112 118 127 
Mean Heart Rate at 
6MW (bpm) 136 129 117 116 114 116 103 102 103 100 87 81 
* indicates p < 0.05, ** indicates p < 0.01 
Several of the trends seen in the ISWT Group are more pronounced in the results of the 
6MWT group. Compared to CONS, SDOT significantly reduced the time spent with SpO] < 
90% by 55 ± 38% (p<0.05), improved the recovery time to baseline Sp02 by 58 ± 42% (p<0.05) 
90 
and increased the mean exercise SpO; from 86.5± 5.0% to 89.9 ± 3.4% (p<0.05). These trends 
all point towards an overall reduction in hypoxemia with SDOT, which is further confirmed by 
an increase in the median exercise Sp02 from 85.3 ± 5.0% to 89.2 ± 4.0% (p<0.05). Between 
CONS and SDOT modes there was a significant difference in the measure of Total Oxygen 
Deficit (TOD), with an average ratio of 3.1 (CONS/SDOT, p<0.05). A trend was also seen to 
improve the minimum saturation by 8 ± 8% (p=0.06), although it did not reach statistical 
significance. The reason for these improvements is evident by comparing the mean exercise 
flow rates for CONS at 1.8 ± 0.5 1pm vs. SDOT at 3.6 ± 0.7 1pm (p<0.01). During exercise with 
SDOT mode, the patients were given a greater flow rate to meet their increased demand. 
Table 7.7: 6MWT Group mode comparison (n = 6) 
Parameter CONS 
(Mean ± SD) 
SDOT 
(Mean ± SD) 
Difference Significance 
(P) 
Median SpOz (%) during 
6MWT 
85.3 ± 5.0 89.2 ± 4.0 4 ± 3 (%) 0.018 
Mean SpO; (%) during 6MWT 86.5± 5.0 89.9 ±3.4 3 ± 2 (%) 0.016 
Mean O2 flow during 6MWT 
(1pm) 
1.8 ±0.5 3.6 ±0.7 1.8 ±0.9 
(1pm) 
0.005 
Total time w Sp02<90% (s) 356 ±250 160±176 55 ± 38 (%) 0.017 
Recovery time to baseline (s) 123 ±71 52 ± 2 8 58 ± 42 (%) 0.021 
Total Oxygen Deficit 2101 ±2156 686 ± 1095 Ratio: 3.1 
CONS/SDOT 
0.045 
However, some of the statistically significant trends seen in the ISWT Group are not 
present in the 6MWT data. For instance, the mean Baseline SpOz did not reveal any difference 
between CONS and SDOT. This is likely a result of the revised target saturation in SDOT mode 
to 93%. The choice of target saturation is therefore an important determining factor governing 
the amount of oxygen consumption during rest. 
Several other physiological measures also did not reveal significant differences. Neither 
the maximum nor mean heart rate appeared to have been dependent on the oxygen mode. Again 
no significant difference in ISWT distance or Borg scores was found. 
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7.5 Discussion 
The results from the 6MWT Group give an indication and approximate scope of 
physiological benefit achievable from automating oxygen flow delivery based upon pulse 
oximetry feedback. During the 6MWT patients spent substantially less time with hypoxemia 
when using SDOT mode, on average more than 55% less than with CONS mode. Furthermore, 
with SDOT the mean Sp02 during exercise was also maintained at the established clinical 
threshold of 90%. As the Six Minute Walking Test is self paced and considered to be more 
representative of activities of daily living, the comparative results between CONS vs. SDOT 
mode would therefore be indicative of the benefits expected by using SDOT in domiciliary and 
outpatient settings. 
From the SDOT oxygen flow profiles measured during the 6MWT, it would also be 
possible to develop systematic criteria to help determine appropriate fixed flow prescriptions. It 
was found that several patient's CONS oxygen prescriptions may have been either excessive 
while at rest and/or sometimes insufficient during exercise. The segmented analysis of the 
SDOT oxygen profile gave objective measures of both the mean resting and exercise oxygen 
demands respectively. This might be a particular use for the SDOT system in clinical use, to 
help assess and automatically titrate optimal oxygen flow rates. In particular the results from the 
self paced 6MWT rather than the ISWT, which is a maximal exercise test, may be more relevant 
to appropriate setting for patients. 
Reviewing the results from the ISWT, it is apparent the magnitude improvement 
between SDOT vs. CONS is relatively smaller compared to the results shown in the 6MWT. As 
discussed in ISWT group results (section 5.4.2) the time spent with SpO] < 90% was reduced by 
only an average of 17%. This is a much smaller effect than that revealed during the 6MWT. As 
hypothesised, this is likely a consequence of the progressively maximal nature of the ISWT. 
During the ISWT, patients became hypoxemic by the end of the test despite receiving a 
maximum of 5 1pm O2 flow. Nevertheless, the minimum arterial oxygen saturations were 
significantly different between the two modes in the ISWT. Despite not completely eliminating 
periods of hypoxemia, SDOT substantially diminished the overall extent of desaturation. When 
92-
patients were permitted to select their own walking pace during the 6MWT, the contrast in 
efficacy between SDOT and CONS increased considerably. 
Another potential contributing factor between the ISWT and 6MWT was the modified 
SDOT controller design. The hunting behaviour was no longer an issue for the SDOT controller. 
This also probably contributed to the difference between the ISWT and 6MWT Groups. In part, 
the revised controller avoided the previously noted over-corrections through a detuning of the 
PI gain parameters. Given the large inter-patient variability seen in the results such as in Table 
7.6, a further improvement might be to develop a set of predetermined PI gain modes 
representing a low, medium, and high sensitivity. Then the sensitivity mode could be selected 
on an individual basis dependent on the particular patient circumstance. This could be 
particularly important when considering the controllers interdependence with the patient's 
physiological circulation time which very changeable depending on the presence and extent of 
cardiac disease. For instance, heart failure which is common in COPD patients can drastically 
increase the time delay. This may help explain why the time delay in this patient study were 
considerably longer than those found in the literature [35,38]. 
Again no significant symptomatic improvement was measured by either the Borg scores 
or the total distance walked. This remains perplexing as a primary aim in selecting the 6MWT 
was to help ascertain a difference in the total distance walked. One possibility might be the 
adjusted course length to 10 meters in order to accommodate the sensor cable limits. The shorter 
course requires patients to turn more frequently, and could reduce the total distance walked. 
However, the crossover comparison meant both the SDOT and CONS would be affected 
similarly and their relative difference should be maintained. Another factor may be the timing 
of the test. All the tests were conducted on a single visit. Particularly for the self paced 6MWT, 
the patient may settle upon a set rhythm or pace when performing the same task repeatedly. If 
resources are available for future studies, the days of the tests might be separated to reduce the 
likelihood of this effect. Given the sample sizes of the ISWT and 6MWT Groups, it is also 
possible the group did not have enough statistical power to determine a subtle effect. 
Although not part of the clinical protocol, prior to revealing the respective order of the 
randomised CONS and SDOT modes, those patients asked to compare the T', 2"'* and 3'*' tests 
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with regards to their breathlessness unknowingly identified the SDOT mode as the instance with 
less dyspnoea. This anecdotal evidence is only provided for consideration in future studies. 
Rather than the subjective Borg scores which refer to an absolute magnitude of breathlessness, 
one might ask the patient to compare and rank the tests in order of their own dyspnoea. This 
might be easier for patients to make direct comparisons, which could identify even subtle 
differences among the therapies. 
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CHAPTER 8 
CONCLUSION & FUTURE DIRECTIONS 
8.1 Introduction 
The conventional approach to determining best clinical treatment has been ascertained 
mainly through studies of evidence based medicine, which treats individuals on the basis of 
observed statistical probabilities. The patient course of treatment and likelihood of positive 
outcomes is based on information collected from controlled trials with sufficiently large sample 
sizes. However with the increasing means for reliable non-invasive monitoring, it is possible to 
develop new bespoke treatments, tailored to suit the needs of the individual patient. These 
bespoke therapies can work to further improve the efficacy of treatment within the individual. 
Saturation Driven Oxygen Therapy (SDOT) is an example of this new type of bespoke 
treatment. By using pulse oximetry feedback measurements, the rate of oxygen delivery can be 
automatically regulated in order to remain responsive to the variable demands of everyday 
living. 
8.2 Summary and Conclusions 
The object of the work presented in this thesis was to describe the systematic approach 
taken to develop and validate the method for automated flow control during oxygen therapy. 
From preclinical patient simulations to randomised pilot clinical studies using standardised 
exercise tests, the evidence shows the potential for SDOT to improve the efficacy of oxygen 
therapy. In Table 8.1 the various methods of evaluation and associated results presented have 
been summarised. 
During the preliminary preclinical investigations, the SDOT controller was developed 
into a Simulink™ computer simulation incorporating a model for the patient dynamic response. 
These simulations were run against a sweep of input disturbance frequencies as well as real 
patient data recorded during overnight oximetry monitoring. The simulation results illustrated 
the potential for SDOT to attenuate fluctuations in the arterial oxygen saturations across a wide 
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range of disturbance frequencies. Furthermore, the results showed that SDOT could improve the 
efficacy of oxygen therapy compared to constant flow (CONS) simulations, on average 
reducing the time spent with SpO] < 90% by of 66%. 
These findings were further substantiated by the outcome of the randomised clinical 
study on oxygen therapy patients during exercise testing. Acting as their own controls, patients 
repeated a standardised exercise test with both SDOT and CONS modes in random order. The 
results indicated a statistically significant improvement in efficacy using SDOT. This was 
verified in both the Incremental Shuttle Walk Test (ISWT) as well as the Six Minute Walking 
Test (6MWT). The effect was more pronounce in the 6MWT group, when compared to CONS, 
SDOT reduced the time spent with SpO; < 90% by an average of 55%. 
Table 8.1: Results summaiy 
Chapter Procedure Description Results Overview 
Ch.2 Closed-Loop Control Simulation 
• Model patient dynamic response 
• SDOT controller design 
• Frequency sweep analysis 
• Controller attenuated input 
disturbance 
• Attenuation was function 
of disturbance frequency 
Ch.3 Patient Data Simulations 
• Input over-night oximetry data 
• Compared SDOT, CONS and 
untreated patient models 
• SDOT could improve 
efficacy of oxygen therapy 
• Time w/ SpO; < 90% 
reduced by SDOT by an 
average of 66% vs. CONS 
Ch.5 Incremental Shuttle Walk Test Group 
• Randomised crossover study, 
SDOT vs. CONS 
• Standardised exercise assessment 
(ISWT) 
• Potential for oxygen 
conservation benefits using 
SDOT 
• Time w/ SpO; < 90% 
reduced by SDOT by an 
average of 17% vs. CONS 
• Decrease in overall depth 
of desaturation 
Ch.6 Control Design Modification 
• Revisde patient model based on 
ISWT data 
• Controller modifications using 
simulations and clinical data 
• Measured lung-to-capillary 
delay time longer than 
predicted 
• Modified SDOT eliminated 
hunting behaviour 
Ch. 7 Six Minute Walk Test Group 
• Randomised crossover study, 
SDOT vs. CONS 
• Standardised exercise assessment 
(6MWT) 
• Improvement in mean 
exercise SpO] with SDOT 
• Time w/ SpO] < 90% 
reduced by SDOT by an 
average of 55% vs. CONS 
96 
8.3 Areas for Future Research 
The preclinical and clinical findings presented are indicative of the physiological 
benefits possible from implementing Saturation Driven Oxygen Therapy. It has been shown that 
SDOT can reduce the incidence of intermittent hypoxaemia associated with the current 
supplemental oxygen treatment. However, additional research will be required to expand the 
limited scope of the clinical results presented in new areas such as sleep, potential long-term 
benefits, and clinical applications. 
8.3.1 Sleep Studies 
The scope of the present clinical evaluation was limited to exercise hypoxaemia. 
Similar to exercise, another condition where arterial oxygen saturations are known to fluctuate 
is sleep. Overnight sleep oximetry and carbon dioxide measurements can be taken overnight for 
up to 8 hrs while the patient sleeps. Overnight sleep studies are another form of routine 
assessments conducted to establish the patient requirement for oxygen therapy. Given the 
positive acute results for SDOT during standardized exercise testing, future pilot research 
should also be planned to evaluate the effects of SDOT during sleep. Both conditions are 
important due to the differences in the time dependent O2 fluctuations between exercise and 
sleep. In practice, the controller will have to manage gradual shifts in saturation as during sleep, 
as well as more quickly changing saturations such as during exercise. Although the original 
clinical study plan called for additional crossover sleep studies, these were removed as a result 
of the limited resources available. 
8.3.2 Health Technology Assessment Proposal 
Nevertheless acute studies during exercise or even sleep can not establish the potential 
long-term benefits to morbidity, mortality, and quality of life from an automated oxygen flow 
regulation for patients. Future studies should aim to quantify the symptomatic and long-term 
health benefits of SDOT. A chronic study of SDOT within the domiciliary setting for LTOT 
patients is therefore necessary to make a determination of the Health Technology Assessment. 
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A Health Technology Assessment is a review conducted by the National Institute for Clinical 
Excellence (NICE) to consider the cost-utility analysis for new treatments. The scope of such 
research would be to evaluate both the clinical and cost effectiveness of SDOT. The following 
is an outline for a future possible Health Technology Assessment. 
Desisn: 
The proposal is for a randomised control study to evaluate the clinical and cost utility of 
Saturation Driven Oxygen Therapy (SDOT) compared to standard Long Term Oxygen Therapy 
(LTOT). Participants will be randomly allocated using the envelope method to either SDOT or 
LTOT study groups and monitored for a period of 6 months. Each participant will be given 
either SDOT or sham SDOT test device to blind the allocated treatment. 
Settins: 
The aim of the study is to evaluate the potential benefits of SDOT within the 
domiciliary setting for outpatients requiring LTOT. Participants will have a baseline hospital 
assessment after initial enrolment into the study. Thereafter, participants will be visited at home 
for the test device installation and instruction, and followed up immediately within the first 
week to ensure proper device use. At the end of the 6 month study period, participants will 
repeat the initial hospital assessment and complete an exit study questionnaire. 
Tarset Population: 
The acceptance criteria for the study will be participants who require chronic 
supplemental oxygen ftilfilling the criteria for LTOT. LTOT is standard treatment for chronic 
hypoxemia in patients with respiratory failure due to conditions such as chronic obstructive 
pulmonary disease, interstitial lung disease, cystic fibrosis, and others. Patients with 
comorbidities which may result in dropping out within 6 months, or other limitations preventing 
their participation during the hospital assessment will be excluded. All participants will be 
recruited on a volunteer basis. 
Health Technolosv Beins Assessed: 
SDOT uses a closed-loop controller capable of automatically vaiying flow-rates during 
oxygen therapy in response to the integrated pulse oximetry measurement. The SDOT stand-
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alone device configuration can be used in series with conventional oxygen supplies like gas 
cylinders or concentrators. The patient is solely required to wear a discrete ear clip sensor 
together with their standard oxygen nasal cannula. 
Pilot clinical results indicate the benefit for SDOT to automatically regulate oxygen 
delivery, enabling patients to fully maximise the benefits of their oxygen therapy. Acute patient 
benefits may include improved symptomatic relief from debilitating shortness of breath, 
improved sleep quality, and greater mobility. Long term patient benefits may include reduced 
strain on the heart thereby leading to a decreased frequency of GP visits and emergency hospital 
admissions. 
Measurement Of Costs And Outcomes: 
The primary measures include the 6 minute walk test to assess exercise ability. Medical 
Research Council (MRC) score for dyspnoea, and relative predicted mortality using the BODE 
index (Body mass index, degree of Obstruction, Dyspnoea, and Exercise capacity). These 
outcomes will be the health related quality of life (HRQL) factors to determine the impact of 
SDOT as compared to LTOT. Secondary measures will include PaCO] as an indication of 
hypercapnia, self-reported sleep quality, total days spent in hospital, and frequency of GP visits 
or hospital admission for respiratoiy related exacerbations. Intra-group and inter-group statistics 
will be determined using a two-sided one sample (paired) and two sample (unpaired) student t-
test, respectively, or the corresponding Wilcoxon signed rank test for non-parametric data. 
Direct treatment costs for SDOT and LTOT will be tracked and provided by the participating 
PCT. Additionally, NHS costs will be determined for GP visits and hospital admissions based 
from official listing published by the Department of Health or other public price listings. Patient 
health outcomes captured in the HQRL measures will be assigned appropriate values using the 
standard choice-based EQ-5D questionnaire. Correspondingly, the quality life adjusted years 
(QALYs) will be calculated and projected over the treatment lifetime. In this instance, the time 
horizon for the cost-effectiveness model will extend for the mean anticipated years requiring 
chronic supplemental oxygen therapy. 
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Sample Size: 
The requisite sample size was determined based upon a review of all the primary 
outcome measures to achieve a power of 90% and a significance level of 5%. The review of 
primary measures revealed the BODE index required the largest samples size, 34 in each group 
to detect a difference of 1 in the BODE index, assuming the group standard deviation of 1.2. 
This has been increased to 40 per group (total of 80), to allow for a predicted dropout from 
treatment of around 20%. 
Project Timetables: 
Full proposal submission approx. 07/2007. 
• Regional Ethics Committee application on 09/2007. 
Project start on 01/2008. 
• Patient enrolment until 07/2008. 
Patient follow-up until 01/2009. 
Data review and final write up completed 05/2009. 
8.3.3 Diagnostic and Other Applications 
The SDOT system could be initially introduced as an objective diagnostic device, 
making it easier to accurately prescribe oxygen therapy for patients. Recently, the British 
Thoracic Society surveyed over 100 GPs and nurses; revealing 56% did not feel any degree of 
confidence in referring a patient for oxygen therapy [51]. As a consequence, to prescribe an 
appropriate fixed-flow oxygen setting, the revised NHS Home Oxygen Service, introduced in 
February 2006, requires patients to undergo four labour-intensive repeat assessments over the 
first 12 months. The automated diagnostic tool will provide systematic and reproducible results 
for assessing oxygen therapy prescriptions. The eventual aim is to develop a therapeutic SDOT 
device for patients with COPD and other respiratory disorders undergoing domiciliary treatment 
with LTOT. The therapeutic device would reduce the latent episodes of intermittent hypoxemia 
associated with oxygen therapy and help reduce patient/GP anxiety over fixed prescriptions. 
In addition, the SDOT system could be used in hospital and emergency acute care to 
prevent oxygen both under or overdosing. In critical care, ambulance and emergency settings 
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some respiratory patients can be susceptible to excessive oxygen doses leading to potentially 
serious complications from increasing CO2. Excessive oxygen can depress the ventillary drive. 
This is a common problem during treatment for respiratory failure in patients with COPD. 
Hypercapnia from CO2 retention can result in acidaemia, blood pH below 7.3, leading to 
depression in cardiorespiratory function and multi-organ failure and is associated with a higher 
incidence of intensive care admission [52,53]. Potentially, the SDOT controller could be 
adapted to incorporate additional transcutaneous CO2 input feedback for better managing 
hypercapic patients. Other potential critical care applications also include paediatrics. SDOT 
would reduce the risks associated with oxygen therapy in premature infants, for whom constant 
flow oxygen can cause permanent complications such as blindness and chronic lung disease 
[54,55]. 
8.4 Future Product Development 
The next area of technical development will be to incorporate SDOT into a single stand-
alone device. In order to facilitate future research, a user friendly device must be developed to 
allow clinicians and patients to access SDOT with only minimal specialised training. This may 
best be done through a commercial entity with an aim toward marketing the technology. 
Through a technology transfer proof of concept award from Imperial Innovation Ltd, the 
company Dynamic Therapeutics Ltd has been formed around the SDOT technology. The 
company has also been awarded additional support by: 
2006-07 Runners up in Tanaka Business School New Business Challenge (£5,000) 
2005-06 Runners up in the Research Councils UK Business Plan Award (£10,000), 
2007 ERA Foundation Award from the Royal Academy of Engineering (£40,000). 
These awards will help Dynamic Therapeutics Ltd accelerate the technology development to 
market. This new company is dedicated to bringing together engineering innovation to meet 
clinical demands working directly with medics and patients to improve the standard of care in 
oxygen therapy. 
Figure 8.1 shows a conceptual SDOT system diagram for the stand-alone unit. The 
laptop has been replaced with a dedicated microprocessor which receives blood oxygen 
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measurements from an integrated pulse oximeter (a non-invasive sensor, typically fitted to the 
patient's ear) and automatically computes the optimum oxygen flow-rate. The microprocessor 
controls a flow valve regulating the delivery of oxygen to the patient. A healthy target range for 
oxygen saturation is achieved using the SDOT feedback control system. The system 
subcomponents shown are integrated into a single stand alone device approximately the size of 
a PDA. This configuration can be used inline with conventional oxygen supplies. The patient is 
solely required to wear a discrete ear clip sensor together with their standard oxygen nasal 
cannula. 
Patient 
Concentrator 
r z ? 
Ear Sensor 
SDOT Device 
Flow Regulator 
Controller A . 
Pulse Oximeter 
Figure 8.1: Integrated SDOT unit 
8.5 Cost-Benefit Model 
As part of the overall assessment of SDOT, it is vital to consider the potential economic 
impact of such new technologies. In a healthcare system with finite resources, it is important to 
balance the clinical benefits together with the potential cost implications. 
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SDOT can enhance quality of life for patients while also decreasing the associated costs 
to the health services. Major savings are achievable through reducing hospital stays and 
emergency admissions. Early intervention is key to preventing deterioration in a patient's 
condition, reducing the need for hospital stays and GP visits [56]. Based upon the published 
clinical and quantified financial data [12,41], the cost-benefit model presented below suggests 
that SDOT could decrease these patients' average yearly hospital stays by more than 15%. 
Currently, oxygen therapy prescriptions require the additional burden of four follow-up visits 
within the first year. SDOT will also eliminate these costly repeat visits, reducing man-hour 
expenditure by 65% (8 hrs per patient) [41]. 
8.5.1 Model Assumptions 
Time span: 3 years 
Rationale - Fixed costs averaged over time span. 3 years is conservative 
estimate since average survival on oxygen therapy is 10 years. 
SDOT unit cost: £555.00 
Rationale — Benchmarked against pulse oximeter & 0 2 concentrators 
SDOT eliminates prescription follow up visits 
Rationale — Automated feedback eliminates fixed prescriptions 
Reduced hospital stav with SDOT bv a minimum of 15% 
Rationale — Recent studies found patients on LTOT spend 25% of each day 
with detrimentally low oxygen. SDOT is estimated to reduce time with low 
oxygen by 60% based on preliminary data. As the NOTT study found a 
proportional relationship between time spent on oxygen therapy and survival, a 
conservative forecast reveals a 15% reduction in hospital stays (25% x 60% = 
15%). 
*These savings could be potentially much greater. A trial conducted by the 
Carlisle PCT showed that proactive home monitoring can reduce hospital stays 
for COPD patients by almost 50% [56]. 
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8.5.2 Model Figures 
Table 8.2: UK Cost benefit model 
United Kindom - 60,000 patients 
Average Annual Cost 
Unit Cost LTOT SDOT Savings 
Oxygen Service Costs 
Fixed: Install £45 15.00 15.00 
Backup £3 1.00 1.00 
Withdrawl £9 3.00 3.00 
SDOT unit £555 n/a 185.00 
Variable: Rental £16/mo 192.00 192.00 
Service £17/quarter 68.00 68.00 
Electric £0.07/hr 485.45 485.45 
Subtotal 764.45 949.45 (£185.00) 
Prescription Costs 
Initial Assessment 4 hrs 136.00 136.00 
Follow-up Visits 8 hrs 272.00 n/a 
Subtotal 408.00 136.00 £272.00 
Hospital Stay Costs (1.3 addmissions/yr) 
LTOT Costs £1,264/stay 1,643.20 n/a 
SDOT Costs (15% reduction) £1,074/stay n/a 1,396.72 
Subtotal 1,643.20 1,396.72 £246.48 
Total Per Patient 2,815.65 2,482.17 £333.48 
NHS Patients On LTOT NHS Cost SDOT Cost Gross Savings Net Savings 
60,000 £169m £(11m) £31 m £20m 
[Figures on costs referenced from 57,58] 
The cost-effectiveness model for the UK indicates SDOT can reduce prescriptions costs 
by £272 (65%) and hospital costs by more than £246 (15%) per patient. Across the NHS, these 
cost reductions would result in a net savings of £20m (12%). 
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Table 8.3: USA Cost benefit model 
United States - 1,700,000 patients 
Average Annual Cost 
Unit Cost LTOT SDOT Savings 
Oxygen Service Costs 
Fixed SDOT unit 
Variable: HOS 
£555 
£928/yr 
n/a 
928.00 
185.00 
928.00 
Subtotal 928.00 1,113.00 (£185.00) 
Prescription Costs 
Initial Assessment 
Follow-up Visits 
4 hrs 
8 hrs 
75.60 
170.00 
75.60 
n/a 
Subtotal 245.60 75.60 £170.00 
Hospital Stay Costs (1.3 addmissions/yr) 
LTOT Costs £2,092/stay 
SDOT Costs (15% reduction) £1,778/stay 
2,719.60 
n/a 
n/a 
2,311.66 
Subtotal 2,719.60 2,311.66 £407.94 
Total Per Patient 3,893.20 3,500.26 £392.94 
US Patients On LTOT OT Cost SDOT Cost Gross Savings Net Savings 
1,700,000 £6,615m £(314m) £981 m £667m 
[Figures on costs referenced from 59] 
The cost-effectiveness model for the US indicates SDOT can reduce prescriptions costs 
by £170 (70%) and hospital costs by more than £407 (15%) per patient. Across the US, these 
cost reductions would result in a net savings of £667m (10%). 
8.6 Closing Remarks 
An interdisciplinary approach was taken in the development and evaluation of the 
Saturation Driven Oxygen Therapy system, considering not only the technical aspects but also 
the potential clinical and economic impact. The progress of this project required a holistic 
perspective to bridge the fields of engineering and medicine in order to find a new solution for 
patients with oxygen therapy. 
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APPENDIX A.1 
Patient Study Reports 
ient No. Study Date Page 
001 24.04.06 110 
002 10.05.06 114 
003 07.07.06 118 
004 11.08.06 122 
005 12.09.06 126 
006 26.09.06 130 
007 26.09.06 134 
008 28.09.06 138 
009 25.10.06 142 
010 Cancelled N/A 
Oil 23.04.07 146 
012 03.05.07 150 
013 30.05.07 154 
014 06.06.07 158 
015 07.06.07 162 
016 12.06.07 166 
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NHS Trust DATE: 24/04/2006 
STUDY SUMMARY 001 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID; 001 Age: 68 Sex: Male Height: 6'1" Study date: 24/04/2006 
Primary Diagnosis: COPD/Asthma Secondary conditions: Parkinson's 
Average No. hospital admission per year: 1-2 Most recent: Feb '06 
Current Inhalers: Seretide, Salbutamol 
Present Therapy: Home & ambulatory oxygen at 2 1pm 
Spirometry: FEVl = .0.6 FEC = 1.4 
II. PRACTICE TEST 
Practice Test Mean Max Min 
Sp02 92.46 96 81 
Flow 2 2 2 
HR 88.46 107 78 
l otal time = 636.3 sec Time Sp02 <90 = 0.29% Missing data = 0% 
Borg Score: Initial = 1 Post ISWT = 5 2 min Post ISWT = 3 
Distance walked = 110m (168 sec) 
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Roval Brompton & Harefield 
NHS Trust DATE: 24/04/2006 
STUDY SUMMARY 001 VER: 1 
III. r' TEST 
Setpoint = 91% 
AUTO Mean Max Min 
Sp02 92.35 98 84 
Flow 1.45 4.2 0 
HR 88.77 109 78 
Total time = 978.9 sec Time Sp02 <90 = 0.167% Missing data = 0% 
Borg Score: Initial = 1 Post ISWT = 5 2 min Post ISWT = 2 
Distance walked = 130m (190 sec) 
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110 
100 
90 
80 
E 
Q. 
a: 
t; 
3 
I 
P 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 320 94.1 93 0% (0 s) 
Preparation 320 500 91.9 90 0% (0 s) 
ISWT 500 690 89.2 85 56.6% (107 s) 
Recovery 690 875 91.5 84 28.2% (52 s) 
Recover to baseline following ISWT = 105 sec 
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Royal Brompton & Harefield 
NHS Trust DATE: 24/04/2006 
STUDY SUMMARY 001 VER: 1 
IV. l""* TEST 
Flow 21pm 
CONS Mean Max Min 
Sp02 93.99 98 81 
Flow 2.0 2.0 2.0 
HR 89.32 114 79 
Total time = 1481.9 sec Time Sp02 <90 = 0.154% Missing data = 0% 
Borg Score: Initial = 1 Post ISWT = 6 2 min Post ISWT = 2 
Distance walked = 140m (200 sec) 
Return ISWT Baseline 
r y 9 0 O 
lime (rr 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 680 96.9 93 0% (0 s) 
Preparation 680 850 94.9 91 0% (0 s) 
ISWT 850 1050 88.2 81 53.5% (107 s) 
Recovery 1050 1450 92.4 81 28.2% (112 s) 
Recover to baseline following ISWT = 165 sec 
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STUDY SUMMARY 001 VER: 1 
Therapy Comparison I SWT Including Recovery 
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NHS Trust DATE: 11/05/2006 
STUDY SUMMARY 002 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 002 Age: 51 Sex: Male Height: 5'0" Study date: 10/05/2006 
Primary Diagnosis: Kyphoscoliosis Secondary conditions: Type 2 respiratory 
failure, pulmonary 
hypertension 
Average No. hospital admission per year: 0-1 Most recent: Feb-Mar '06 
Current Inhalers: Becotide 
Present Therapy: Home & ambulatory oxygen at 11pm 
Spirometry: FEVl = .0.65 FEC = 0.93 
H. PRACTICE TEST 
0.0 1pm 
Practice Test Mean Max Min 
Sp02 93.5 99 78 
Flow 0 0 0 
HR 112.1 150 96 
Total time = 1259 sec Time Sp02 <90 = 26.0% Missing data = 0% 
Borg Score: Initial = 0 Post ISWT = 3 2 min Post ISWT = 1 
Distance walked = 360m (340 sec) 
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NHS Trust DATE: 11/05/2006 
STUDY SUMMARY 002 VER: 1 
III. 1"' TEST 
Setpoint = 91% 
AUTO Mean Max Min 
Sp02 94.7 98 86 
Flow 0.8 4.2 0 
HR 113.3 147 93 
Total time = 1259 sec Time Sp02 <90 ^ 
Borg Score: Initial = 0 Post ISWT = 5 
Distance walked = 490m (402 sec) 
: 9.6% Missing data = 0% 
2 min Post ISWT = 2 
Return Baseline ISWT 
^ - 1 4 0 E 
1 3 0 " ^ 
m 
1201% 
110^ 
100 S 
8 10 12 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 340 96.9 96 0% (0 s) 
Preparation 320 423 96.2 94 0% (0 s) 
ISWT 423 825 92.0 86 19.5% (78 s) 
Recovery 825 1150 94.9 87 10.8% (35 s) 
Recover to baseline following ISWT = 109 sec 
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Royal Brompton & Harefield 
NHS Trust DATE: 11/05/2006 
STUDY SUMMARY 002 VER: 1 
IV. 2"° TEST 
Flow 11pm 
CONS Mean Max Min 
Sp02 95.3 100 80 
Flow 1.0 1.0 1.0 
HR 114.7 147 92 
Total time = 1023 sec Time Sp02 <90 ^ 
Borg Score: Initial - 0 Post ISWT = 5 
Distance walked = 450m (372 sec) 
18.3% Missing data = 0% 
2 min Post ISWT = 1 
Baseline ISWT Return 
140 g. 
100 Q) 
8 10 
T i m e (mini) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 (%) Percent Time Sp02 < 90 
Baseline 0 200 99.0 97 0% (0 s) 
Preparation 200 298 98.9 98 0% (0 s) 
ISWT 298 670 92.6 84 30.0% (112 s) 
Recovery 670 1000 94.7 80 23.1% (78 s) 
Recover to baseline following ISWT = 193 sec 
1 1 8 -
Royal Brompton & Harefield 
NHS Trust DATE: 11/05/2006 
STUDY SUMMARY 002 VER: 1 
Therapy Comparison I SWT including Recovery 
CONS 
AUTO 
A U T O 
Q . 
JQ 130 
CD 125 
120 
O) 
C O N S 
A U T O 
Default flow 1 1pm 
700 
800 
100 200 300 400 
Time (s) 
500 600 700 800 
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Royal Brompton & Harefield 
NHS Trust DATE: 07/07/2006 
STUDY SUMMARY 003 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
1. HISTORY 
ID: 003 Age: 55 Sex: Female Height: 5'2" Study date: 07/07/2006 
Primary Diagnosis: COPD Secondary conditions: N/A 
Average No. hospital admission per year: 0 Most recent: N/A 
Current Inhalers: Seretide, Spiriva 
Present Therapy: No current oxygen therapy 
Spirometry: FEVl = .0.7 FEC = 1.35 
II. PRACTICE TEST 
0.0 Ipm 
Practice Test Mean Max Min 
Sp02 95 N/A 86 
Flow 0 0 0 
HR N/A N/A N/A 
Total time = N/A Time Sp02 <90 = N/A Missing data = N/A 
Borg Score: Initial — 2 Post ISWT = 3 2 min Post ISWT = 2 
Distance walked = 350m (315 sec) 
Notes* Shuttle walk conducted 1 week prior, no practice test was repeated during study 
- 1 2 0 -
Royal Brompton & Harefield 
NHS Trust DATE: 07/07/2006 
STUDY SUMMARY 003 VER: 1 
III. 1"' TEST 
Setpoint = 91% 
AUTO Mean Max Min 
Sp02 94.9 98 83 
Flow 0.8 4.8 0 
HR 107.8 158 80 
Total time = 1476 sec Time Sp02 <90 = 14.2% Missing data = 0% 
Borg Score: Initial = 1 Post ISWT = 4 2 min Post ISWT = 2 
Distance walked - 400m (352.5 sec) 
Return ISWT Baseline 
14oE-
(U 
120 m 
ct: 
8 10 12 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 192 96.7 95 0% (0 s) 
Preparation 192 361 97.5 97 0% (0 s) 
ISWT 361 714 91.0 87 37.5% (132 s) 
Recovery 714 1200 95.0 83 15.9% (77 s) 
Recover to baseline following ISWT = 152 sec 
- 1 2 1 -
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NHS Trust DATE: 07/07/2006 
STUDY SUMMARY 003 VER: 1 
IV. 2"" TEST 
Flow 11pm 
CONS Mean Max Min 
Sp02 94.4 99 78 
Flow 1.0 1.0 1.0 
HR 102 151 78 
Total time = 1462 sec Time Sp02 <90 • 
Borg Score: Initial = 0.5 Post ISWT = 3 
Distance walked = 470m (330 sec) 
18.9% Missing data = 
2 min Post ISWT = 1 
0% 
100 
90 
CM o 
Q. 
CO 80 
5 
^ 4 
E 
^ 3 
0 
Baseline Prep 
ui—vrS A 
10 
10 
ISWT 
15 
15 
T i m e ( m i n ) 
Return 
20 
20 
160 _ 
140 Q. 
120 Q) 
m 
100 CC 
so I 
2l° 
25 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 564 97.5 96 0% (0 s) 
Preparation 564 774 97.3 95 0% (0 s) 
ISWT 774 1104 88.6 79 59.4% (196 s) 
Recovery 1104 1462 93.4 78 22.4% (84 s) 
Recover to baseline following ISWT = 226 sec 
- 1 2 2 -
Royal Brompton & Harefield 
NHS Trust DATE: 07/07/2006 
STUDY SUMMARY 003 VER: 1 
100 
Therapy Comparison I SWT including Recovery 
Setpoint at 91 
700 
A U T O 
300 400 
Time (s) 
A U T O 
300 400 
Time (s) 
A U T O 
C O N S 
Default flow 1 1pm 
700 
300 400 
Time (s) 
700 
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Royal Brompton & Harefield 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 004 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID; 004 Age: 61 Sex: Male Height: 5'1" Study date: 11/08/2006 
Primary Diagnosis: Kyphoscoliosis Secondary conditions: 
Average No. hospital admission per year: 2 Most recent: June '06 
Current Inhalers: Becotide, Ventolin 
Present Therapy: Home & ambulatory oxygen at 2 1pm 
Spirometry: FEVl = 0.5 FEC = 0.6 
H. PRACTICE TEST 
2.0 1pm *Portable cylinder w/ conserver 
Practice Test Mean Max Min 
Sp02 86 92 68 
Flow 2 2 2 
HR 78.7 98 67 
Total time = 1230 sec Time Sp02 <90 
Borg Score: Initial = 0.5 Post ISWT = 4 
Distance walked = 180m (240 sec) 
69.0% Missing data = 0% 
2 min Post ISWT = 2 
ISWT Return Baseline 
90 o 
80 ro 
O 80 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 004 VER: 1 
III. 1"' TEST 
Flow 2 1pm 
CONS Mean Max Min 
Sp02 90.6 96 66 
Flow 2.0 2.0 2.0 
HR 86.5 110 75 
Time Sp02 <90 = 24.1% Total time = 1518 sec 
Borg Score: Initial = 0 Post ISWT = 4 
Distance walked = 240m (285 sec) 
Vlissing data = 0% 
2 min Post ISWT = 1 
Return ISWT Baseline 
90 (0 
O 80 
10 15 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 400 95.4 94 0% (0 s) 
Preparation 400 940 92.7 88 9.3% (50 s) 
ISWT 940 1225 82.80 69 71.5% (203 s) 
Recovery 1225 1518 87 66 38.7% (113 s) 
Recover to baseline following ISWT = 173 sec 
* False start to test during 6"* minute. Stopped shuttle walk due to Sat < 70% 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 004 VER: 1 
IV. 2°" TEST 
AUTO Mean Max Min 
Sp02 90.6 96 81 
Flow 2.4 4.8 0.1 
HR 85.3 108 76 
Total time = 1021 sec Time Sp02 <90 = 28.9% Missing data = 0% 
Borg Score: Initial = 0.5 Post ISWT = 4 2 min Post ISWT = 1 
Distance walked = 200m (255 sec) 
Baseline Return ISWT 
90 (0 
O 80 
10 12 
T i m e ( m i n ) 
14 16 
Recover to baseline following ISWT - 61 sec 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 800 1020 92.0 87 18.3% (40 s) 
Preparation 0 205 89.9 81 33.8% (65 s) 
ISWT 205 460 88/7 82 51.2% (130 s) 
Recovery 460 800 91.5 83 17.8% (60 s) 
1 2 6 -
Royal Brompton & Harefield 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 004 VER: 1 
100 
Setpoint at 91 
Therapy Comparison I SWT including Recovery 
600 
CO 8 0 
A U T O 
C O N S 
A U T O 
C O N S 
A U T O 
C O N S 
Default flow 2 Ipm 
600 
3 0 0 
Time (s) 
600 
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Royal Brompton & Harefield f W R 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 005 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 005 Age: 57 Sex: Female Height: 5'5" Study date: 12/09/2006 
Primary Diagnosis: COPD Secondary conditions: n/a 
Average No. hospital admission per year: 6 Most recent: June '06 
Current Inhalers: Salbutamol, Beclomethasome, Ipratropium 
Present Therapy: Home & ambulatory oxygen at 11pm 
Spirometry: FEVl = 0.25 FEC = 0.5 
II. PRACTICE TEST 
CONS 1.0 1pm 
Practice Test Mean Max Min 
Sp02 87.7 92 75 
Flow 1 1 1 
HR 108 129 96 
Total time = 1078 sec Time Sp02 <90 — 60.6% Missing data = 0% 
Borg Score: Initial = 0.5 Post ISWT = 9 2 min Post ISWT = 7 
Distance walked = 70m (120 sec) 
Baseline rswT Return 
1 2 0 o" 
(U 
110 "to 
a: 
CM 85 
% ™ 
5 
^ 4 
E 
^ 3 
^ 1 
0. 8 
T i m e 
ic 
( m i n ) 
12 14 16 18 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 005 VER: 1 
AUTO Mean Max Min 
Sp02 88.9 95 80 
Flow 3.1 5.0 0.1 
HR 110 134 97 
Total time = 1 )64 sec Time Sp02 <90 = 44.2% Missing data = 
Borg Score: Initial = 1 Post ISWT = 9 2 min Post ISWT = 7 
Distance walked = 180m (240 sec) 
0% 
Baseline Prep ISWT Return 
lOOr 
95 
SR 90 
CN 85 o 
a . 80 U) 
75 
7 o j 
U 10 12 14 16 
8 10 
T i m e ( m i n ) 
140 
120 = 
100 
E 
Q. 
<U 
" T O 
a: 
•e 
03 
0) 
X 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 (%) Percent Time Sp02 < 90 
Baseline 0 330 90.5 86 35.6% (109 s) 
Preparation 330 440 91.6 90 0% (0 s) 
ISWT 440 680 85.4 82 92.5% (221 s) 
Recovery 680 1060 89.1 80 35.9% (136 s) 
Recover to baseline following ISWT = 157 sec 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 005 VER: 1 
IV. 2°" TEST 
Flow 2 1pm 
CONS Mean Max Min 
Sp02 86.0 93 72 
Flow 2 2 2 
HR 109 133 96 
Total time = 794 sec Time Sp02 <90 = 61.2% Missing data = 0% 
Borg Score: Initial = 2 Post ISWT = 9 2 min Post ISWT = 5 
Distance walked = 140m (200 sec) 
Baseline ISWT Return 
120 0) 
CN 85 
1100: 
100 5 
6 8 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 (%) Percent Time Sp02 < 90 
Baseline 0 200 88.7 85 61.8% (122 s) 
Preparation 200 260 91.1 89 3.4% (2 s) 
ISWT 260 460 81.4 76 99.5% (199 s) 
Recovery 460 790 86.1 72 49.8% (164 s) 
Recover to baseline following ISWT = 187 sec 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 005 VER: 1 
100 
I SWT + Recovery 
Setpoint at 91 
A U T O 
C O N S 
A U T O 
C O N S 
A U T O 
C O N S 
Default flow 2 1pm 
600 
600 
300 
Time (s) 
600 
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Roval Brampton & Harefield 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 006 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 006 Age: 69 Sex: Male Height: 5'8" Study date: 26/09/2006 
Primary Diagnosis: COPD Secondary conditions: Diabetes 
Average No. hospital admission per year: 3 Most recent: Sept '06 
Current Inhalers: Spiriva, Seretide 
Present Therapy: Home & ambulatory oxygen at 2 Ipm 
Spirometry: FEVl = 0.65 FEC = 1.3 
n . PRACTICE TEST 
CONS 2.0 1pm 
Practice Test Mean Max Min 
Sp02 95.2 96 92 
Flow 2 2 2 
HR 100.6 117 93 
Total time = 857 sec Time Sp02 <90 = 0% Missing data = 0% 
Borg Score: Initial = 0.5 Post ISWT = 4 2 min Post ISWT = 3 
Distance walked = 50m (90 sec) 
Baseline ISWT Return 
100 (D 
- 132 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 006 VER: 1 
III. 1"' TEST 
CONS 2.0 1pm 
AUTO Mean Max Min 
Sp02 95.1 97 93 
Flow 2 2 2 
HR 123.8 140 113 
Total time = 613 sec 
Borg Score: Initial = 1 Post ISWT 
Distance walked = 60m (105 sec) 
Time Sp02 <90 = 0% Vlissing data = 0% 
2 min Post ISWT = 4 
Return ISWT Baseline 
CN 94 
T i m e ( m m ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 117 95.5 95 0% (0 s) 
Preparation 117 239 95.3 95 0% (0 s) 
ISWT 239 344 94.5 93 0% (0 s) 
Recovery 344 610 95.0 93 0% (0 s) 
Recover to baseline following ISWT = 84 sec 
- 133 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 006 
— ZTTl — 
VER: 1 
Setpoint = 91% 
CONS Mean Max Min 
Sp02 93.6 98 89 
Flow 0.6 4.2 0 
HR 103.8 125 89 
Total time = 939 sec Time Sp02 <90 
Borg Score: Initial = 2 Post ISWT = 7 
Distance walked = 80m (132 sec) 
= 5.9% Missing data = 0% 
2 min Post ISWT = 4 
Baseline ISWT Return 
120 Q. 
110 (U 
to 
l o o c r 
tL 
90 (0 
CN 94 
6 8 
T i m e ( m i n ) 
Recover to baseline following ISWT = 70 sec 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 100 481 94.2 93 0% (0 s) 
Preparation 481 612 92.7 90 0% (0 s) 
ISWT 612 744 91.3 89 23.7% (31 s) 
Recovery 744 938 93.3 89 12.4% (24 s) 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 006 VER: 1 
100 
Setpoint at 91 
A U T O 
A U T O 
Q l 125 
- Q 
CO 1 2 0 
S 115 
A U T O 
efauit flow 2 Ip 
4 0 0 
4 0 0 
150 2 0 0 2 5 0 
Time (min) 
4 0 0 
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NHS Trust DATE: 1 1 / 0 8 / 2 0 0 6 
STUDY SUMMARY 0 0 7 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 007 Age: 53 Sex: Female Height: 5 ' 4 " Study date: 26/09/2006 
Primary Diagnosis: C O P D Secondary conditions: OSA, Diabetes 
Average No. hospital admission per year: 0 Most recent: 2001 
Current Inhalers: Salbutamol, Seretide, Ipratropium 
Present Therapy: 16 hrs home oxygen at 1-1.5 Ipm 
Spirometry: F E V l = 1.25 F E C = 1.9 
II. P R A C T I C E TEST 
CONS 1.0 Ipm 
Practice Test Mean Max Min 
S p 0 2 92.3 95 88 
Flow 1 1 1 
H R 113 147 91 
Total t ime = 753 sec Time S p 0 2 <90 
Borg Score: Initial = 0.5 Post ISWT = 6 
Distance walked = 80m (132 sec) 
8 . 6 % Missing data = 0 % 
2 min Post ISWT = 0.5 
100 
^ 95 
CM 
O 
^ 90 
85, 
5 
^ 4 
E 
0 3 
" - 1 
0, 
"u~~Lru 1_ 
Baseline Prep ISWT 
6 
T i m e 
Return 
160 ^ 
140 (D 
ro 
120 CC 
1 0 0 1 
10 12 
8 
( m i n ) 
10 12 14 
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NHS Trust DATE: 1 1 / 0 8 / 2 0 0 6 
STUDY SUMMARY 0 0 7 VER: 1 
III. 1"' TEST 
Flow 11pm 
A U T O Mean Max Min 
S p 0 2 92.3 94 88 
Flow 1 1 1 
H R 110 145 88 
Total t ime - 651 sec Time S p 0 2 <90 
Borg Score: Initial = 0 Post ISWT = 5 
Distance walked = 80m (132 sec) 
10.9% Vlissing data = 0 % 
2 min Post ISWT = 1 
Return Baseline ISWT 
1 0 0 tV3 
T i m e ( m m ) 
Phase Begin (s) End (s) Mean 
S p 0 2 (%) 
Min S p 0 2 
(%) 
Percent Time 
S p 0 2 < 90 
Baseline 0 200 93 92 0% (0 s) 
Preparation 200 269 93^2 92 0% (0 s) 
ISWT 269 401 91.4 89 20.3% (26.8 s) 
Recovery 401 650 91.8 88 18.0% (45 s) 
Recover to baseline following ISWT = 98 sec 
- 1 3 7 -
Roval Brompton & Harefield f ? / M 
NHS Trust DATE: 11/08 /2006 
STUDY SUMMARY 0 0 7 VER: 1 
CONS Mean Max Min 
S p 0 2 92.1 95 88 
Flow 0.8 4.6 0 
HR 102 149 80 
Total time = 1522 sec Time S p 0 2 <90 
Borg Score: Initial = 0 Post ISWT = 5 
Distance walked = 110m (168 sec) 
5.0% Missing data = 0% 
2 min Post ISWT = 0.5 
Baseline 
100 
CM 
O 
o. 
CO 
95 
90 
10 
5 
^ 4 
^ 1 
0. 
10 
T i m 
15 
e (mini) 
Return 
160 
140 g 
(D 
120 m 
(T 
100 
<\) 
I 
3 ^ ° 
30 
Phase Begin (s) End (s) Mean 
S p 0 2 (%) 
Min S p 0 2 
(%) 
Percent Time 
S p 0 2 < 90 
Baseline 0 800 92.2 89 0.4% (3 s) 
Preparation 800 1002 91.8 88 9.4% (19 s) 
ISWT 1002 1170 90.9 88 29.2% (49 s) 
Recovery 1170 1520 92.9 88 1.4% (5 s) 
Recover to baseline following ISWT = 54 sec 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 007 VER: 1 
Setpoint at 91. 
A U T O 
C O N S 
A U T O 
A U T O 
C O N S 
Default flow 11pm 
100 200 3 0 0 
Time (min) 
4 0 0 5 0 0 600 
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Royal Brompton & Harefield [JLU 
NHS Trust 
STUDY SUMMARY 0 0 8 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
I. HISTORY 
DATE: 1 1 / 0 8 / 2 0 0 6 
VER: 1 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
ID: 008 Age: 67 Sex: M a l e Height: 5 ' 8 " Study date: 28/09/2006 
Primary Diagnosis: C O P D Secondary conditions: 
Average No. hospital admission last year: 5 Most recent: 2006 
Current Inhalers: Salbutamol, Seretide, Ipratropium 
Present Therapy: Home and Ambulatory at 1-2 1pm 
Spirometry: F E V l = 0.65 FEC = 1.7 
n . PRACTICE TEST 
C O N S 2.0 1pm 
Practice Test Mean Max Min 
S p 0 2 93.8 - -
Flow 2 2 2 
H R 90 - -
Total t ime = 1267 sec Time S p 0 2 <90 = N/A Missing data = 6 . 7 % 
Borg Score: Initial = 2 Post ISWT = 8 2 min Post ISWT = 4 
Distance walked = 70m (120 sec) 
Note: Large section of missing data during ISWT, not able to find reliable sensor 
position 
Baseline Return 
Q . 
W 85 
100 (0 
8 10 
T i m e (nnii 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 008 VER: 1 
Flow 2 1pm 
AUTO Mean Max Min 
Sp02 91.8 95 82 
Flow 2 2 2 
HR 100.8 148 63 
Total time = 600 sec Time Sp02 <90 
Borg Score: Initial = 0.5 Post ISWT = 7 
Distance walked = 80m (132 sec) 
22.2% Missing data = 5.8% 
2 min Post ISWT = 3 
Baseline ISWT Return 
(N 90 100 (D 
Q. 
W 85 
E 
| 2 
0. 
100 2C 0 
T 
3 0 0 
m e ( s e c ) 
4 0 0 5 0 0 600 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 400 600 93.6 92 0% (0 s) 
Preparation 600 648 94.1 94 0% (0 s) 
ISWT 648 780 89.1 86 58.7% (77 s) 
Recovery 780 1000 91.4 82 25.5% (56 s) 
Recover to baseline following ISWT =112 sec 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 008 VER: 1 
IV. 2"" TEST 
CONS Mean Max Min 
Sp02 92.5 95 86 
Flow 1.9 4.6 0 
HR 103 138 72 
Total time = 786 sec Time Sp02 <90 • 
Borg Score: Initial - 0.5 Post ISWT = 8 
Distance walked = 80m (132 sec) 
10.8% Missing data = 
2 min Post ISWT = 2 
0% 
ISWT Return Baseline 
CN 90 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 250 92.8 91 0% (0 s) 
Preparation 250 408 92.5 88 7.0% (11 s) 
ISWT 408 540 91.0 88 16.7% (22 s) 
Recovery 540 780 92.9 86 21.0% (50 s) 
Recover to baseline following ISWT = 57 sec 
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Royal Brompton & Harefield f i V i S 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 008 VER: 1 
Setpoint at 93 
S - 88 
A U T O 
C O N S 
A U T O 
C O N S 
ro 100 
ct 
A U T O 
Default flow 2 Ipm 
4 0 0 
4 0 0 
1 5 0 2 0 0 2 5 0 
Time (s) 
4 0 0 
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Roval Brompton & Harefield fiV/W 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 009 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
Sex: Female Height: 5'5.5" Study date: 25/10/2006 
Secondary conditions: Diabetic, 
ID: 009 Age: 70 
Primary Diagnosis: COPD 
Pacemaker 
Average No. hospital admission last year: 5 Most recent: 2006 
Current Inhalers: Salbutamol 
Present Therapy: Home and Ambulatory at 2 1pm 
Spirometry: FEVl = 0.65 FEC = 0.9 
H. PRACTICE TEST 
CONS 2.0 1pm 
Practice Test Mean Max Min 
Sp02 90.9 98 85 
Flow 2 2 2 
HR 104.6 141 78 
Total time = 1001 sec Time Sp02 <90 = 33.3 
Borg Score: Initial = 1 Post 6MWT = 10 
Distance walked - 100m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 3 
Baseline 6MWT Return 
Q- 90 
10 
e ( m i n ) 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 009 VER: 1 
III. 1'' TEST 
AUTO Mean Max Min 
Sp02 91.8 99 85 
Flow 2 2 2 
HR 110.3 155 78 
Total time = 880 sec Time Sp02 <90 
Borg Score: Initial = 1 Post 6MWT = 7 
Distance walked = 100m (6 min test) 
25.2% Missing data = 0% 
2 min Post 6MWT = 3 
Baseline 6MWT Return 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 275 91.1 85 19.3% (47 s) 
Preparation 275 320 97.5 94 0% (0 s) 
6MWT 320 680 91.4 86 36.3% (131 s) 
Recovery 680 880 92.0 86 22.4% (45 s) 
Recover to baseline following 6MW' = 65 sec 
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NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 009 
T*7 ^nd 
VER: 1 
Total time = 1 )96 sec Time Sp02 <90 = 13.1% 
Borg Score: Initial = 0.5 Post 6MWT = 10 
Distance walked = 105m (6 min test) 
CONS Mean Max Min 
Sp02 92.2 98 85 
Flow 2.6 4.4 0 
HR 105.8 172 75 
Missing data = 0% 
2 min Post 6MWT = 
Baseline 6MWT Return 
P- 90 
10 12 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 Percent Time 
Sp02 < 90 
Baseline 0 430 91.8 87 10.5% (45 s) 
Preparation 430 470 95.6 94 0% (0 s) 
6MWT 470 830 91.7 85 21.1% (76 s) 
Recovery 830 1100 93.0 88 8.5% (23 s) 
Recover to baseline following 6M = 45 sec 
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Royal Brompton & Harefield 
Setpoint at 93 
NHS Trust DATE: 11/08/2006 
STUDY SUMMARY 009 VER: 1 
A U T O 
r u 
A U T O 
ro 1 3 0 
A U T O 
C O N S 
Default flow 2 Ipm 
200 3 0 0 4 0 0 
Time (min) 
5 0 0 600 7 0 0 
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NHS Trust DATE: 23/04/2007 
STUDY SUMMARY 011 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: Oil Age: 61 Sex: Female Height: 4'11" Study date: 23/04/2007 
Primary Diagnosis: COPD Secondary conditions: HTN 
Average No. hospital admission last year: 1 Most recent: Nov, 2006 
Current Inhalers: Spiriva, Symbicort 
Present Therapy: Home and Ambulatory at 11pm 
Spirometry: FEVl = 0.59 FEC = 1.79 
H. PRACTICE TEST 
CONS 1.01pm 
Practice Test Mean Max Min 
Sp02 90.8 96 81 
Flow 1 1 1 
HR 111.6 186 88 
Total time = 1124 sec Time Sp02 <90 = 31.3 
Borg Score: Initial = 0.5 Post 6MWT = 10 
Distance walked = 220m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 4 
Baseline 6MWT Return 
160 
CM 90 
W 85 
8 10 12 
T i m e ( m i n ) 
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Royal Brompton & Harefield 
NHS Trust DATE: 23/04/2007 
STUDY SUMMARY 011 VER: 1 
III. 1"' TEST 
Total time = 1 
AUTO Setpoint 93%, Controller V5 
AUTO Mean Max Min 
Sp02 93.5 96 89 
Flow 1.5 4.7 0 
HR 101.8 173 82 
)96 sec Time Sp02 <90 ^ 
Borg Score: Initial = 0 Post 6MWT = 7 
Distance walked = 190m (6 min test) 
1.3% Missing data = 0% 
2 min Post 6MWT = 2 
Baseline 6MWT Return 
160 P . 
^ 90 
O 
Q. 
w 85 
8 10 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 240 93.9 93 0% (0 s) 
Preparation 240 320 93.0 92 0% (0 s) 
6MWT 320 680 91.8 89 3.9% (14 s) 
Recovery 680 1090 94.8 93 0% (0 s) 
Recover to baseline following 6MW'^  ' = 7 sec 
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Royal Brompton & Harefield 
NHS Trust DATE: 23/04/2007 
STUDY SUMMARY 011 VER: 1 
CONS Flow 11pm 
CONS Mean Max Min 
Sp02 91.4 97 83 
Flow 1 1 1 
HR 102 134 80 
Total time = 932 sec Time Sp02 <90 = 34.8% 
Borg Score: Initial = 0 Post 6MWT = 10 
Distance walked = 175m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 1 
Baseline 6MWT Return 
160 A 
cs 90 
Q . 
W 85 
I' 
6 8 10 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 160 95.0 94 0% (0 s) 
Preparation 160 235 94.4 93 0% (0 s) 
6MWT 235 595 8&2 83 83.9% (302 s) 
Recovery 595 930 94.6 85 6.9% (23 s) 
Recover to baseline following 6MW'^  ' = 78 sec 
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Royal Brompton & Harefield fiVTS 
NHS Trust DATE: 23/04/2007 
STUDY SUMMARY 011 VER: 1 
100 
98 
96 
9 4 
9 2 
8 90 
Q . 
CO 8 8 
86 
8 4 
82 
80. 
/ IL 1 Ul J 
-
1 1 1 1 1 
S O O T 
C O N S 
100 2 0 0 3 0 0 4 0 " 
Time (s) 
5 0 0 6 0 0 7 0 0 800 
ro 1 3 0 
120 -
200 3 0 0 4nn 
T i m e ( s ) 
5 0 0 600 7 0 0 800 
Default flow 11pm 
100 200 3 0 0 4 0 0 
T i m e ( s ) 
5 0 0 600 7 0 0 800 
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Royal Brompton & Harefield f N I f j 
NHS Trust DATE: 03/05/2007 
STUDY SUMMARY 012 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
I. HISTORY 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
ID: 012 Age: 64 Sex: Male Height: 5'9" Study date: 03/05/2007 
Primary Diagnosis: COPD Secondary conditions: OSA 
Average No. hospital admission last year: 0 Most recent: N/A 
Current Inhalers: Seritide 
Present Therapy: Night only at 1.5 1pm (w/ CPAP) 
Spirometry: FEVl = 1.39 FEC = 2.21 
II. PRACTICE TEST 
CONS 1.5 1pm 
Practice Test Mean Max Min 
Sp02 91.1 95 83 
Flow 1.5 1.5 1.5 
HR 94.9 129 79 
Total time = 1160 sec Time Sp02 <90 = 31.2 
Borg Score: Initial = 1 Post 6MWT = 2 
Distance walked = 360m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 1 
Basel! 6MWT Return 
i I m 
120 g 
^ 88 
2 .86 
CO 84 
-90 ^ 
80 ^ 
8 10 
T i m e ( m 
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Royal Brompton & Harefield 
NHS Trust DATE: 03/05/2007 
STUDY SUMMARY 012 VER: 1 
III. 1" TEST 
AUTO Setpoint 93%, Controller V5 
AUTO M e a n M a x M i n 
Sp02 92.7 98 89 
Flow 2.2 4.9 0.1 
HR 91.2 172 58 
Borg Score: Initial = 0.5 Post 6MWT = 1 
Distance walked = 3700m (6 min test) 
= 5.0% Missing data = 3.2% (36s) 
2 min Post 6MWT = 1 
Baseline Return 6MWT 
125 N 
100 ro 
9- 88 
8 10 
T i m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 230 9 2 . 4 89 2.7% (6 s) 
Preparation 2 3 0 3 4 0 9 4 . 2 9 3 0 % ( 0 s) 
6MWT 3 4 0 7 0 0 9 0 . 6 89 1 4 . 2 % ( 5 1 s) 
Recovery 7 0 0 1 1 3 0 9 4 . 1 9 0 0 % ( 0 s) 
Recover to baseline following 6MWT = *40 sec 
(Recovery time interpolated due to missing data section in return) 
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Royal Brompton & Harefield ^ 
NHS Trust DATE: 03/05/2007 
STUDY SUMMARY 012 VER: 1 
IV. 2"" TEST 
CONS Flow 1.51pm 
CONS Mean Max Min 
Sp02 90.9 97 84 
Flow 1.5 1.5 1.5 
HR 93.6 139 68 
005 sec Time Sp02 <90 - 36.6% VHssing data Total time = 1 
Borg Score: Initial = 0.5 Post 6MWT = 1 
Distance walked = 370m (6 min test) 
0% 
2 min Post 6MWT = 1 
lOOr 
95 
CM 90 
C) 
Q . 
CO 85 
80 U 
5 
^ 4 
E 
^ 3 
0, 
Baseline Prep 6MWT 
10 
8 10 
T i m e ( m i n ) 
Return 
14 16 
140 
F 
120 Q. iD 
0) 
100 m 
(T 
80 • t m 
0) 
T. 
14 16 18 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 230 928 91 0% (0 s) 
Preparation 230 310 94.3 93 0% (0 s) 
6MWT 310 670 87 84 82.8% (298 s) 
Recovery 670 1000 92.2 86 21.2% (70 s) 
Recover to baseline following 6MW = 93 sec 
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Royal Brompton & Harefield f t / / ^ l 
NHS Trust DATE: 03/05/2007 
STUDY SUMMARY 012 VER: 1 
Ketnnint at 9^ 
9- 9 0 
3 0 0 4 0 0 5 0 0 
Time (s) 
800 
OJ 100 
100 zoo 3 0 0 4 0 0 5 0 0 Time (s) 
600 7 0 0 8 0 0 
Default flow 1.5 Ipm 
3 0 0 4 0 0 
Time (s) 
800 
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Royal Brompton & Harefield 
NHS Trust DATE: 30/05/2007 
STUDY SUMMARY 013 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 013 Age: 49 Sex: Female Height: 5'3" Study date: 30/05/2007 
Primary Diagnosis: COPD Secondary conditions: N/A 
Average No. hospital admission last year: 3 Most recent: May 07 
Current Inhalers: Nebs: Atrovent/ Salbutamol, Symbicos 
Present Therapy: Home and Ambulatory 
Spirometry: FEVl = 0.55 FEC = 1.3 
II. PRACTICE TEST 
CONS 2 Ipm 
Practice Test Mean Max Min 
Sp02 89.1 97 76 
Flow 2 2 2 
HR 85.3 126 66 
Total time = 1166 sec Time Sp02 <90 = 35.6 
Borg Score: Initial = 0 Post 6MWT = 4 
Distance walked = 230m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 
100 
95 
CN 
O 85 
CO 
5 
^ 4 
E 
^ 3 
l l 
Baseline Prep 6MWT 
10 12 
8 10 12 
T i m e ( m i n ) 
Return 
E 
Q. 
1 0 0 ^ 
m 
a: 
•c 
s 
16 18 20 
16 18 20 
156-
Royal Brompton & Harefield 
NHS Trust DATE: 30/05/2007 
STUDY SUMMARY 013 VER: 1 
III. 1"' TEST 
AUTO Setpoint 93%, Controller V5 
AUTO Mean Max Min 
Sp02 91.3 96 84 
Flow 3.1 4.9 0.4 
HR 83.5 117 65 
Total time = 1256 sec Time Sp02 <90 = 24.8% 
Borg Score: Initial = 0 Post 6MWT — 5 
Distance walked = 320m (6 min test) 
ylissing data = 0% 
2 min Post 6MWT = 2 
100 
CN 90 
O 
Q. 
(D 
80, 
5 
^ 4 
E 
^ 3 
S 2 
Prep 
I L 
2 4 
6MWT 
10 
8 10 
T i m e (mini) 
Return 
14 16 
14 16 
Baseline 
E 
Q . 
1 0 0 ^ 
s 
X 
18 20 
18 20 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 (%) 
Percent Time 
Sp02 < 90 
Baseline 1000 1250 93.0 92 0% (0 s) 
Preparation 0 341 92.2 89 3.0% (10 s) 
6MWT 341 701 8&3 84 70.6% (254 s) 
Recovery 701 1000 92.6 85 15.7% (47 s) 
Recover to baseline following 6MW' 79 sec 
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Roval Brompton & Harefield 
NHS Trust DATE: 30/05/2007 
STUDY SUMMARY 013 VER: 1 
CONS Mean Max Min 
Sp02 87.6 96 67 
Flow 2 2 2 
HR 85.4 137 65 
Total time = 1121 sec Time Sp02 <90 = 42.2% 
Borg Score: Initial = 0 Post 6MWT = 5 
Distance walked = 320m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 
Baseline 6MWT Return 
_g) 
100 m 
(T 
(N 
O 80 
1° 
10 
m e ( m i n ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 310 93.5 92 0% (0 s) 
Preparation 310 310 91.5 89 2.0% (3 s) 
6MWT 455 815 82.4 67 75.0% (270 s) 
Recovery 815 1120 85.6 73 65.6% (200 s) 
Recover to baseline following 6MWT = 231 sec 
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Royal Brompton & Harefieid 
NHS Trust DATE: 30/05/2007 
STUDY SUMMARY 013 VER: 1 
Setp^int at 9.1 
100 200 3 0 0 4 0 0 
Time (s) 
5 0 0 600 7 0 0 
a> ro 100 ce 
S 90 
100 200 3 0 0 4 0 0 
Time (s) 
5 0 0 600 7 0 0 
g 
5 
4 . 5 
4 
3 . 5 
3 
2 . 5 
2 
1 . 5 
1, 
1 0 0 2 0 0 3 0 0 4 0 0 
Time (s) 
Default flow 2 1pm 
5 0 0 600 7 0 0 
- 159-
Royal Brompton & Harefield 
NHS Trust DATE: 06/06/2007 
STUDY SUMMARY 014 VER: 1 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 014 Age: 69 Sex: Male Height: 6'2" Study date: 06/06/2007 
Primary Diagnosis: EAA/IPF features Secondary conditions: AF 
Average No. hospital admission last year: 3 Most recent: June 07 
Current Inhalers: Prednisolone Carbocysteine 
Present Therapy: Home and Ambulatory 
Spirometry: FEVl = 2.25 FEC = 2.75 
H. PRACTICE TEST 
CONS 3 1pm 
Practice Test Mean Max Min 
Sp02 95.5 99 87 
Flow 3 3 3 
HR 93.8 164 47 
Total time = 1224 sec Time Sp02 <90 ^ 
Borg Score: Initial = 0 Post 6MWT = 4 
Distance walked = 270m (6 min test) 
0.9 Missing data = 0% 
2 min Post 6MWT = 2 
Baseline 6MWT Return 
i W l 
CN 90 1 0 0 CO 
5 
^ 4 
E 
^ 3 
I 2 
0. 
0 15 
T i m e ( m i n ) 
20 25 
- 1 6 0 -
Roval Brompton & Harefield 
NHS Trust DATE: 06/06/2007 
STUDY SUMMARY 014 VER: 1 
CONS 3 1pm 
AUTO Mean Max Min 
Sp02 95.0 97 91 
Flow 3.0 3.0 3.0 
HR 102.7 120 91 
Total time = 1076 sec Time Sp02 <90 = 0% 
Borg Score: Initial = 0 Post 6MWT = 3 
Distance walked = 305m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 0.5 
Baseline 6MWT Return 
(U 
100 to 
cr 
CN 95 
5 
^ 4 
E 
^ 3 
0 
8 10 
T i m e ( m i n ) 
12 14 16 18 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 (%) Percent Time Sp02 < 90 
Baseline 0 300 95J 93 0% (0 s) 
Preparation 300 420 96.4 94 0% (0 s) 
6MWT 420 780 95.0 91 0% (0 s) 
Recovery 780 1050 94.3 92 0% (0 s) 
Recover to baseline following 6MW'^  ' = 35 sec 
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Roval Brompton & Harefield f J / i M 
NHS Trust DATE: 06/06/2007 
STUDY SUMMARY 014 VER: 1 
AUTO Setpoint 93%, Controller V5 
Total time = 1238sec Time Sp02 <90 = 3.6% 
Borg Score; Initial = 0 Post 6MWT = 4 
Distance walked = 290m (6 min test) 
CONS Mean Max Min 
Sp02 92.6 97 87 
Flow 1.9 4.1 0 
HR 97.6 121 75 
Missing data = 0% 
2 min Post 6MWT ^ 
Baseline 6MWT Return 
100 m O 92 
if) 90 
80 (U 
T i m e ( m m ) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 (%) Percent Time Sp02 < 90 
Baseline 0 300 93.7 91 0% (0 s) 
Preparation 300 420 93.2 91 0% (0 s) 
6MWT 420 780 91.3 87 10.6% (38 s) 
Recovery 780 1200 92.6 89 1.8% (7 s) 
Recover to baseline following 6MW'^  ^  = 104 sec 
Note: During SDOT mode, the pulse oximeter communication timed out causing a 
reset in the control system. As a result, data during the 6MWT is not 
representative of the intended SDOT mode. 
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Royal Brompton & Harefield fiViPlI 
NHS Trust DATE: 06/06/2007 
STUDY SUMMARY 0 1 4 VER: 1 
Setpoint qt 9.1 
100 200 3 0 0 4 0 0 5 0 0 
T i m e (s) 
6 0 0 7 0 0 800 
CL 1 1 0 
a> 
co 1 0 5 ce 
S 100 
100 200 3 0 0 4 0 0 5 0 0 
T i m e (s) 
6 0 0 7 0 0 800 
4 .5 
4 
3 .5 
3 
i 2 .5 
O 2 
u_ 
1.5 
1 
0 .5 
O, 
/I f\ 
Al\Ar Default flow 3 1pm i J y v U i l 
[ K 
; 
100 200 3 0 0 4 0 0 5 0 0 
T i m e (s) 
600 7 0 0 800 
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Royal Brompton & Harefieid 
NHS Trust DATE: 07/06/2007 
STUDY SUMMARY 016 VER: 1 
Academic Unit of S leep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
ID: 015 Age: 72 Sex: Male Height: 173 Study date: 07/06/2007 
Primary Diagnosis: ILD/Cyptogenic Organizing Pneumonia Secondary 
conditions: N/A 
Average No. hospital admission last year: 0 Most recent: June 07 
Current Inhalers: Prednisolone/Symbicoa 
Present Therapy: Home and Ambulatory 
Spirometry: FEVl = 1.4 FEC = 1.5 
II. PRACTICE TEST 
Total time = 1 
CONS 2 pm 
Practice Test Mean Max Min 
Sp02 94 96 91 
Flow 2 2 2 
HR 95.6 110 84 
50 sec Time Sp02 <90 = 0 
Borg Score: Initial = 2 Post 6MWT = 4 
Distance walked = 175m (6 min test) 
Missing data = 0% 
2 min Post 6MWT = 3 
Baseline 6MWT Return 
Q- 92 
5 
^ 4 
E 
^ 3 
i 2 U_ 
8 10 12 
Time (min) 
14 16 18 20 
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Royal Brompton & Harefield fT/Jji'l 
NHS Trust DATE: 07/06/2007 
STUDY SUMMARY 015 
W T V 1 VER: 1 
AUTO Mean Max Min 
Sp02 93.7 100 91 
Flow 1.2 4.7 0 
HR 94.8 121 85 
Total time 
Borg Score: Initial = 2 Post 6MWT 
Distance walked = 245m (6 min test) 
Time Sp02 <90 = 0% 
4 
Missing data = 0% 
2 min Post 6MWT = 2 
100 
98 
^ 96 
(N 
O 94 
" 92 
90, 
5 
^ 4 
E 
^ 3 
0 2 
^ 1 
0, 
Baseline 
c n j u L T ^ m n f - i 
Prep 6MWT 
10 15 2D 
10 15 
Time (min) 
23 
Return 
1 3 0 ^ 
120 a . 
JD 
110 Q) 
ro 
100 t r 
90 I 
25 
25 30 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 600 93.6 93 0% (0 s) 
Preparation 600 780 94.8 91 0% (0 s) 
6MWT 780 1140 93.1 91 0% (0 s) 
Recovery 1140 1550 94.0 92 0% (0 s) 
Recover to baseline following 6MWT = 57 sec 
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Royal Brompton & Harefield 17(114 
NHS Trust DATE: 07/06/2007 
STUDY SUMMARY 0 1 5 
TIT- ^ 
VER: 1 
CONS Flow 2 1pm 
Borg Score: Initial = 2 Post 6MWT = 5 
Distance walked = 305m (6 min test) 
0% 
CONS Mean Max Min 
Sp02 93.5 97 90 
Flow 2 2 2 
HR 93.9 112 80 
Missing data = 0,69% 
2 min Post 6MWT = 2 
Baseline 6 M W T Return 
160 
140 E 
<N 94 
5 
^ 4 
E 
^ 3 
Li_ 
10 15 
Time (nin) 
20 25 
- 1 0 0 (u 
80 ro 
60 ^ 
40 "g 
-20 ^ 
30 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 500 94.0 91 0% (0 s) 
Preparation 500 930 95.0 92 0% (0 s) 
6MWT 930 1290 91.9 90 0% (0 s) 
Recovery 1290 1550 94.0 90 0% (0 s) 
Recover to baseline following 6MW'^  = 76 sec 
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Royal Brompton & Harefield fZ / fM 
NHS Trust DATE: 07/06/2007 
STUDY SUMMARY 0 1 5 VER: 1 
Setpoint s^ t 91 
100 200 3 0 0 4 0 0 5 0 0 
T i m e (s) 
600 7 0 0 800 
ca 105 
S 100 
100 zoo 3 0 0 4 0 0 
T i m e (s) 
5 0 0 6 0 0 7 0 0 800 
Default flow 2 Ipm 
100 200 3 0 0 4 0 0 5 0 0 
T i m e (s) 
6 0 0 7 0 0 800 
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Royal Brompton & Harefield W / r t 
NHS Trust DATE: 12/06/2007 
STUDY SUMMARY 016 VER: 1 
Academic Unit of S leep and Breathing 
Royal Brompton Hospital 
Sydney Street, London SW3 6NP 
Dr Anita Simonds 
Tel. 020 7351 8911 
A.Simonds@rbht.nhs.uk 
I. HISTORY 
ID: 016 Age: 61 Sex: Male Height: 165cm Study date: 12/06/2007 
Primary Diagnosis: COPD Secondary conditions: Asbestosis 
Average No. hospital admission last year: 4 Most recent: Jan 07 
Current Inhalers: Simbicor 
Present Therapy: Home and Ambulatory 
Spirometry: FEVl = 0.6 FEC = 1.3 
H. PRACTICE TEST 
CONS 2.5 1pm 
Practice Test Mean Max Min 
Sp02 90.6 98 79 
Flow 2.5 2.5 2.5 
HR 96.9 138 27 
Total time = 1504 sec Time Sp02 <90 = 22.9 
Borg Score: Initial = 0 Post 6MWT = 5 
Distance walked = 270m (6 min test) 
Missing data - 1.5% 
2 min Post 6MWT = 2.5 
Baseline 6MWT Return 
5 
^ 4 
E 
^ 3 
o 2 
^ 1 
0. 10 15 
me (min) 
20 25 30 
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Roval Brompton & Harefield 
NHS Trust DATE: 12/06/2007 
STUDY SUMMARY 016 VER: 1 
AUTO Setpoint 93%, Controller V5 
Total time = 1341 sec Time Sp02 <90 = 32.3% 
Borg Score: Initial = 0 Post 6MWT = 5 
Distance walked = 360m (6 min test) 
AUTO Mean Max Min 
Sp02 89.7 96 78 
Flow 3.4 4.9 0.4 
HR 92.1 118 49 
Missing data = 0% 
2 min Post 6MWT = 2.5 
Baseline 6MWT Return 
me (mm) 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 570 92.1 88 7.7% (43 s) 
Preparation 570 670 93.0 91 0% (0 s) 
6MWT 670 1030 83.7 78 90.0% (324 s) 
Recovery 1030 1330 91.0 81 22.3% (67 s) 
Recover to baseline following 6MW'^  " = 85 sec 
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Roval Bromoton & Harefield 
NHS Trust DATE: 12/06/2007 
STUDY SUMMARY 016 VER: 1 
CONS Flow 2.5 1pm 
CONS Mean Max Min 
Sp02 86.6 95 58 
Flow 2.5 2.5 2.5 
HR 93.4 127 47 
Total time = 1378 sec Time Sp02 <90 = 54.2% 
Borg Score: Initial = 0 Post 6MWT = 3.5 
Distance walked = 360m (6 min test) 
Missing data = 0 % 
2 min Post 6MWT = 1 
Baseline 6MWT Return 
1 2 0 Q. 
1 0 0 CD 
CD 
80 Dc: 
60 I 
Q 70 
5 
^ 4 
E 
^ 3 
^ 1 
0. 
flO 15 
Time (min) 
20 25 
Phase Begin (s) End (s) Mean 
Sp02 (%) 
Min Sp02 
(%) 
Percent Time 
Sp02 < 90 
Baseline 0 500 90.4 87 27.1% (135 s) 
Preparation 500 580 923 91 0% (0 s) 
6MWT 580 940 79.3 58 84.7% (305 s) 
Recovery 940 1370 87.3 58 70.9% (305 s) 
Recover to baseline following GMW^ ' = 193 sec 
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Roval Brompton & Harefield f iV i r t 
NHS Trust DATE: 12/06/2007 
STUDY SUMMARY 016 VER: 1 
Sjetpoint 9 3 
100 200 3 0 0 4 0 0 5 0 0 
Time (s) 
600 7 0 0 800 
- s d o t 
- c o n s 
3 0 0 4 0 0 
T ime (s) 
5 0 0 600 7 0 0 800 
Default flow 2.5 1pm 
4 0 0 
T ime (s) 
5 0 0 600 7 0 0 800 
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APPENDIX A.2 
FEEDBACK FLOW-RATE CONTROLLER 
INSTRUCTION FOR USE 
PILOT STUDY USE ONLY 
TABLE OF CONTENTS 
INTRODUCTION pg 2 
1. POWER UP SYSTEM pg 2 
2. SYSTEM START UP / CALIBRATION pg 3 
3. SYSTEM OPERATION pg 4 
4. SHUT DOWN pg 5 
5. TROUBLE SHOOTING / CONTACT INFORMATION pg 5 
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INTRODUCTION 
This project involves the assimilation between conventional oxygen therapy 
technology and non-invasive pulse oximetry. The system configuration is in compliance 
with the instruction for use of all the incorporated CE Marked devices. For electrical 
safety, an isolation circuit is provided by the Nellcor N200 Pulse Oximeter to prevent 
the patient from exposure to mains power supply. No other electrical connections are in 
proximity of the patient. 
The Feedback Controller can operate in one of two modes. Either as a 
conventional fixed flow-rate oxygen therapy as determined by the patient default flow-
rate, or as a closed-loop controller regulating the oxygen flow-rate based upon the 
feedback measurement from the pulse oximeter. 
ATTENTION 
Device is only intended for use in conjunction with a limited clinical 
pilot study and not for general patient use. Before use, operator must 
read and understand this IFU and the component manuals for the 
associated Nellcor N200 pulse oximeter. 
1. POWER UP SYSTEM 
1.1. Connect serial cables to Com 1 & 2 as shown per FIG. 1. 
1.2. Plug in AC power for the pulse oximeter, PC controller, and flow regulator 
to the 220V main. 
1.3. Cormect the oxygen tubing and nasal cannula to the O2 supply source per 
FIG. 1. Make sure to inspect the tubing to be free of any damage or 
obstruction. Sufficient length of tubing needs to be provided as not to 
restrict patient movement during the evaluation. 
1.4. Turn on Nellcor N200 pulse oximeter. 
1.5. Switch N200 pulse oximeter mode to fast averaging signal. Note the setting 
is automatically set to the factory default each time the unit is powered on. 
1.6. Turn on the PC controller. 
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O2 Source 0 2 tubing Flow Regulator Nasal Cannula Patient 
w/ manual 
flow valve 
A 
PC Controller 
Com 1 
Serial 
adapter 
Ear Sensor 
USB 
Com 2 
Pulse 
Oximeter 
FIG.l System Diagram 
2. SYSTEM START UP / CALIBRATION 
2.1. On the PC, launch Matlab and GUI based executable. Each time the 
program is launched, an automated calibration will be conducted. 
Royal Brompton & Harefield 
NHS Trust 
AUTO-LTOT CONTROLLER 
Please open manual flow valve to 5 Ipm 
Then Initiate calibration below 
Start Up Calibration 
CAUTION: This Device is for Investigational Use ONLY 
2.2. Follow on screen instruction for flow-rate calibration. Open the manual 
flow valve to 5 1pm (+/- 0.5 1pm) to be verified by flow regulator. At the 
conclusion of the calibration sequence, the flow-rate of oxygen will be 
closed by the flow regulator imtil the start of the study. 
2.3. Enter patient study identification into the prompt window along with the 
patient default flow-rate as determined at rest. Make sure to use the buttons 
provided to select between exercise (SWT) or overnight (Sleep) evaluation. 
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Also select between first or second assessment. This enables the PC to 
randomly determine the sequence of therapy to ensure a blind cross-over 
study. 
AUTO-LTOT CONTROLLER 
Calibration complete. Please enter patient info 
Patient ID - Study Type-
© S W T 
O Sleep 
-Assessment-
© 1st 
0 2 n d 
Defalut Flow Rate 
Finish 
2.4. Securely place the oximetry ear sensor on the patient as described by the 
manufacture's instructions and connect it to the N200 unit. 
2.5. Verify the saturation displayed on the PC corresponds to the measurement 
given on the pulse oximeter. 
2.6. Prior to initiating the study, place the patient nasal cannula securely in 
position. 
WARNING 
Although, the pulse oximeter audible alarm can be disabled as 
described in the N200 operators manual, do NOT disable it if patient 
safety could be compromised. 
3. SYSTEM OPERATION 
3.1. Once the start up / calibration procedure has been completed and the patient 
is read to begin the study, select the FINISH button from the calibration 
window. This will begin the oxygen therapy to the patient. 
3.2. During this time the PC will record and monitor the patient saturation in 
response to the given oxygen flow-rate. Other information such as heart 
rate will also be stored in the electronic study record. Data will be collected 
until the STOP button is selected. 
3.3. The patient saturation will be continuously displayed on both the PC 
Controller and the pulse oximeter. If at anytime during the study, the 
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patient safety may be compromised the system should stopped immediately. 
The controller should always be monitored by the study doctor. In addition 
if the PC Controller encounters an error, a message will be displayed and 
the system will close down. 
Controller 
AUTO-LTOT CONTROLLER 
— Saturation (%)-
90 
STOP 
-Status 
Patient ID 
Study Type 
Active 
3.4. To terminate the study, press the STOP button at any time. All data will be 
written to the directory "C:/Data/" with a file name corresponding to the 
Patient Study ID and Time/Date stamp. The files are stored as tab 
delineated ASCII text. The randomly allocated therapy option will be 
included in the data file. Only at the end of the study will this information 
become available. 
3.5. After the STOP button is selected, the executable will automatically close. 
This will also stop the flow of oxygen. 
4. SHUTDOWN 
4.1. Disconnect the patient from the nasal cannula and remove the ear sensor. 
4.2. Completely close the manual flow valve and disconnect the oxygen tubing 
leading to the flow regulator. 
4.3. Shut down and unplug the PC. 
4.4. Unplug the power adapter for the flow regulator. 
4.5. Turn off and unplug the N200 pulse oximeter. 
5. TROUBLE SHOOTING / CONTACT INFORMATION 
In the event of any error message or system issues do not attempt to conduct any 
maintenance. Please just refer to the listed contact information below. Do not use the 
equipment if there is any evidence of a potential compromise in patient safety. 
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Royal Brompton Hospital 
Chief Investigator: Dr Anita Simonds. 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital Tel. 020 7351 8911 
Sydney Street, London SW3 6NP E-mail: A.Simonds@rbht.nhs.uk 
Imperial College London 
Dr. Robert J Dickinson 
Department of Bioengineering 
Imperial College London 
South Kensington Campus, Tel. 020 7594 5662 
London SW7 2AZ E-mail: robert.dickinson@imperial.ac.uk 
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APPENDIX A.3 
Brompton, Harefield & NHLI Ethics Committee F//' ^  
Royal Brompton Hospital 
Sydney Street 
LONDON SW3 6NP 
Telephone: 020 7351 8437 
Facsimile: 020 7351 8437 
27 October 2005 
Dr. Anita K Simonds 
Consultant in Respiratory Medicine 
Academic Unit of Sleep and Breathing 
Royal Brompton Hospital, Sydney Street, 
London SW3 6NP 
Dear Dr. Simonds 
Full title of study: Pulse Oximetry Based Feedback Flow-Rate Control For 
Long-Term Oxygen Therapy 
REC reference number: 05/Q0404/102 
Thank you for your letter of 20 October 2005, responding to the Committee's request 
for further information on the above research and submitting revised documentation. 
This has been considered on behalf of the Committee by the Chairman. 
Confirmation of ethical opinion 
On behalf of the Corrmiittee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised. 
Ethical review of research sites 
The favourable opinion applies to the research sites listed on the attached form. 
Conditions of approval 
The favourable opinion is given provided that you comply vyith the conditions set out in 
the attached document. You are advised to study the conditions carefully. 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Version Dale 
Application l(4th time 
locked) 
20 September 2005 
Investigator CV 1 20 September 2005 
Protocol 28 July 2005 
GP/Consultant Information Sheets 2 25 October 2005 
Participant Information Sheet 2 20 October 2005 
Participant Consent Form 27 July 2005 
Investigator's Brochure Oximax Dura Y Ear Clip - Directions for Use 
Investigator's Brochure Nellcor N200 Pulse Oximeter Operator's Manual 
Investigator's Brochure Linde Medical Sensors AG Tosca 500 Operating Publ No. 
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Manual 520.81.001/0 
Response to Request for Further Information 20 October 2005 
Letter from Sponsor and confirmation of indemnity cover 18 August 2005 
Feedback Flow-Rate Controller IFU for Pilot Study Use Only Rev:A 25 July 2005 
Research governance approval 
The study should not commence at any NHS site until the local Principal Investigator 
has obtained final research governance approval from the R&D Department for the 
relevant NHS care organisation. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
05/Q0404/102 Please quote this number on all correspondence 
Yours sincerely 
Christian Pearson 
Administrator 
Email: ethics@rbht.nhs.uk 
Enclosures: Standard approval conditions 
Site approval form 
Copy to: Mr G Roper, Imperial College London 
R&D Department Royal Brompton Hospital 
Mr M G lobbi (electronically) 
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APPENDIX A.4 
Investigational Device Detailed Software Code 
Matlab Function List 
LTOT.m 
Calibration.m 
Controller.m 
GuiPrint.m 
OutFlow.m 
SampleRate.m 
EndSim.m 
Simulink Diagrams 
AUTO.mdl 
CONS.mdl 
function varargout = LTOT(varargin) 
% LTOT M-file for LTOT.fig 
% LTOT, by itself, creates a new LTOT or raises the existing 
% singleton*. 
% 
% H = LTOT returns the handle to a new LTOT or the handle to 
% the existing singleton*. 
% 
% LTOT{'CALLBACK',hObject,eventData,handles,...) calls the local 
% function named CALLBACK in LTOT.M with the given input 
arguments. 
% 
% LTOT('Property','Value',...) creates a new LTOT or raises the 
% existing singleton*. Starting from the left, property value 
pairs are 
% applied to the GUI before LTOT_OpeningFunction gets called. An 
% unrecognized property name or invalid value makes property 
application 
% stop. All inputs are passed to LTOT_OpeningFcn via varargin. 
% 
% *See GUI Options on GUIDE'S Tools menu. Choose "GUI allows 
only one 
% instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
% Copyright 2002-2003 The MathWorks, Inc. 
% Edit the above text to modify the response to help LTOT 
% Last Modified by GUIDE v2.5 29-Jul-2005 13:38:21 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct{'gui_Name', mfilename, ... 
'gui_Singleton', gui_Singleton, ... 
'gui_OpeningFcn', @LTOT_OpeningFcn, ... 
'gui_OutputFcn', @LTOT_OutputFcn, ... 
'gui_LayoutFcn', [] , ... 
'gui_Callback', []); 
if nargin && ischar(varargin{1}) 
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gui_State.gui_Callback = str2func{varargin{1}); 
end 
if nargout 
[varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}) 
else 
gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
% Executes just before LTOT is made visible. 
function LTOT_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject handle to figure 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% varargin command line arguments to LTOT (see VARARGIN) 
% Choose default command line output for LTOT 
handles.output = hObject; 
%%% Change to correct directory 
%cd('C:\Matlab71\work\GUI\'); 
% Update handles structure 
guidata(hObject, handles); 
% UIWAIT makes LTOT wait for user response (see UIRESUME) 
% uiwait(handles.figurel); 
% Outputs from this function are returned to the command line. 
function varargout = LTOT_OutputFen(hObject, eventdata, handles) 
% varargout cell array for returning output args (see VARARGOUT); 
% hObject handle to figure 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% Get default command line output from handles structure 
varargout{l} = handles.output; 
% Executes on button press in pushbuttonl. 
function pushbuttonl_Callback(hObject, eventdata, handles) 
% hObject handle to pushbuttonl (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
State = 1 ; % Manual Override statement 
Tag = waitbar(0,'Please wait... verifying oximeter communication'); 
%%% Check serial connection to Pulse Oximeter 
s = serial('C0M5'); % Default: 9600 Buad, 8 bits, no parity, 1 stop 
fopen(s); 
fprintf(s,'M'); % Request monitor status; 
%rply = fscanf(s); 
% if rply ~= ???? 
% State = 0; 
% end 
fclose(s); 
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%%% Check serial connection to Flow Regulator 
waitbar(0,Tag,'Please wait... verifying flow regulator 
communication'); 
for i=l:30, % computation here % 
waitbar(i/100); 
end 
s = serial('C0M4'); % Default; 9600 Buad, 8 bits, no parity, 1 stop 
fopen(s); 
fprintf(s,'M'); % Request status? 
%rply = fscanf(s); 
% if rply ~= ???? 
% State = 0; 
% end 
fclose(s); 
%%% Cycle Flow Regulator 
waitbar(.3,Tag,'Please wait... calibrating flow regulator'); 
for i=31:60, % computation here % 
waitbar(i/100); 
end 
%%% Set flow to 0 1pm 
for i=61:99, % computation here % 
waitbar(i/100); 
end 
waitbar(1,Tag,'Complete'); 
close(Tag); 
if State 
%%% launch Calibration GUI 
Calibration; 
else 
errordlg('Calibration Failure','Error'); 
end 
% Executes during object creation, after setting all properties. 
function figurel_CreateFcn(hObject, eventdata, handles) 
% hObject handle to figurel (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles empty - handles not created until after all CreateFcns 
called 
- 183 -
function varargout = Calibration(varargin) 
% CALIBRATION M-file for Calibration.fig 
% CALIBRATION, by itself, creates a new CALIBRATION or raises the 
existing 
% singleton*. 
% 
% H = CALIBRATION returns the handle to a new CALIBRATION or the 
handle to 
% the existing singleton*. 
% 
% CALIBRATION('CALLBACK',hObject,eventData,handles,...) calls the 
local 
% function named CALLBACK in CALIBRATION.M with the given input 
arguments. 
% 
% CALIBRATION('Property','Value',...) creates a new CALIBRATION 
or raises the 
% existing singleton*. Starting from the left, property value 
pairs are 
% applied to the GUI before Calibration_OpeningFunction gets 
called. An 
% unrecognized property name or invalid value makes property 
application 
% stop. All inputs are passed to Calibration_OpeningFcn via 
varargin. 
% 
% *See GUI Options on GUIDE'S Tools menu. Choose "GUI allows 
only one 
% instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
% Copyright 2002-2003 The MathWorks, Inc. 
% Edit the above text to modify the response to help Calibration 
% Last Modified by GUIDE v2.5 02-Aug-2005 10:23:15 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name', mfilename, ... 
'gui_Singleton', gui_Singleton, ... 
'gui_OpeningFcn', @Calibration_OpeningFcn, ... 
'gui_OutputFcn', @Calibration_OutputFcn, ... 
'gui_LayoutFcn', [] , ... 
'gui_Callback', []); 
if nargin && ischar(varargin{1}) 
gui_State.gui_Callback = str2func(varargin{1}); 
end 
if nargout 
[varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
% Executes just before Calibration is made visible. 
function Calibration_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject handle to figure 
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% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data {see GUIDATA) 
% varargin command line arguments to Calibration (see VARARGIN) 
% Choose default command line output for Calibration 
handles.output = hObject; 
handles.ID = -1; 
handles.Flow = -1; 
handles.Set_Point =91; % Defualt setpoint 
% Update handles structure 
guidata(hObject, handles); 
% UIWAIT makes Calibration wait for user response (see UIRESUME) 
% uiwait(handles.figurel); 
% Outputs from this function are returned to the command line. 
function varargout = Calibration_OutputFcn(hObject, eventdata, 
handles) 
% varargout cell array for returning output args (see VARARGOUT); 
% hObject handle to figure 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% Get default command line output from handles structure 
varargout{l} = handles.output; 
function editl_Callback(hObject, eventdata, handles) 
% hObject handle to editl (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% Hints: get(hObject,'String') returns contents of editl as text 
% str2double(get(hObject,'String')) returns contents of editl 
as a double 
%%% Enter Patient ID to handles.ID 
handles.ID = str2double(get(hObject,'String')); 
% Update handles structure 
guidata(hObject, handles); 
% Executes during object creation, after setting all properties. 
function editl_CreateFcn(hObject, eventdata, handles) 
% hObject handle to editl (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles empty - handles not created until after all CreateFcns 
called 
% Hint: edit controls usually have a white background on Windows. 
% See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
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function edit3_Callback(hObject, eventdata, handles) 
% hObject handle to edit3 {see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% Hints: get(hObject,'String') returns contents of editS as text 
% str2double(get(hObject,'String')) returns contents of edit3 
as a double 
Enter Patient ID to handles.ID 
handles.Flow = str2double(get(hObject,'String' 
% Update handles structure 
guidata(hObject, handles); 
% Executes during object creation, after setting all properties. 
function edit3_CreateFcn(hObject, eventdata, handles) 
% hObject handle to edit3 (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles empty - handles not created until after all CreateFcns 
called 
% Hint: edit controls usually have a white background on Windows. 
% See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0, 'defaultUicontrolBackgroundColor' ) ) 
set(hObject,'BackgroundColor','white'); 
end 
% Executes on button press in pushbuttonl. 
function pushbuttonl_Callback(hObject, eventdata, handles) 
% hObject handle to pushbuttonl (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
%%% Get Study Type Buttongroup 
[Arg] = get(handles.uipanel2,'Children'); 
button2 = Arg(l); 
buttonl = Arg(2); 
switch get(handles.uipanel2, 'SelectedObject') % Get Tag of selected 
object 
case buttonl 
handles.Study = 'SWT'; 
case button2 
handles.Study = 'SLP'; 
end 
%%% Get Assessment Buttongroup 
[Arg] = get(handles.uipanel3,'Children'); 
buttonl = Arg(l); 
button2 = Arg(2); 
State = 0; 
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switch get(handles.uipanel3,'SelectedObject') % Get Tag of selected 
object 
case buttonl 
handles.Ass = 'IST'; 
Determine Therapy in random order 
if rand(l)>0.5 
handles.Therapy = 'AUTO'; 
else 
handles.Therapy = 'CONS'; 
end 
case button2 
handles.Ass = '2ND'; 
.STY' 
Look for 1st Assessment Record 
Path = 'C:/Data/'; 
List = dir(Path); 
File = [nuin2str (handles . ID, ' %03 . Of ' ) handles . Study ' 1' 
Marker = 0; 
for i = 1:size(List,1) 
F = List(i).name; 
if strmatch(F,File); 
Marker = i; 
end 
end 
if Marker ~=0 
%%% Open 1st Assessment data 
Data = textread([Path File],'%s'); 
Data = cell2mat(Data(2)); 
if Data == 'AUTO' 
handles.Therapy = 'CONS'; 
elseif Data =='CONS' 
handles.Therapy = 'AUTO'; 
end 
else 
%%% No prior record found 
errordlg('No Prior Record Found','Error: 2nd Assessment'); 
error{'No Prior Record Found'); 
end 
end 
%%% Manaul Over-ride Therapy Selection 
if strmatch('on', get(handles.CONS,'Checked')) 
handles.Therapy = 'CONS'; 
end 
if strmatch('on', get(handles.AUTO,'Checked')) 
handles.Therapy = 'AUTO'; 
end 
%%% Check variables 
if handles.Flow <= 5 & handles.Flow >= 0 
if handles.ID == -1 I isempty(handles.ID) 
errordlg('Enter Patient Info','Error'); 
else 
%%% Look up prior Patient Data in 'C:/Data/' 
%%% File name = <ID: 3 digxStudy: 3 charxAss: 1 dig>.sty 
Path = 'C:/Data/'; 
List = dir(Path); 
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File = [num2str(handles.ID,'%03.Of') handles.Study 
handles.Ass(1) '.STY']; 
Marker = 0; 
for i = 1:size(List,1) 
F = List(i).name; 
if strmatch(F, File); 
Marker - i; 
end 
end 
handles.File = [Path File]; 
if Marker == 0 
Launches Controller 
close all; 
Controller(handles.ID,... 
handles.Flow,... 
handles.Study,... 
handles.Ass,... 
handles.File,... 
handles.Therapy,... 
handles.Set_Point); %%% Pass GUI Patient info 
else 
close all; 
errordlg('Prior Data Recorded For This Study','Cannot 
Over-Write Data'); 
end 
end 
else 
errordlg('Default Flow Must Be Between 0-5 1pm','Error'); 
end 
% Executes on key press over figurel with no controls selected. 
function figurel_KeyPressFcn(hObject, eventdata, handles) 
% hObject handle to figurel (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
function Untitled_3_Callback(hObject, eventdata, handles) 
% hObject handle to Untitled_3 (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
function Random_Callback(hObject, eventdata, handles) 
% hObject handle to Random (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
set(handles.Random,'Checked','on'); 
set(handles.CONS, 'Checked', 'off ) ; 
set(handles.AUTO, 'Checked', 'off); 
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% Update handles structure 
guidata(hObject, handles); 
% 
function Main_Callback(hObject, eventdata, handles) 
% hObject handle to Main (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
function AUTO_Callback(hObject, eventdata, handles) 
% hObject handle to AUTO (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
set(handles.Random,'Checked','off'); 
set(handles.AUTO,'Checked','on'); 
set(handles.CONS,'Checked','off'); 
% Update handles structure 
guidata(hObject, handles); 
function CONS_Callback(hObject, eventdata, handles) 
% hObject handle to CONS (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
set(handles.Random,'Checked','off); 
set(handles.CONS,'Checked','on'); 
set(handles.AUTO,'Checked','off); 
% Update handles structure 
guidata(hObject, handles); 
% 
function Manual_Callback(hObject, eventdata, handles) 
% hObject handle to Manual (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
function Set_Point_Callback(hObject, eventdata, handles) 
% hObject handle to Set_Point (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
Default{1} = num2str(handles.Set_Point); 
Reply = inputdlg('Enter Saturation Set Point <DEFAULT = 91%>','Change 
Set Point',1,Default); 
Reply = cell2mat(Reply); 
if isempty(Reply) 
Reply = '0'; 
end 
Reply = str2num(Reply); 
if Reply > 70 & Reply <100 
handles.Set_Point = Reply; 
else 
handles.Set_Point = 91; 
errordlg('Set Point must be between 70-100... Value = 
Defualt','Error'); 
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end 
% Update handles structure 
guidata(hObject, handles); 
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function varargout = Controller(varargin) 
% CONTROLLER M-file for Controller.fig 
% CONTROLLER, by itself, creates a new CONTROLLER or raises the 
existing 
% singleton*. 
% 
% H = CONTROLLER returns the handle to a new CONTROLLER or the 
handle to 
% the existing singleton*. 
% 
% CONTROLLER('CALLBACK',hObject,eventData,handles,...) calls the 
local 
% function named CALLBACK in CONTROLLER.M with the given input 
arguments. 
% 
% CONTROLLER('Property','Value',...) creates a new CONTROLLER or 
raises the 
% existing singleton*. Starting from the left, property value 
pairs are 
% applied to the GUI before Controller_OpeningFunction gets 
called. An 
% unrecognized property name or invalid value makes property 
application 
% stop. All inputs are passed to Controller_OpeningFcn via 
varargin. 
% 
% *See GUI Options on GUIDE 'S Tools menu. Choose "GUI allows 
only one 
% instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
% Copyright 2002-2003 The MathWorks, Inc. 
% Edit the above text to modify the response to help Controller 
% Last Modified by GUIDE v2.5 26-Jul-2005 13:42:12 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct{'gui_Name', mfilename, ... 
'gui_Singleton', gui_Singleton, ... 
'gui_OpeningFcn', @Controller_OpeningFcn, ... 
'gui_OutputFcn', @Controller_OutputFcn, ... 
'gui_LayoutFcn', [] , ... 
'gui_Callback' , []); 
if nargin && ischar(varargin{1}) 
gui_State.gui_Callback = str2func(varargin{1}); 
end 
if nargout 
[varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
% Executes just before Controller is made visible. 
function Controller_OpeningFcn(hObject, eventdata, handles, varargin) 
- 191 -
% This function has no output args, see OutputFcn. 
% hObject handle to figure 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% varargin command line arguments to Controller (see VARARGIN) 
% Choose default command line output for Controller 
warning off all 
global handles 
handles.output = hObject; 
% Display Hospital Logo 
set(hObject, 'Units', 'pixels'); 
handles.banner = imread{'RBH.bmp'); % Read the image file 
axes(handles.axesl); 
imshow(handles.banner) ; 
%%% Sort input arguments 
Argl = varargin(1);Arg2 = varargin(2);Arg3 = varargin(3);Arg4 = 
varargin(4);Arg5 = varargin(5);Arg6 = varargin(6);Arg7 = varargin(7) 
handles.ID = cell2mat(Argl); %Patient ID number 
handles.Flow = cell2mat(Arg2); %Default Flow rate 
handles.Study = cell2mat(Arg3); %Study Type 
handles.Ass = cell2mat(Arg4); %Assessment 
handles.File = cell2mat(Arg5); %File 
handles.Therapy = cell2mat(Arg6); %Therapy 
handles.Set_Point = cell2mat(Arg7); %Set Point 
handles.Sat = handles.Set_Point; % Saturation 
handles.time = 0 ; % Time 
handles.FlowRate = 0 ; % Flow-rate 
%%% Update GUI text 
set(handles.text2,'String',['ID ' num2str(handles.ID)]); 
set(handles.texts,'String',['Default Flow ' num2str(handles.Flow) ' 
1pm']); 
set(handles.text4,'String',['Study Type: ' handles.Study]); 
set(handles.texts,'String',['Set Point ' num2str(handles.Set_Point) 
%']); 
drawnow; % Update figure window 
%%% Open Serial connections 
handles.ComFlow = serial('C0M4'); % Default: 9600 Buad, 8 bits, no 
parity, 1 stop 
handles.ComOxmt = serial('C0M5'); % Default: 9600 Buad, 8 bits, no 
parity, 1 stop 
fopen(handles.ComFlow); 
fopen(handles.ComOxmt); 
Write Header Information to file 
fid = fopen(handles.File,'w'); 
fprintf(fid,'TYPE:\t%s\n',handles.Therapy); 
fprintf(fid,'PATIENT:\t%s\n',num2str(handles.ID)); 
fprintf(fid,'STUDY:\t%s\n',handles.Study); 
fprintf(fid, 'ASSESSMENT:\t%s\n', handles. Ass); 
fprintf(fid,'DEFAULT FLOW (1pm):\t%s\n',num2str(handles.Flow)); 
fprintf(fid, 'SET POINT (%%) :\t%s\n',num2str(handles.Set_Point)); 
fprintf(fid, 'Time (sec)\tSat (%%)\tFlow (1pm)\n'); 
fclose(fid); 
%%% Launch simulink program 
switch handles.Therapy 
case 'AUTO' 
- 192 
%%% Run AUTO simulink 
load_system('AUTO'); 
set_param('AUTO/Set_Point','Value',num2str(handles.Set_Point)); 
%set_param('AUTO', 'SimulationCommand', 'start') % Use instead 
of simO cmd 
Execute realtime timmer 
Period = 1.0; 
handles.t = timer('TimerFcn','set_param{''AUTO'', 
''SimulationCommand'', ''continue 
'Period', Period, ... 
'StartDelay', Period,... 
'ExecutionMode', 'fixedRate', ... 
'StartFcn', 'global tO; tO = clock; set_param(''AUTO'' , 
''SimulationCommand'', ''start 
start(handles.t); 
case 'CONS' 
%%% Run CONS simulink 
load_system('CONS ') ; 
set_param('CONS/Default Flow','Value',num2str(handles.Flow)); 
%%% Execute realtime timmer 
Period = 1.0; 
handles.t = timer('TimerFcn','set_param(''CONS, 
''SimulationCommand'', ''continue'');',... 
'Period', Period, 
'StartDelay', Period,... 
'ExecutionMode', 'fixedRate', 
'StartFcn', 'global tO; tO = clock; set_param(''CONS'', 
''SimulationCommand'', ''start'');'); 
start(handles.t); 
end 
% Update handles structure 
guidata(hObject, handles); 
% UIWAIT makes Controller wait for user response (see UIRESUME) 
% uiwait(handles.figurel); 
% Outputs from this function are returned to the command line. 
function varargout = Controller_OutputFcn(hObject, eventdata, handles) 
% varargout cell array for returning output args (see VARARGOUT); 
% hObject handle to figure 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
% Get default command line output from handles structure 
varargout{1} = handles.output; 
% Executes on button press in pushbuttonl. 
function pushbuttonl_Callback(hObject, eventdata, handles) 
% hObject handle to pushbuttonl (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
%%% Close Simulink program 
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set_parain (handles.Therapy, 'SimulationCommand', 'stop'); 
stop(handles.t); 
clear global tO; 
Close serial Connections 
fclose(handles.ComFlow); 
fclose(handles.ComOxmt); 
%%% Close Matlab 
close all; 
clear all; 
clear global handles; 
%exit; 
% If Enable == 'on', executes on mouse press in 5 pixel border. 
% Otherwise, executes on mouse press in 5 pixel border or over 
pushbuttonl. 
function pushbuttonl_ButtonDownFcn(hObject, eventdata, handles) 
% hObject handle to pushbuttonl (see GCBO) 
% eventdata reserved - to be defined in a future version of MATLAB 
% handles structure with handles and user data (see GUIDATA) 
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function Out = GuiPrint(In) 
global handles 
Value = In; 
Get Current Saturation 
fprintf(handles.ComOxmt, 'S'); % Request saturation; 
%Value = fscanf(handles.ComOxmt); 
handles.Sat = Value; 
% <Error check?> 
%%% Update Screen 
set(handles.texts,'String',num2str(Value,'%3.Of')); 
drawnow; % Update figure window 
Output Saturation 
Out = Value; 
function Out = OutFlow(In) 
global handles 
Value = In; 
%%% Set Current Flow 
fprintf(handles.ComFlow,'S'); % Request saturation; 
%Value = fscanf(handles.ComFlow); 
% CError check?> 
%%% Output 
Out = Value; 
function Out = SampleRate(In) 
Out = In; 
global handles; 
global to 
%%% Write Data to file 
handles.FlowRate = In; 
Value = [handles.time handles.Sat handles.FlowRate]; 
dlmwrite(handles.File, Value,'-append', 'delimiter','\t','precision' 
'% 7 . I f ) ; 
%%% Real Time Stopwatch 
set_param(handles.Therapy, 'SimulationCommand', 'pause'); 
tl = clock; 
handles.time = etime(tl,tO); 
%%% Use program to terminate simulation internally 
function Out = EndSim(In) 
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Out = In; 
%%% Simulation commands 
%set_param('AUTO', 'SimulationCommand', 'stop') 
% where 'sys' is the name of the system and 'cmd' is 'start', 'stop', 
% 'pause', 'continue', or 'update'. 
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Abstract: While Long-Term Oxygen Therapy 
(LTOT) is standard treatment in Chronic 
Obstructive Pulmonary Disease (COPD), optimal 
delivery of supplemental oxygen for patients remains 
uncertain. The fixed flow-rates set during LTOT are 
unresponsive to patients' fluctuations in oxygen 
requirement. In many COPD patients, arterial 
oxygen saturation (SpOz) while receiving LTOT falls 
below an acceptable threshold (Sp02<90%) for 
extended periods during routine daily activities. 
Using a closed-loop PID controller, we describe a 
method of actively varying flow-rates in response to 
the measured oxygen demand. We have 
demonstrated how SpO; measurements from pulse 
oximetry can be integrated into an automated flow-
rate controller. Initial simulation findings indicate 
an optimized matching between oxygen supply and 
demand, maintaining SpOi above threshold to 
maximize therapeutic efficacy. The study illustrates 
the potential to significantly improve the efficacy 
and economic delivery of this widespread therapy. 
Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is 
estimated to aflfect over 900,000 people living in the UK, 
with a combined annual direct and indirect cost to the 
NHS of approximately £982,000,000. Long-Term 
Oxygen Therapy (LTOT) has been shown to increase 
survival among patients with COPD. The "Nocturnal 
Oxygen Therapy Trial' demonstrated that an average of 
19 hours versus 12 hours of oxygen therapy per day led 
to a proportional reduction in mortality [1]. As well as 
an increased survival, other recognized benefits include 
a decrease in hypoxia-induced elevations of 
haemoglobin, increased stroke volume index, improved 
exercise tolerance, and improvement in quality of life 
[2,3]. Despite the positive benefits of LTOT, even short 
periods of hypoxemia can lead to right ventricular 
hypertrophy from increased pulmonary arteiy pressure 
and pulmonary vascular resistance [3]. 
As oxygen flow-rates remain fixed during LTOT, 
delivery will not respond to patients' fluctuations in 
oxygen demand. Several recent outpatient studies using 
ambulatory pulse oximetry confirmed the existence of 
hypoxemic periods during LTOT. Over the course of 
daily activities, corroborating studies revealed an 
average of approximately 25% of the monitored period 
spent with a Sp02 <90% [4,5,6], By eliminating these 
periods of hypoxemia there may be further proportional 
health, practical and economic benefits. We report 
preliminary results on a closed-loop controller capable 
of actively varying flow-rates during LTOT in response 
to the measured pulse oximetry. 
Materials and Methods 
Figure 1 illustrates the feedback system schematic. 
A microprocessor receives measurements from a pulse 
oximeter and automatically computes the optimum 
oxygen flow-rate. The controller outputs a signal to a 
flow regulator managing the delivery of oxygen to the 
patient. An oxygen saturation target of 91% is 
maintained by changing the flow-rate subject to 
feedback from the pulse oximetry. This control scheme 
has been preliminarily implemented in a computer 
simulation on Simulink™ via a closed-loop 
proportional-integral-derivative (PID) algorithm. The 
controller is evaluated using a model to approximate the 
patient oxygen saturation response. 
Flow Regulator 
1 
Source 
Patient 
Oximeter Controller 
Figure 1: Active LTOT, close-loop schematic 
The closed-loop simulation consists principally of 
two components, the Controller and Patient models as 
shown in Figure 2. The controller computes the error (E) 
between the target setpoint and measured oximetry 
value. It then determines the oxygen flow-rate output to 
the patient. The patient saturation is modelled as a 
composite value, dependent on the oxygen flow rate and 
a local arbitrary disturbance. Each of these two main 
components is discussed in detail below. The simulation 
also accounts for the 1 Hz discrete sampling rate from 
the pulse oximeter. 
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Figure 2; Top level Simulink™ block diagram 
A PID controller constitutes the active 
subcomponent of the control algorithm. The PID 
function used extensively in controls is given in Eqn.l. 
Overall, the PID function endeavours to correct for any 
input errors (E). The response (U) of the PID function is 
characterized by the proportional (Kp), integral (K|) and 
derivative (Kp) parameters. The output, U, can be 
viewed as the oxygen flow-rate in liters/minute. The 
PID function can also be expressed in terms of its 
Laplace transfer function as in Eqn.2. 
[/(O = /(Tf E ( 0 + AT/ T (1) 
Kj^S^ +KpS+Kf 
(2) 
Since the simulation assumes a maximum sampling 
rate from the pulse oximeter of 1 Hz, a discrete filter has 
also been incorporated into the control algorithm. A 
Butterworth lowpass filter is used to screen out higher 
frequencies near the sampling rate. It also reduces the 
potentially detrimental affects of noise or spurious 
measurement from the pulse oximeter. In addition, the 
filter will ensure a stable flow-rate response from the 
control algorithm. The fransfer function for the first 
order lowpass filter is presented below. 
WiS) = A+AS' 
l+BS - 1 (3) 
Ojomeoy 
(Po), an arbitrary disturbance (D), and an 
oxygen flow-rate dependence (F). Combined 
together, their sum represents the patient PaOz 
in mmHg. Po can be considered the default 
value. In the absence of any disturbance or 
oxygen flow, this baseline level 
approximately yields a 91% saturation. 
Pa02{t) = P o D{t) + F{t) (4) 
Where Po ~ 60mmHg 
D(r) = - 3 + 3 cos ine{27rf) (5) 
Where/= Frequency (Hz) 
The arbitrary disturbance, D(t), introduces 
fluctuations from the baseline level. These fluctuations 
simulate the conditions possible in COPD patients 
during changing exertion or sleep. Negative 
disturbances will induce hypoxemia (PaO: < 60mmHg), 
while positive values raise the PaOz > 60mmHg. For the 
purpose of the simulation, D(t) is given by a cosine 
function with a bias of -3 and amplitude 3, oscillating 
between 0 and -6 mmHg. Nevertheless, any arbitrary 
input can be given to the system. Eventually the model 
could receive actual patient oximetry recordings. 
Capturing the oxygen flow-rate dependence, F(t), 
requires a more complicated differential equation. A 
change in the fraction of inspired oxygen (F1O2), takes 
time to diffuse dovra to the blood capillaries where the 
pulse oximetry measures the oxygen saturation. This is 
known as the lung-to-capillary circulatory time. By 
looking at the response to a step change in F1O2 
illusfrated in Figure 4, two phases can be identified. The 
time from onset until a measurable change in saturation 
is know as dead time (T,). The lag time (T2) is 
approximately the time between the first measurable 
change and the final stable measurement. 
Representative Input Step Response 
As a patient safety matter, the oxygen flow-rate must 
have a maximum and minimum limit. In the control 
algorithm this is accomplished via a non-linear 
saturation regulator. The minimum flow-rate limit is 0 
1/min, and the maximum limit has been set to 5 1/min. 
Thus the flow controller can only output values within 
this predetermined range. The Simulink block diagram 
for the controller is depicted in Figure 3. 
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Figure 3: Simulink™ Flow Controller block diagram 
The model representing the patient saturation 
response is best described mathematically. The function 
(Eqn.4) governing the patient's arterial pressure of 
oxygen has three distinct components; a baseline level 
Figure 4: Flow-rate step response 
Several studies have investigated the lung-to-
capillary circulatory time based on pulse oximetry 
measurement [7,8]. It appears sensor placement is a key 
factor affecting the lung-to-capillary time. Pulse 
oximetry is commonly obtained from sensors at the foot, 
hand or ear. Overall, measurements from the ear 
displayed the shortest delay times. Ear sensor 
measurements also were the least sensitive to error from 
either exercise or cold [9]. Based upon these studies, T, 
and T2 are approximately 6 and 15 seconds, respectively 
[10]. However, these values are certain to contain 
variability between patients from physiological 
parameters such as shunt fraction, respiratory rate, heart 
rate, cardiac output. 
In order to model the lag time (T2), F(t)* is given by 
the differential equations for a mass-spring-damper 
system. Eqn. 6 defines the dynamic behaviour as a 
function of oxygen flow-rate. M,B,K are all parameters 
given to the model to yield the appropriate lag time. 
Furthermore, the dead-time (T,) is also included in 
corresponding transfer function, Eqn.7. Since F(t) must 
be in mmHg, a sensitivity factor a is utilized. This 
factor is derived from the following relationship. For 
each additional 1/min of oxygen flow-rate provided, the 
F1O2 increases by approximately 3% [11]. 
F(t)* = M 
dt" dt • + Kx{t-T^) (6) 
* — -sZ 
MS^+BS+K 
- ] 
F{t) = aF{t) '• 
(7) 
(8) 
Ultimately, the pulse oximeter measures the oxygen 
concenfration in terms of percent saturation. The 
saturation can be calculated from the arterial oxygen 
pressure using the Severinghaus oxyhemoglobin 
dissociation relationship [12] shown in Figure 5. The 
combined patient saturation value is then feedback into 
the closed loop controller. 
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Figure 5: Oxyhemoglobin disassociation curve 
The closed-loop system response is evaluated at 
frequencies between 10'^  to 10"' Hz. A frequency sweep 
has been implemented across the disturbance function. 
Measurements can be made at any point throughout the 
simulation to evaluate variables of interest. Two 
variables are worth particular focus; the Sp02(t) as 
measured by the pulse oximeter, and the flow-rate(t) as 
output by the flow controller. These measurements will 
demonstrate the response and efficacy of the controller. 
Also, a deviation measurement is defined as the 
maximum difference between target saturation and the 
Sp02 for a given disturbance frequency. 
Futhermore, these values can be compared against 
an untreated patient model. In the unfreated model, the 
disturbance will directly produce fluctuations in 
oximetry measurements. A ratio of the maximum 
deviation between the confrolled model versus the 
unfreated model can illustrate the attenuation provided 
by the closed-loop system. The unfreated model also 
serves as the reference for any phase comparisons. 
Results 
The system is first evaluated analytically through the 
study of its transfer functions. This will give insight into 
the dynamic response and stability of the confroller. The 
linear transfer function (Eqn.9) can be simply derived 
from the system diagram in Figure 6. It relates the 
oximetry output (O2) to both the target input (T) and 
disturbance fUnction (D). Since the target input (T) does 
not vary with time, the equation can be rewritten as in 
Eqn. 10. This form of the equation yields the system 
output in terms of an input disturbance function (D). It 
should be noted that the analytical fransfer function only 
applies while the system remains linear. At high 
frequencies, the saturation regulator infroduces a non-
linear response. 
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Figure.6: Transfer function diagram 
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O l - 1 
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(9) 
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Figure 7 is a Bode plot of the theoretical system 
response across a range of disturbance frequencies. This 
plot gives the magnitude of attenuation in Decibels. The 
negative magnitudes demonstrate a decrease in the O2 
fluctuation with respect to the disturbance signal. 
However, positive values indicate an amplification in 
the disturbance. For frequencies less than 10"^  Hz, the 
analytical predictions are acceptable. The flow 
controller is successful in significantly attenuating the 
disturbance. Nevertheless, the linear transfer function 
solution reveals an undesirable region of amplification 
around 10"" Hz. This feature is due to the limitations of 
the 1 Hz pulse oximeter sampling rate. Furthermore, the 
controller must account for the time delay from the 
lung-to-capillary circulatory time. Together, these 
effects limit the systems ability to effectively manage 
disturbance with a period close to the lag time. This 
region of amplification is eliminated in the confroller 
through the use of the non-linear saturation regulator. At 
this time, the non-linear element is not easily 
incorporated into the analytical evaluation. 
Bode Plot: System Response 
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Figure 7: System Transfer Function 
Hence the following results are taken directly from 
the simulation results. A plot of the simulated flow 
controller's effectiveness is given in Figure 8. 
Corroborating the theoretical results, the attenuation 
increases in relation to the period of the disturbance. At 
steady state or at rest, the controller will automatically 
provide the optimum therapeutic oxygen flow-rate. It 
can then significantly suppress disturbances with 
periods greater than a couple of minutes. Even for high 
frequency disturbances, the flow controller will still 
correct the bias offset. Notice the stable dynamic 
behaviour illustrated in the simulated controller 
effectiveness (Figure 8). Unlike the analytical solution 
from the system transfer function, there is no region of 
amplification as in Figure 7. 
Bode Plot: Effectiveness 
DQ 10! 
In terms of clinical effectiveness, the controller 
response must be analyzed in context of the oxygen 
flow-rate output to the patient. The controller suppresses 
a measured disturbance in the pulse oximetry by 
regulating the oxygen flow to the patient. In order to 
correct for a deviation in Sp02, the oxygen flow-rate 
must be adjusted in phase and with the proper 
magnitude. This will attenuate the deviations in Sp02 
away from the target value. Three representative 
simulation results are provided in Figures 9, 10, & 11 
They demonstrate the controller response and 
effectiveness for disturbance frequencies at 10'^^, 10"^  
and 10"' ^  Hz respectively. 
As predicted, the flow confroller proved most 
effective for low frequency disturbances below 10'^  Hz. 
The upper plot in Figure 9 compares the oxygen 
saturation of the untreated model (No-LTOT) against 
the Active-LTOT. From the lower plot in Figure 9, it is 
evident that the oxygen flow-rate follows closely in 
phase with the disturbance function at low frequencies. 
The result is very minor deviations from the target 
saturation of 91% using Active-LTOT. In this example, 
the disturbance with a period of five minutes is 
suppressed by better than -17 dB. 
Frequency: 10^-25 Hz 
— No-_TO 
AntK/e TDT 
4 5 6 
Tine (min) 
. ICl-g 
Flov/-rale i 
Tine (min) 
Diatjrbancc ^  ^ 
If ^ 
Figure 9: Simulation Results for 10^ ^ Hz disturbance. 
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Bottom: O2 Flow-rate plotted with Disturbance 
As the period of the disturbance decreases, the 
observed suppression also diminishes. Figure 10 is the 
simulation results for a disturbance frequency of 10"^  Hz 
with a period of about 1.5 minutes. While the oxygen 
flow-rate still fracks the disturbance function, there is 
greater discrepancy in the phase and magnitude of the 
flow confroller response. The resulting attenuation for 
this disturbance frequency is approximately -10 dB. 
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Figure 8: Attenuation in SpO] fluctuations 
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Figure 10: Simulation Results for 10" Hz disturbance, 
Attenuation. = -lOdB 
Top: Sp02 for Active-LTOT and No-LTOT 
Bottom: O2 Flow-rate plotted with Disturbance 
In the Figure 11, the disturbance frequency is 10"' ^  
Hz with a period of about 30 seconds. Here the 
amplitude of the flow-rate response no longer 
corresponds with the disturbance function. Instead the 
flow-rate settles around an elevated average value. For 
high frequency disturbances above 10"'^ Hz, the 
attenuation approaches -6 dB. Note that the Sp02 
fluctuates with the same amplitude in Figure 11 despite 
the Active-LTOT. However, the flow-controller does 
manage to correct the bias of the disturbance to be 
around 91%. Even with high frequency disturbances, 
the flow controller achieves a mean saturation near the 
target saturation value. 
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Figure 11: Simulation Results for 10"' ^ Hz disturbance 
Attenuation. = -6dB 
Top: Sp02 for Active-LTOT and No-LTOT 
Bottom: O2 Flow-rate plotted with Disturbance 
For high frequencies, the controller design is 
intended to reject the input signal. Combining the 
lowpass Butterworth filter with the non-linear saturation 
element, successfully regulates the flow-rate output. As 
previously mentioned, large fluctuations in flow-rate are 
potentially detrimental if their frequency exceeds the 
patient's respiratory rate. Alternatively, the simulation 
results indicate the flow controller attempts to find an 
optimum stable average flow-rate. 
The plots in Figures 9 - 1 1 illustrate the transition in 
flow controller's dynamic response between lower to 
higher disturbance frequencies. 
Discussion 
The simulation results demonstrate the overall 
effectiveness of the Active-LTOT. The flow controller 
provides beneficial improvement in oxygen saturation, 
throughout the range of possible disturbance frequencies. 
Eliminating the need for a single prescription flow-rate, 
the Active-LTOT can automatically respond to a 
patient's changing needs. 
The controller parameters have been iteratively 
tuned through trial and error to provide the best overall 
response. These preliminary results provided are 
representative of the controller behaviour. With 
additional refinement the dynamic response may yield 
fiirther improvement. However, it is expected the 
system parameters will have to be somewhat modified 
to better accommodate patient variability not present in 
the current simulation. One step towards bridging the 
gap would be to input patients' real-time pulse oximetry 
as the disturbance flmction in the simulation. 
Measurements taken during different activities, such as 
exercise and sleep, might provide fiirther insight into the 
effectiveness of the controller. Even basic information 
regarding the various frequency components present in 
the real-time signals would be beneficial towards 
iterating the control algorithm and parameters. 
While the simulation may approximate the 
effectiveness of the Active-LTOT, there remains a 
question as how patients will adapt to the responsive 
therapy. In actuality, patients can not be viewed as 
strictly static components. As the oxygen saturation 
fluctuates within the body, the patient will naturally 
attempt to compensate. The dynamic interaction 
between the flow controller and the patients' instinctive 
response will be particularly interesting to study. 
Conclusions 
The aim is to develop the first automated closed-
loop, flow-rate control device for patients with COPD 
undergoing treatment with LTOT. Simulation results 
indicate the benefit for this method to actively regulate 
LTOT. As part of the next phase in development. The 
PID parameters will next be validated against a database 
of patient oximetry trend measurements. True 
physiological measurements contain a wide range of 
signal fi-equencies as well as a significant amount of 
noise and artefacts. Before moving towards clinical 
implementation, the controller will have to demonstrate 
an appropriate response using actual patient measured 
input signals. 
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Modeling closed loop system for 
controlling oxygen therapy 
lobbi M\ Dickinson RJ^ 
Department of Bioengineering, Imperial College, 
London, UK 
Background and purpose 
Long-Term Oxygen Therapy (LTOT) has been 
shown to increase survival among patients with 
Chronic Obstructive Pulmonary Disease (COPD). 
Other recognized benefits include improvements in 
exercise tolerance and cardiac function (lower 
pulmonary artery pressure, increased stroke 
volume) f1l. Despite these positive benefits, even 
shnrt nftrinds nf hynoxemig may contribute to the 
vs u r 
yoisening cardiac function jl]- Cuireni LTOT 
i j i i i y j iAUu O A v y c n nOvVb. n w H C t ? v>2 U t j U v c l y 
demand. Several recent outpatient studies using 
r\i <-ivrmd.fr\/ H-at/a r^z-vrifirmorl q vie f o r i / - i f 
h'w't^ riVfisrr^ ir' rtarirwHc f f f ^ ? f V,,'£ar t h s r-n: :rca 
of routine daily activities, corroborating studies 
monitored period spent with a detrimentally low 
oxygen saturation (Sp02 <90%) [2]. We report 
preliminary results on a closed loop controller 
capable of actively varying flow-rates during LTOT 
in response to the measured pulse oximetry. 
Method 
Figure 1 illustrates the closed loop system diagram. 
A microprocessor receives oxygen saturation 
measurements from a pulse oximeter, and 
automatically computes the optimum flow-rate. The 
controller in turn controls a proportional flow valve, 
regulating the delivery of oxygen to the patient. A 
healthy target range of oxygen saturation (approx. 
91%) is maintained using the feedback from the 
pulse oxirneuy. This contioi sciierne has ueen 
preliminarily implemented in a computer simulation 
via a modified closed loop RID algorithm. The 
controller is evaluated using a mode! to replicate 
the patient oxygen saturation response as 
described by the non-linear oxyhemoglobin 
dissociation curve, and also incorporating a second 
order transfer function with a fixed dead and lag 
time. Disturbances are input into the patient model 
as time oscillating cosine functions to represent 
patient fluctuations in oxygen saturation. 
Flow Regulator 
1 
Source 
Patient 
Oximeter Controller 
Results 
The preliminary results demonstrate potential to 
maintain patient saturation levels near a target 
threshold. In the model, a disturbance causes large 
fluctuations in the patient's pulse oximetry 
measurement. The controller can automatically 
suppress a measured disturbance in the pulse 
oximetry by compensating the oxygen flow to the 
patient. Figure 2A depicts a representative sample 
simulation. The disturbance with a period of 5 min 
was attenuated by approximately 20dB. By using a 
RID algorithm, the Active LTOT not only attenuates 
the magnitude of fluctuations but also corrects for 
any static offset fron, uiC- " 
the attenuation is a function of the input 
disturbance frcqiicncy. Figure 2B shews th 
m n t r n l l p r r p c n n n c p a r r n « s a r a n n p nf r l ict i irhanrp 
frequencies The attenuation is greatest for low 
frequencies, however the resDonse is stable 
throughout. Ultimately the controller response is 
sampling rate. Furthermore, the PiD controller can 
No-LTOT 
Active lUI 
5 » 
Time (min) 
10 
Freq (Hz) 
Figure 1; Closed loop system schematic 
Figure 2; (Top) Sample oximetry disturbance, 
(Bottom) Bode frequency plot 
The aim is to develop an automated closed loop, 
flow-rate control device for patients undergoing 
treatment with LTOT Our simulation results 
indicate the potential benefit for this method to 
actively regulate LTOT. The final device in 
development is currently being validated against a 
database of patient oxiirieu y bend nieasurernents, 
prior to clinical testing. 
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OXIMETRY FEEDBACK FLOW CONTROL 
SIMULATION FOR OXYGEN THERAPY 
Mario G. lobbi, BSc\ Anita K. Simonds, MD, FRCP^ 
and Robert J. Dickinson, PhD' 
lobbi MG, Simonds AK, Dickinson RJ. Oximetry feedback flow 
control simulation for oxygen therapy. 
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A B S T R A C T . Object ives . For many with Chronic Obstructive 
Pulmonary Disease (COPD), arterial oxygen saturation while 
receiving Long-Term Oxygen Therapy (LTOT) falls below 
an acceptable threshold (Sp02<90%) for extended periods 
during routine daily activities. Using a closed-loop controller, 
we have evaluated a simulated method to automatically 
regulate the oxygen flow-rate in response to the measured 
oxygen demand. Methods . The closer -loop control scheme 
was implemented in a computer simui.nion on Simulink™. 
Feedback from a pulse oximeter was used to maintain a target 
Sp02 of 91% by changing the ox^'^eu flow-rate to the 
patient. The controller was evaluated using a model to 
approximate the patient's arterial oxygen saturation response, 
including hypoxic events from artificial disturbances as well as 
recorded patient oximetry data. Results. The simulated 
controller produced improvement in arterial oxygen 
saturation throughout a wide range of disturbance 
frequencies. It suppressed disturbances with periods greater 
than a couple of minutes by more than -10 dB. When 
evaluated with patient oximetry recordings, the controller on 
average reduced the time spent with arterial blood saturation 
below threshold by 76%. Given the same volume of oxygen, 
the closed-loop controller also produced a 63% improvement 
compared to fixed flow-rate LTOT. Conclusions. The 
simulation findings indicate an optimized matching between 
oxygen supply and demand, maintaining SpO? above 
threshold to improve therapeutic efficacy compared to 
standard LTOT. 
KEY W O R D S , oxygen inhalation therapy, COPD, feedback, 
oximetry. 
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In the U K nearly 900,000 people have Chron ic 
Obstructive Pulmonary Disease ( C O P D ) , and around half 
as many again are living with undiagnosed chronic airflow 
obstruction [1]. This accounts for a combined annual 
direct and indirect cost to the U K National Health Service 
of approximately $1.7 billion [1]. According to the 
American Lung Association, C O P D claims the hves of 
over 100,000 annually, and is ranked as the fourth leading 
cause of death. T h e corresponding U S annual healthcare 
expendi ture for C O P D exceeds $18 billion. L o n g - T e r m 
Oxygen Therapy ( L T O T ) is standard t reatment in C O P D 
patients as it can increase exercise ability and improve 
long- term outcomes. 
Cont inuous oxygen therapy is k n o w n to increase sur-
vival among patients with C O P D [2, 3]. T h e Nocturnal 
Journal of Clinical Monitoring and Competing 
Oxygen Therapy Trial demonstrated that an average of 19 
hours versus 12 h of oxygen therapy per day led to a 
proportional reduction in mortality [2]. Other recognized 
benefits from L T O T include a decrease in hypoxia-in-
duced elevations of haemoglobin, lower pulmonary artery 
pressure and vascular resistance, increased stroke volume 
index, improved exercise tolerance, and subjective 
improvement in quality of life [4, 5]. Unfortunately with 
the current delivery of L T O T , the patient's varying 
oxygen demand may not be well matched by the fixed 
flow-rate oxygen delivery. 
At present L T O T is delivered by an oxygen cylinder or 
concentrator delivering a constant prescribed flow of 
oxygen. Several recent outpatient studies using ambula-
tory pulse oximetry confirmed the existence of hypox-
emic periods despite L T O T [6, 7,]. Over the course of 
daily activities, corroborating studies revealed an average 
of approximately 25% of the monitored period spent with 
a SpO? < 90% [8, 9]. This indicates patients are not real-
izing the fuU potential benefit of oxygen therapy. Since it 
is known that brief periods of hypoxemia can lead to right 
ventricular hypertrophy from increased pulmonary artery 
pressure and pulmonary vascular resistance [10], it is 
important to ensure that L T O T patients do not spend a 
significant percentage of time below the established 
oxygen saturation threshold (Sp02 > 90%). In addition, 
some patients are particularly oxygen sensitive and pro-
viding too much oxygen can be harmful. In C O P D 
patients with hypercapnia, too much oxygen can depress 
ventilatory drive thereby worsening CO2 retention. In 
these patients it is particularly critical not to over-supply 
oxygen during acute exacerbations. With the present 
fixed-flow oxygen delivery systems, the patient's oxygen 
demand is not well matched and does not achieve the 
maximum potential health and economic benefits. 
Our aim is to evaluate a closed-loop, flow-rate control 
method for patients undergoing treatment with LTOT. 
The controller uses arterial oxygen saturation measure-
ment from pulse oximetry to automatically regulate 
oxygen flow-rate during treatment. Feedback from the 
pulse oximeter is used to maintain the patient SpOa 
within an ideal range. The hypothesis to be tested is that 
this Saturation Driven Oxygen Therapy (SDOT) will 
more accurately match patient need to oxygen supply 
than conventional fixed flow-rate LTOT. The evaluation 
involves simulating the response by creating a mathe-
matical model of the patient oxygen response. 
Previous studies have attempted to control the oxygen 
concentration of mechanical ventilators in acute hospital 
settings [11, 12]. Feedback from a pulse oximeter enabled 
a controller to manage the oxygen-air mixer during 
mechanical ventilation. In these studies the controller was 
effective for patients, with an average recovery from 
hypoxic events within 2 min. Another study on very low 
birth-weight infants, subject to frequent episodes of 
hypoxia which are difficult to manage manually, used a 
closed-loop controller to maintain the Sp02 at a fixed 
level. The study demonstrated an improvement in oxygen 
saturation over the monitored period compared to the 
manual control [13]. 
M E T H O D S A N D M A T E R I A L S 
Figure 1 is a schematic of the proposed closed-loop 
S D O T system. A microprocessor receives measurements 
from a pulse oximeter and computes the optimum oxygen 
flow-rate. The controller then outpi ts a signal to a flow 
regulator managing the delivery of o..vgen to the patient. 
An oxygen saturation target of 91% is maintained by 
changing the flow-rate subject to fee ib.xk from the pulse 
oximetry. The control scheme for this system has been 
implemented in a computer simulation on Simulink^" 
(Mathworks Inc, Massachusetts USA) using a closed-loop 
proportional-integral-derivative (FID) algorithm. The 
controller is evaluated using a model developed to 
approximate the patient oxygen saturation response. 
Simulation and flow controller 
The S D O T simulation consists principally of two com-
ponents, the Controller and the Patient model as shown in 
Figure 2. The controller computes the error (E) between 
the target setpoint and measured oximetry value. It then 
determines the oxygen flow-rate output to the patient. 
The patient saturation is modelled as a composite value, 
dependent on the oxygen flow rate and a local distur-
bance. Each of the main components is discussed in detail 
below. The simulation also accounts for the discrete 
sampling from the pulse oximeter which is assumed to 
have a sampling rate of 1 Hz. 
The controller was based around t le well-known PID 
algorithm used extensively in controls whose function is 
given in Equation (1), where E is Ti.. input error (dif-
ference between actual and target Sp02), U is the oxygen 
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Fig. 1. Acliue LTOT, closed-loop schematic. 
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Fig. 2. Top level block diagram. 
flow rate in 1/min, and Kp K, are the proportional, 
integral and derivative parameters. Overall, the PID 
function endeavours to correct any input errors. The 
response of the PID function is characterized by the 
parameters ^Cp, K, and Kp. The output (U) can be viewed 
as the oxygen flow-rate in liters per minute (1/min). The 
PID function can also be expressed in terms of its Laplace 
transfer function as in Equation (2). 
U{t) = KpE{t) +K\ E{t)clt + K d 
dEjt) 
dt 
U(S) 
KdS^ + KpS + K\ 
(1) 
(2) 
In1 
P I D Contro l ler S a t u r a t i o n 
- K D 
Out1 
Discrete Filter 
represents the patient PaOa in m m H g . Pq can be 
considered the default value. In the absence of any 
disturbance or oxygen flow, this baseline level is set to 
60 m m H g (approximately 91% saturation). 
A first order Butterworth lowpass filter was used to 
screen out higher frequencies near the sampling rate to 
reduce the potentially detrimental aflfects of noise or 
spurious measurement from the pulse oximeter. T o 
ensure a stable flow-rate response from the control algo-
rithm the Butterworth lowpass filter (cut-off frequency: 
6.5 niHz) was apphed to the PID output. 
For patient safety, the oxygen flow-rate must include 
maximum and minimum limits. This is accomplished via a 
non-linear saturation regulator. The minimum flow-rate 
limit is 0 1/min, and the maximum limit has been set to 
5 1/min. Thus the flow controller can only output values 
within this predetermined range. A controller block dia-
gram is depicted in Figure 3. 
Modelling the patient response 
The patient arterial oxygen concentration (Pa02) is 
modelled by the function given in Equation (3). This 
function has three distinct components: a baseline level 
(P()), an arbitrary disturbance (Pj), and an oxygen flow-
rate dependence (Pf). Combined together, their sum 
P a O 2 ( 0 = Po + f d ( 0 +-PKO (3) 
wherePo ~ 60mmHg. 
The arbitrary disturbance, Pd(f). is a driving function 
that introduces fluctuations from the baseline level. These 
fluctuations simulate the variable conditions possible in 
C O P D patients during changing exertion or sleep. Neg -
ative disturbances wiU in luce hypoxemia 
(PaO? < 60mmHg), while positive, values raise the 
P a 0 2 > 60mmHg. Initial tests of the simulation used Pd(t) 
as given in Equation (4), a cosine fu.iction with a bias of 
- 3 and amplitude 3, oscillating between 0 and - 6 m m H g . 
The frequency of the cosine disturbance was varied be-
tween 10"^ and 10" ' Hz. Nevertheless, any arbitrary in-
put can be given to the system. The simulation is later 
validated using actual patient oximetry recordings as the 
driving input. 
P d ( ( ) = - 3 -h 3 COS(271 * / * 0 (4) 
w h e r e / = Frequency (Hz) 
A sample patient response for a step change in oxygen 
flow-rate is shown in Figure 4. Looking at the patient 
response, two time constants can be identified. The time 
from onset until a measurable change in saturation is 
know as the dead time (T,). The lag time (T?) is the time 
Representative Input Step Response 
a 0.8 
S 
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S, 0.6 
u 0.4 
1 » 0.2 
— 7. tput Response 
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Time 
Fig. 3. Flow Controller block diagram. Fig. 4. Flow-rate step response. 
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between the first measurable change and the final stable 
measurement. A change in the inspired oxygen concen-
tration takes time to diffuse down to the blood capillaries 
where the pulse oximetry measures the oxygen saturation. 
This is known as the lung-to-capillary circulatory time 
[14]. 
Several studies have investigated the lung-to-capillary 
circulatory time based on pulse oximetry measurement 
[14, 15]. It appears that sensor placement is a key factor 
affecting the lung-to-capillary time. Pulse oximetry is 
commonly obtained from sensors at the foot, hand or ear. 
Overall, measurements firom the ear displayed the shortest 
delay times. Ear sensor measurements also were the least 
sensitive to error from either exercise or cold [16]. Based 
upon these studies, T, and T2 are approximately 6 and 
15 s, respectively [17]. However, these values are certain 
to contain variability between patients from physiological 
parameters such as shunt fraction, respiratory rate, heart 
rate, cardiac output. 
T o represent the patient's oxygen flow-rate dependence, 
Pf (t), is described by a second order linear differential 
equation. Equation 5 relates the oxygen flow-rate (U) to 
the arterial oxygen concentration. M, B, K are all param-
eters given to the model to yield the appropriate lag time 
(T2). Furthermore, the dead-time (T,) is also included in 
corresponding transfer function. Equation (6). Since Pt{t) is 
in inmHg, a sensitivity factor (a) is utilized. This factor is 
derived from the rule of thumb that for each additional 1/ 
min of oxygen flow-rate provided, the fraction of inspired 
oxygen increases by approximately 3% [18]. W e assumed 
a corresponding direct relationship in the Pa02 of 3% in-
crease for each 1/min of oxygen flow-rate. 
Oxyhemoglobin Dissociation Curve 
F{t) de-
F(S) a* e -sT, 
1 
MS- + BS + K 
(5) 
(6) 
The pulse oximeter measures the arterial oxygen con-
tent in terms of percent saturation rather than m m H g . 
The approximate saturation can be theoretically related to 
the arterial oxygen pressure using the Severinghaus oxy-
hemoglobin dissociation relationship [19] shown in 
Figure 5. This relates the PaOz (mmHg) to the arterial 
oxygen saturation ( S p O j which can be shifted by specific 
factors such as blood pH, and P a C O ; that influence the 
oxyhaemoglobin dissociation. The final S p 0 2 value is 
then fed back into the closed loop controller. 
Soluf&lion Threjhotd 
0 10 20 30 40 50 60 70 80 90 
P a 0 2 (mmHg) 
Fig. 5. Oxyhaemoglobin disassociation curve. 
The S D O T system response is modelled at disturbance 
frequencies between 10 ^ and 10 ' Hz. Simulated 
responses of the SpOi measured by the pulse oximeter, 
and the oxygen flow-rate determined by the controller 
were obtained which directly relate to clinically relevant 
parameters. Also, a deviation measure is defined as the 
maximum difference between target saturation and the 
S p 0 2 for a given disturbance frequency. 
These values have been compared against a simulation 
of an untreated patient with no si' jplemental oxygen. 
S D O T is hypothesized to attenuate fluctuations by 
appropriately varying the oxygen flov, -ate. A ratio of the 
maximum deviation between the controlled model versus 
the untreated model illustrates the attenuation provided 
by the closed-loop system. For reference, the block dia-
gram of the patient model has been provided below in 
Figure 6. 
Patient data set 
Patient data were obtained from five subjects with C O P D 
during overnight pulse oximetry monitoring. These 
C O P D patients were undergoing routine clinical assess-
ment for oxygen therapy to detect the presence of noc-
turnal hypoxia. Measurements were taken using a Nellcor 
N200 pulse oximeter, and values stored locally to a P C at 
5 s intervals. Recordings were taken over 8 h while the 
patients slept. All data were anonymized at the clinic prior 
to the analysis. O f the five recordings, only the three 
studies contained significant hypoxic events. T w o data 
sets revealed less than 2% of the monitored period with 
S p 0 2 < 90%, and have been excluded from this discussion 
as no supplemental oxygen was requ red. 
Arterial oxygen saturation measurei.-.ents from the pulse 
oximeter are integer values between ''V'-nd 100%, with an 
accuracy o f + 2% in the range between /O and 100%. The 
pulse oximeter also utilizes a default 5 - 7 s averaging filter 
lobbi et al: Feedback Flow Control 
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Fig. 6. Patient model block diagram. 
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Fig. 1. Representative patient overnight pulse oximetry data. 
to compensate for any motion artefact. From the repre-
sentative plot shown in Figure 7, it is apparent these pa-
tients experienced large fluctuations in their oxygen 
saturation. The percentage of the monitored time found 
with S p 0 2 < 90 was 55%, 27%, and 12% for patients 1, 2 
and 3, respectively. 
To incorporate the patient recordings into the con-
troller simulation, the data sets were resampled to 1 Hz 
using linear interpolation. The patient data was trans-
formed from Sp02 to the corresponding Pa02 using the 
inverse of the general Severinghaus oxyhemoglobin dis-
sociation relationship. Then this value is subtracted by 
60 m m H g to obtain a net disturbance wavefonn for the 
computer simulation. Thus these patient disturbance sig-
nals retain aU the challenges associated with real-time 
physiological measurement such as signal noise and arte-
facts. 
R E S U L T S 
Controller response frequency analysis 
In terms of clinical effectiveness, the controller response 
must be analysed in tenns of its ability to suppress a 
measured disturbance in the pulse oximetry by regulating 
the oxygen flow to the patient. T w o representative sim-
ulation results are provided in Figures 8 and 9. They 
demonstrate the controller response and effectiveness for 
disturbance fi^equencies at 3.2 and 32 niHz respectively. 
The flow controller proved most efliective for low 
frequency disturbances below 10 mHz (periods greater 
than 1.5 min). The upper plot in Figure 8 demonstrates 
the attenuation of S D O T compared against the untreated 
model (No-OT) . From the lower plot in Figure 8, it is 
evident that the oxygen flow-rate follows closely in phase 
with the disturbance function at low frequencies. The 
result is very minor deviations from the target saturation 
of 91% using SDOT. In this example, the disturbance 
with a period of 5 min is suppressed by better than 
- 1 7 dB. 
As the period of the disturbance decreases, the observed 
suppression also diminishes. In the Figure 9, the distur-
bance frequency is 32 mHz with a period of about 30 s. 
Here the amplitude of the flow-rate response no longer 
corresponds with the disturbance function. Instead the 
flow-rate setdes around an elevated a- erage value. In high 
firequency disturbances above 32 mt iz , the attenuation 
approaches - 6 dB. Note that the SpO • iuctuates with the 
same amplitude in Figure 9 despite the SDOT. However, 
the flow-controUer does manage to correct the bias of the 
disturbance to be around 91%. Even with high frequency 
disturbances, the flow controller achieves a mean satura-
tion near the target saturation value. 
For high fi-equencies, the controller design is intended 
to reject the input signal. Combining the lowpass But-
terworth filter with the non-linear saturation element 
successfully regulates the flow-rate output. As previously 
mentioned, large fluctuations in flow-rate are potentially 
detrimental if their frequency exceeds the patient's respi-
ratory rate. The simulation results indicate the flow 
controller attempts to find an optimum stable average 
flow-rate. The plots in Figures 8, 9 illustrate the transition 
in flow controller's dynamic response between lower to 
higher disturbance frequencies. 
A plot of the simulated flow controller's effectiveness is 
given in Figure 10. As seen in the two previous examples, 
the attenuation increases in relation to the period of the 
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Fig. 8. Simnlation Results for 3.2 mHz disturbance, Attenuation = -17dB Top: SpOj for SDOT and No-OT, Bottom: O2 Flow-rate plotted with 
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Fig. 9. Simulation Results for 32 mFIz disturbance, Attenuation 6dB Top: Sp02for SDOT and No-OT, Bottom: O2 Flow-rate plotted with 
Disturbance. 
disturbance. At steady state or at rest, the controller will Controller response patient data analysis 
automatically provide the optimum therapeutic oxygen 
flow-rate. It can then significantly suppress disturbances These preliminary results are representative of the con-
with periods greater than a couple of minutes. Even for troller behaviour. However, the system parameters may 
high frequency disturbances, the flow controller will stiU have to be modified to better accommodate patient var-
correct the bias offset. lability not present in the simulation described, and the 
lobbi ct al.: feedback Flow Control 
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Fig. W. SDOT attenuation in SpO2 fluctuations. 
response of the controller to real patient data was evalu-
ated. A typical result is shown in Figure 11 where the 
original Sp02 recording is displayed together with the 
S D O T results. As the saturation falls below the 91% set-
point, the controller responds by increasing the Oo flow-
rate. Whenever the saturation rises above the set point, 
the controller then decreases the O? flow-rate. Overall the 
controller response can rapidly react to compensate for 
fluctuations in the patient SpO^ and reduce the extent and 
severity of desaturation events. 
A summary of the efiectiveness of the controller is 
presented in Table 1. The S D O T group represents the 
results of automatically regulating the O2 flow-rate via the 
closed-loop controller. The efliect of Constant-Flow 
L T O T was also simulated. The oxygen flow-rate was 
normalized with respect to the S D O T group to yield 
equivalent oxygen consumptions. For each simulated 
therapy, the percent of time spent with hypoxemia (sat-
uration less than 90%) was calculated. The percentage of 
time spent with hypoxemia for S D O T was compared 
with both the original untreated data, and that predicted 
with constant flow L T O T . The simulation results indicate 
the potential benefits of implementing closed-loop oxy-
gen flow control. Figure 12. O n average among the three 
patients, S D O T reduced the time spent with arterial 
blood saturation below threshold by 76% (range 58-86%). 
Moreover, given the same volume of oxygen, S D O T 
produced a 63% (range 36—79%) improvement compared 
to conventional Constant-Flow L T O T . Such results 
highlight the improved efficacy of the closed-loop control 
method. 
D I S C U S S I O N 
The simulated closed-loop flow control demonstrates 
beneficial improvement in oxygen sa'uration, throughout 
a range of possible disturbance free uencies (10s < peri-
od < 15min). These pre-chnical results were further ver-
ified by simulations of saturations ba' e<. on actual patient 
sleep data where S D O T produced a 63% improvement 
compared to standard L T O T . 
The present simulation results demonstrate the feasi-
bility and potential effectiveness of the closed-loop flow 
controller. Eliminating the need for a single prescribed 
flow-rate, the S D O T automatically responds to a patient's 
changing needs. Nevertheless, it remains uncertain what 
symptomatic relief patients may experience from the 
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Fig. 11. Typical section of controller simnlation results; Top: Pulse oximetry' of SDOT (solid line) vs Patient Recording (doited line); Bottom: Simnlated 
Oxygen flow-rate. 
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Table 1. Comparison of therapies 
Group Variables Patient 1 Patie? I Patient 3 
No-OT Mean Overnight Sa02 (%) 88.8 91.8 95.1 
Standard Dev SaO; (%) 4.6 2.3 3.3 
Percent Time vw' Sa02 < 90 (%) 55.1 27.3 12.1 
Recording Duration (min) 483 483 483 
SDOT Mean Overnight Sa02 (%) 91 92.5 95.4 
Standard Dev Sa02 (%) 2.6 1.6 2.7 
Percent Time vw' SaO? < 90 (%) 22.9 4.3 1.8 
Mean flow-rate (1/min) 2.3 0.9 0.4 
O2 equivalent C o n s t - L T O T Mean Overnight Sa02 (%) 90.7 92.3 95.3 
Standard Dev Sa02 (%) 3.7 2.1 3.2 
Percent Time vw' Sa02 < 90 (%) 36 15.9 8.5 
Therapy Comparison 
Patient 1 Patient 2 Patient 3 Average 
laNo Oxygen OFixeU Flow • SOOT | 
Fig. 12. Comparison graph; patient data results. 
respiratory rate, and shunt fraction. These parameters 
differ be tween patients and even within the same patient 
depending on the circumstance. Thus the control 
parameter may require fu ture modif icat ion to prevent 
potential complications not encountered within the data 
sets such as hunting. Whi le these positive results indicate 
the potential of the closed-loop m chod, they do not 
provide evidence to the robustness o . ' t he technique. 
T h e simulation approximates the potential effectiveness 
of the S D O T , however it is uncertf..i) h o w patients will 
adapt to the responsive therapy. As the oxygen saturation 
fluctuates wi thin the body, the patient wiU naturally at-
tempt to compensate. T h e dynamic interaction be tween 
the flow controller and the patients' instinctive response 
wiU be particularly interesting to study clinically. 
improved oxygen therapy. This is the focus of our future 
research, collaborating wi th the Royal Brompton Hospital 
in an ongoing feasibility cUnical study. In the double-
blind randomised crossover study, S D O T is being c o m -
pared against standard oxygen therapy in 15 patients wi th 
C O P D during exercise. T h e study aims to determine the 
possible acute patient benefits which may include 
improved relief f rom debilitating shortness of breath, and 
greater mobility. Long tenn , patients might benefit f rom 
reduced strain on the heart thereby leading to a decreased 
frequency of emergency hospital admissions. 
Study limitations 
T h e model paraineters have largely been selected based 
upon average values from literature. For instance the 
lung-to-capillary t ime is influenced by several physio-
logical variables such as heart-rate, cardiac output . 
Supported by Universities UK, Overseas Research Student Award 
Scheme. A part of this work was presented at the 3rd European 
Medical & Biological Engineering Conference - Prague, 23rd Nov 
2005. The assistance of Michelle Chatwin at the Royal Brompton 
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Arterial Oxygen Saturation Feedback to Control Oxygen Flow Rate During 
Exercise in COPD Patients 
M. lobbi, BS\ M. Nuila, MD^ A. Tooth, PT^ R.J. Dickinson, PhD' and A.K. 
Simonds, MD .^ 'imperial College London, London, England and ^Royal Bntnipton 
Hospital, London, England. 
Royal Brompton Hospital Clinical Research Committee, and Universities UK 
Rational 
Despite receiving oxygen therapy, many COPD patients experience extended periods 
of hypoxaemia during routine daily activities. Using feedback control, we evaluated 
an automatic method to regulate O2 flow rate in response to changes in arterial oxygen 
saturation (Sp02). This was compared to standard fixed flow oxygen therapy during 
an incremental shuttle walk test (ISWT) in a double blind crossover study in COPD 
patients. 
Methods 
The pulse oximeter SpOi measurement is continually fed to a PC, which computes the 
O2 flow rate to maintain a target SpOi > 91%. The O2 flow rate was varied using a 
digital flow regulator, connected to a cylinder which delivers oxygen to the patient via 
a nasal cannulae. In addition to this automatic feedback mode (AUTO), the controller 
has a constant mode (CONS) which delivers the standard fixed flow ra'e oxygen 
therapy. 
Six COPD patients (mean age 57.5, range 51-68 years, mean FEVl 25.6% j^"edicted) 
carried out repeated ISWT while receiving AUTO or CONS oxygen delivery in 
random order, with a 45min rest between tests. Heart-rate, SpOa, and O2 flow were 
recorded initially from rest until 5min after completing the ISWT. The total distance 
walked was noted, and participants ranked breathlessness using a modified Borg score 
before, immediately after, and 2 min post the ISWT. 
Results 
Compared to CONS, AUTO delivery significantly reduced the time spent at Sp02<90 
by 17±13% (p<0.05), improved the recovery time to baseline SpOz by 39±17% 
(p<0.01) and decreased the minimum Sp02 from 77.5±7.6% to 83.8±2.8% (p<0.05). 
No significant difference in ISWT distance or Borg scores was found. 
Conclusion 
The results demonstrate the feasibility and potential for feedback control to reduce the 
extent of hypoxaemia during exercise in COPD patients compared to standard 
ambulatory oxygen therapy. 
